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The most recent class of P-lactams, the carbapenems, have been an effective treatment
for infections caused by multi-resistant strains ofAcinetobacter baumannii however,
there are now increasing reports of emerging carbapenem-resistant isolates
world-wide, which severely threatens the successful treatment of patients infected by
these bacteria. The mechanism of this resistance in Acinetobacter spp. has been
attributed to a combination of reduced outer membrane permeability and loss of outer
membrane proteins. More recently however, several reports have identified
P-lactamases as a major mechanism. The main aim of this thesis was therefore to
ascertain the importance of P-lactamase activity as a mechanism of carbapenem
resistance in clinical isolates ofAcinetobacter from several countries.
A total of 54 clinical isolates from Argentina, Turkey, Hong Kong, Spain and
Singapore were investigated. The majority of isolates were identified as
A. baumannii. Antimicrobial susceptibility testing detected resistance in all isolates to
the majority of antimicrobials tested. A total of 69% of isolates demonstrated MIC
values of imipenem above the recommended breakpoint value, of which the highest
percentage resistance was observed in the isolates from Argentina and Singapore
(89% and 82% respectively). A significantly lower level of resistance (38.9%) was
observed to meropenem.
A modified microbiological assay detected imipenem inactivation in all
imipenem-resistant isolates, of which 61% produced an unknown P-lactamase of pi
7.0 (main band). Inhibitor overlays of IEF gels demonstrated that this P-lactamase
was a serine active-site enzyme that was able to bind imipenem. Kinetic studies with a
crude p-lactamase extract of representative strain 790 failed to detect imipenem
hydrolysis. A modified assay was subsequently employed to detect hydrolysis over a
longer period of time. The rate of hydrolysis was calculated as 0.75 nmoles min"1 ml"1
of sample and the specific activity as 0.055 nmoles min"1 mg"1 of protein. Curing
experiments with isolate 790 resulted in the loss of the p-lactamase of pi 7.0 and a
subsequent reduction in the MIC value of imipenem to a susceptible level (16 mg/L to
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0.5 mg/L). In addition, the modified microbiological assay detected an 11-fold
decrease in the specific rate of imipenem hydrolysis with the cured strain (0.005
nmoles min"1 mg"1 of protein). These findings provided strong evidence that this
p-lactamase was associated with plasmid-mediated carbapenemase activity. The
enzyme was subsequently named ARI-2. Kinetic studies of ARI-2 following partial
purification by anion exchange and gel filtration chromatography revealed that it was
primarily a penicillinase. Slow hydrolysis of imipenem was detected, but not
meropenem. Slow hydrolysis of oxacillin and cloxacillin was also detected,
suggesting that ARI-2 belonged to molecular class D. This was further substantiated
by inhibition of enzyme activity by sodium chloride. The Mr of ARI-2 was estimated
as 35.5 kDa.
Extraction of plasmid DNA from isolate 790 revealed the presence of a plasmid of
approximately 40 kb in the parent but not in the cured strain, which provided further
evidence that the blaAri_2 gene was plasmid-located. PCR analysis failed to reveal
homology between bla^si.2 and the class D ARI-1 P-lactamase. However,
hybridization studies demonstrated some homology with this enzyme.
Analysis of ARI-2-producing isolates from Argentina, Turkey, Hong Kong and Spain
by PFGE identified 5 main clusters. Four of these comprised strains from Argentina
which suggested that horizontal transfer of the ARI-2 gene had occurred. Clonal
spread was detected in the isolates from Turkey, which comprised the 5th cluster. The
RFLP patterns of the single isolates from Spain and Hong Kong differed markedly
from each other and from the main clusters.
Antimicrobial susceptibility studies of imipenem-resistant isolates detected variations
in their sensitivities to 7 fluoroquinolones. Significant resistance was demonstrated to
ciprofloxacin and norfloxacin however, the newer quinolones (sparfloxacin,
trovafloxacin, grepafloxacin and moxifloxacin) were more active with significantly
lower MIC50 and MIC90 values observed. A total of 62% of imipenem-resistant
isolates from Argentina were resistant to all of the fluoroquinolones tested. A
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serine-83 to leucine gyrk mutation was detected in all isolates with a ciprofloxacin
MIC value of > 2 mg/L. The majority of isolates with ciprofloxacin MIC values of
> 16 mg/L also contained a serine-80 to leucine parC mutation. However, this
mutation was not present in 5 isolates with ciprofloxacin MIC values of 16 mg/L. A
Glu-84 to Leu change was detected in one of these isolates, which suggested that
different mutations, or indeed other mechanisms of quinolone resistance may be
important in Acinetobacter.
A study of the efficacy of sulbactam was performed with carbapenem-sensitive clinical
isolates from Scotland and with carbapenem-resistant isolates form Argentina, Spain
and Hong Kong. The lowest MIC values were demonstrated with the carbapenem-
sensitive isolates from Scotland (MIC range of 0.5 - 2.0 mg/L). The highest MIC
values were observed with the isolates from Argentina (MIC range 2 - >16 mg/L).
Sulbactam did not have a significant inhibitory effect against isolates with MIC values
of > 4 mg/L at concentrations above this level. However, a decrease in growth rate of
an isolate with a MIC value of 0.5 mg/L was detected. The combined activity of
imipenem and sulbactam was evaluated. Although bactericidal synergy was detected
with one strain, this combination failed to produce a similar effect with 2 other strains,
suggesting that the combined effect of imipenem and sulbactam cannot be predicted
and is very much strain-dependent.
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1.1 The post-antibiotic era?
In 1969, the US Surgeon General testifying to Congress stated rather ambitiously, "The
time has come to close the book on infectious disease". As we enter a new century,
many microbiologists believe that nothing is further from the truth, and that we are, in
fact, on the verge of a medical disaster that will return us to the days before penicillin
where minor infections may prove lethal because we do not have the antibiotic 'armoury'
to deal with them (Kendell, 1994). This unthinkable scenario has been attributed mainly
to the remarkable ability of bacteria to adapt and survive, no matter what antimicrobial
bullets are fired at them. Clinicians are now all too frequently faced with treating patients
infected by multi-resistant bacteria which are often susceptible to only one or two
antibiotics at the most. This is an extremely worrying situation, considering there are
now over 250 antibiotics available commercially. The market was crowded with many of
these compounds in the 1980s, which many believe led to a degree of complacency on the
part of the pharmaceutical industry, perhaps assuming the battle against bacterial
infections had already been won.
Today, the heavy use of antibiotics in farm animals and the selective pressure exerted by
over-use of many of these broad-spectrum drugs in hospitals, has ensured that bacteria
continue to develop resistance at an alarming rate. Moreover, the organisms responsible
for many hospital, or nosocomial infections, are evolving continuously. Bacteria such as
Acinetobacter and Stenotrophomonas species were considered to be of relatively low
virulence in humans. Now, they are accepted pathogens in infections of intensive therapy
unit (ITU) patients. Scientists are now having to broaden their horizons beyond the
development of antimicrobial analogues and are endeavouring to search for new
therapeutic strategies.
2
1.2 An historical background to the antibiotic era
Although both natural and artificial substances have been used to treat infectious diseases
throughout history, many of these treatments were purely topical (Selwyn, 1983). It was
not until the twentieth century that agents with antimicrobial properties were studied for
treating systemic disease.
Paul Ehrlich did much to bridge the gap between the dye industry and microbiology with
his research on aniline dyes and arsenical compounds for the treatment of protozoan
diseases. He based his experiments on the important and fundamental principle of
'selective toxicity' (Ehrlich et al., 1913). Subsequently, the bacteriologist, Gerhard
Domagk demonstrated that a dye, prontosil red, could be used to cure experimental mice
infected with Streptococcus pyogenes (Domagk, 1935). It was noticed, however, that
the antibacterial activity of this dye could not be demonstrated in vitro. A research group
in France finally solved this mystery by demonstrating that the active agent, a
sulphanilamide group, was enzymatically released from the dye complex within the body
(Trefouel et al., 1935). By altering the nature of the substitution on the amino group of
this moiety, chemists were able to produce pharmacokinetically improved compounds,
resulting in synthetic sulphonamides which heralded the start of the chemotherapeutic era
as we know it today.
1.2.1 The P-Iactams- antibiotics from the soil
1.2.2 The penicillins
The discovery of the first of this important class of antibiotics, penicillin, by Alexander
Fleming in 1929 is renowned, and is considered one of the most significant medical
findings of our age (Fleming, 1929). As was the case with several of the
naturally-occurring antibiotics, its discovery was due mainly to a chance observation.
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Fleming noticed that a mould, Penicillium notation, which had contaminated a culture
plate of Staphylococcus aureus, inhibited growth of the bacteria. The crude material
originally extracted from the mould was found to include a number of compounds duly
named penicillins F, K, X and G. The latter, also known as benzylpenicillin, was the most
active and was subsequently chosen for further development.
One of the first documented uses of penicillin as a treatment was in 1930 when a doctor
who was a former pupil of Alexander Fleming, used a crude extract of Penicillium to
successfully treat a case of ophthalmia neonatorum (reviewed by Wainwright and Swan,
1986). However, due to difficulties in production and purification, the clinical value of
penicillin as an effective chemotherapeutic agent was not realised until the mid-1940s,
mainly due to the pioneering work ofHoward Florey and Ernst Chain in Oxford (Chain et
al, 1940).
The isolation of the penicillin nucleus, 6-amino-penicillanic acid (6-APA) in 1959 was a
major event in the history of the (3-lactams as it allowed the addition of novel side-chain
structures and thus paved the way for the production of many semi-synthetic penicillins
(Rolinson, 1979). One of the main objectives of the work on 6-APA was to produce new
penicillins which would be effective against the increasing number of penicillin-resistant
staphylococci already emerging in hospitals (Barber and Whitehead, 1949). Indeed, these
strains started to appear within a few years of the widespread use of penicillin G. The
cause of this resistance was due to the production of an enzyme penicillinase
(P-lactamase) which inactivated the antibiotic by hydrolysing the P-lactam ring (Kirby,
1944). By the time 6-APA had been isolated, the incidence of resistance was as high as
80% in many hospitals (Rolinson, 1979). To date, a vast number of penicillins have been
developed in an attempt to counteract the ever-increasing problem of bacterial resistance.
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1.2.3 The cephalosporins
The discovery of penicillin prompted many scientists to look for new antibiotic-producing
organisms. In 1945, a bacteriologist, Giuseppi Brotzu, studied the microbial flora of
seawater near a sewage outfall in Sardinia, and came across a strain of Cephalosporium
acremonium which secreted a substance with activity against a number of Gram-positive
and Gram-negative bacteria. Due to lack of facilities and expertise, he passed a culture of
the mould to Florey's team in Oxford for further analysis. Their studies revealed a
number of antibiotic substances. However, it was not until the mould was grown on a
much larger scale that these were identified.
The first was named cephalosporin P because it demonstrated activity against certain
Gram-positive bacteria (Burton and Abraham, 1951). Sufficient amounts of this could
not be obtained for clinical trials. However, another antibiotic substance, cephalosporin
N was discovered from the extraction procedure used to obtain cephalosporin P. This
was active against both Gram-negative bacteria and penicillin-sensitive staphylococci, and
was undoubtedly the same substance that Brotzu had originally found. It was then
revealed that this antibiotic was inactivated by a penicillinase from Bacillus cereus
(Newton and Abraham, 1954) and was subsequently renamed penicillin N. Because of
the difficulties in successfully isolating it, this compound was never produced in quantity
by the pharmaceutical industry, however, a small amount of another substance was found
during an attempt to establish the molecular formula of penicillin N by chromatography.
This was named cephalosporin C, the first and original member of the class of antibiotics
known as the cephalosporins (Newton and Abraham, 1955). Unlike penicillin N,
cephalosporin C was relatively acid-stable and demonstrated a high resistance to
inactivation by B. cereus and staphylococcal penicillinases. Although it was used in the
treatment of urinary tract infections in children (Fleming, 1963), cephalosporin C did not
play a major role in the treatment of infections caused by penicillinase-producing
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staphylococci, as by this time the semi-synthetic penicillins were very much in the
therapeutic spotlight.
The chemical structure of cephalosporin C was eventually confirmed by x-ray
crystallography (Crowfoot and Maslen, 1961), which allowed the identification of two
groups within the structure that could potentially be modified. As with the development
of the penicillins, the nucleus of cephalosporin C, 7-amino-cephalosporanic acid (7-
ACA), needed to be isolated if this was to prove successful. Although attempts were
made to achieve this, it was not until the pharmaceutical industry became involved that an
efficient chemical method of isolation was found which allowed 7-ACA to be prepared in
large quantities (Morin et al., 1962). The semi-synthetic cephalosporins had arrived.
The common feature of the p-lactams is the presence of a 4-membered P-lactam ring
structure (Figure 1.1) which is essential for antimicrobial activity.
1.3 Structure of the penicillin nucleus
The penicillins, or penams, are characterised by a fused heterocyclic structure which
consists of the P-lactam ring, a 5-membered sulphur-containing thiazolidine ring and a
side chain (Figure 11). Manipulation of this side chain essentially alters the spectrum of
activity and pharmacokinetics of the compound (Figure 1.2). Unlike the cephalosporins,
the C6 position of the molecule is the only site on the nucleus that can be substituted.
1.3.1 Classification of the penicillins
Benzylpenicillin, exhibits good activity against many Gram-positive cocci and
Gram-positive bacilli however, it is susceptible to staphylococcal P-lactamases and is
labile to gastric acid. The objective of early research following the isolation of 6-APA
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was therefore to synthesise narrow-spectrum penicillins similar to benzylpenicillin but
with better oral absorption qualities, and to produce compounds which were stable to
staphylococcal P-lactamases and had activity against penicillin-resistant staphylococci
(Figure 1.3).
Figure 1.1 Structure of 6-amino-penicillanic acid (6-APA)
P-lactam ring thiazolidine ring
The natural penicillins
Benzylpenicillin is still the choice drug for many Gram-positive infections.
Phenoxymethylpenicillin (penicillin V) (Figure 1.2) is an oral derivative of penicillin which




These compounds have an acyl side-chain that sterically inhibits the action of penicillinase
by preventing opening of the (3-lactam ring. Methicillin was the first of this group to be
developed (Figure 1.2). Others include oxacillin, nafcillin, cloxacillin and dicloxacillin
(the latter two are for oral use). They have good activity against both Staphylococcus
species and Streptococcus species, but no activity against Gram-negative bacteria.
Although these antibiotics are often first choice therapy for many staphylococcal
infections, the emergence ofmethicillin-resistant S. aureus in the early 1980s has curtailed
their usefulness (Cookson and Phillips, 1990).
Extended-spectrum penicillins
Aminopenicillins
These were the first group of penicillins developed with activity against Gram-negative
bacteria. Ampicillin is an a-amino derivative of benzylpenicillin (Figure 1.2).
Amoxycillin is closely related to ampicillin in both chemical structure and antibacterial
activity but has better absorption. Both initially had activity against many Gram-negative
bacteria (except Klebsiella and Pseudomonas spp.), including Escherichia coli, Proteus
mirabilis, Salmonella and Shigella spp., but resistance has limited their use against many
of these strains.
Carboxypenicillins
Carbenicillin was developed by the substitution of the amino group of ampicillin for a
carboxyl group (Figure 1.2). Subsequent substitutions on carbenicillin produced the
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thienyl variant, ticarcillin. Both have improved activity against Gram-negative bacilli,
including P. aeruginosa, which is intrinsically resistant to most of the p-lactams.
Ureidopenicillins
Examples of these ampicillin derivatives include mezlocillin and azlocillin (Figure 1.2).
The major advantage of this group of penicillins is their enhanced activity against
P. aeruginosa.
(3-Iactamase inhibitors
This strategy was approached to counteract resistance as a result of p-lactamase
production. Beta-lactamase inhibitors have only weak antibacterial activity but increase
the activity of certain P-lactams when they are combined with them (Maiti et al., 1998).
Clavulanic acid
This is a bicyclic oxapenam (Figure 1.2) produced by Streptococcus clavuligerus (Brown
et al., 1976; Reading and Cole, 1977), and is a powerful inhibitor of most class A and
some class D P-lactamases. Classes B and C are unaffected. Clavulanic acid is used in
combination with amoxycillin or ticarcillin. Its efficacy has prompted the production of
several semi-derivatives however, the original inhibitor remains the most effective (Maiti
etai, 1998).
Sulbactam
This penam sulphone (Figure 1.2) displays potent inhibitory activity against primarily
class A enzymes, but also has a greater affinity for class C p-lactamases than clavulanic
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acid (English et al., 1978). It is commercially available in combination with ampicillin, or
in some countries with cefoperazone.
Tazobactam
This inhibitor is a penam sulphone derivative (from modification of the 2-methyl groups
of sulbactam) that has a broader spectrum of inhibitory activity than sulbactam and
clavulanic acid, which includes most class A and some class D (3-lactamases, and the
AmpC enzymes ofEnterobacteriaceae (Aronoff et al., 1984; Maiti et al., 1998).
BRL 42715
This belongs to a class of 6-(substituted methylene) penem inhibitors (Bennett et al.,
1991), and is a good inhibitor of a broad range of P-lactamases with a serine residue at
their active-site (Farmer et al., 1994). However, as a result of its chemical instability and
short half life in humans, it is no longer produced for clinical use.
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Figure 1.3 Classification of the penicillins
NATURAL PENICILLINS




ORALLY ABSORBED PENICILLINS SIMILAR TO BENZYLPENICILLIN
Phenoxypenicillins



















PENICILLINS ACTIVE AGAINST Pseudomonas aeruginosa





Temocillin (6 a-methoxy derivative of ticarcillin)
PENICILLIN PLUS p-LACTAMASE INHIBITORS
Amoxycillin-Clavulanic acid Ampicillin-Sulbactam
Ticarcillin-Clavulanic acid Piperacillin-Tazobactam
Adapted from Wright, 1999; Sutherland, 1997
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1.4 Structure of the Cephalosporins
All the cephalosporins have a 6-membered dihydrothiazine ring fused to the p-lactam ring
(Figure 1.4). The extra carbon of the ring carries an additional side chain, the nature of
which often affects the pharmacokinetic behaviour of the molecule, and in some cases,
the degree of toxicity. A major advantage of the cephalosporins over the penicillins is
that there are two positions (Ri and R2) on the molecule that can be modified (Figures 1.4
and 1.5).
Figure 1.4 Structure of 7-aminocephalosporanic acid (7-ACA)
O
II H





P-lactam ring dihydrothiazine ring
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Figure 1.5. Chemical structures of the R1 and R2 cephalosporin
side-chains
R1 R2
Group 1 - e.g. Cephalothin
— ch2—o —c-ch3
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— ch2— o— c— ch3
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R1 R2
Group 5 - e.g. Cefixime
Group 6 - Broad-spectrum e.g. Ceftazidime
Group 6 - Medium-spectrum e.g. Cefoperazone
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1.4.1 Classification of the cephalosporins
The groups listed below differentiate these compounds based on the route of
administration, their degree of antimicrobial activity and stability to bacterial
(3-lactamases. Members of each group are listed in figure 1.6.
Group 1
These parental compounds were developed in response to a need for more effective
antibiotics against staphylococci. They have moderate antimicrobial activity and have
relative stability to staphylococcal (3-lactamase. However, they are hydrolysed by many
of the Enterobacteriaceae. The first compounds to be developed in this group were
cephalothin and cephaloridine.
Group 2
Compounds within this group are administered orally and demonstrate moderate
resistance to some of the enterobacterial ^-lactamases. The first of these compounds to
be developed was cephalexin which has a methyl group at C3 (Figure 1.5). This was
followed by cefaclor, which has a chlorine in place of the methyl group, and cephradine,
which has the phenyl group of cephalexin replaced by a cyclohexadiene group.
Group 3
These are all parental compounds and include the related group the cephamycins which
share the common feature of a methoxy group attached to the 7-a-position of the
P-lactam ring conferring stability to the structure. This group displays moderate
antimicrobial activity and includes activity against the anaerobe, Bacteroidesfragilis.
17
Group 4
This group includes parenteral compounds with potent antimicrobial activity and
resistance to a wide range of (i-lactamases. They are characterised by the presence of an
N-acyl side-chain containing a 2-aminothiazole group (Figure 1.5).
Group 5
The compounds within this group originate from an attempt to improve the intrinsic
activity of the previous oral cephalosporins. Although they have improved activity
against many of the enterobacteria, their spectrum against the Gram-positives is not as
good.
Group 6
These parenteral compounds are characterised by their activity against P. aeruginosa and
resistance to a wide range of (3-lactamases
Group 7
This group includes the parenteral compounds cefepime and cefpirome which have
enhanced 3-lactamase stability, potent activity against enterobacteria and enhanced
activity against staphylococci.
Groups 1 and 2 are often referred to as the 'first' generation cephalosporins, group 3 the
second, groups 4, 5 and 6 the third, and group 7 the fourth generation.
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Figure 1.6 Classification of the cephalosporins





















GROUP 4 - Parenteral, improved intrinsic activity and P-lactamase stability
Cefotaxime Ceftriaxone Cefodizime
Ceftizoxime Cefmenoxime Latamoxef (Oxacephem)
GROUP 5 - Oral, improved p-lactamase stability
Cefdinir Cefprozil Cefetamet Ceftibuten
Cefixime Cefteram Cefpodoxime
GROUP 6 - Parenteral, activity against P. aeruginosa
Broad spectrum - Ceftazidime Medium spectrum - Cefoperazone
Cefpimazole
Cefpiramide
Narrow spectrum - Cefsulodin
GROUP 7 - Parenteral, enhanced P-lactamase stability, potent activity against
enterobacteria
cefipime cefpirome
Adapted from Wise, 1997
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1.5 Other P-lactams
There are a vast number of antimicrobial agents that are related to the penicillins and
cephalosporins (Figure 1.7). Those with therapeutic use are described below.
1.5.1 Oxacephems, cephamycins and carbacephems
These compounds are all closely related to the cephalosporins. The sulphur of the
oxacephems and the carbacephems are substituted by an oxygen and a carbon
respectively. The cephamycins have a a-methoxy group at position 7 (Figure 1.7).
1.5.2 Monobactams
This group of natural monocyclic compounds (which also includes the nocardicins) are
produced by bacteria. They frequently have a a-methoxy group attached to the p-lactam
ring, a feature shared by the cephamycins. Aztreonam was the first of these compounds
to be clinically used and is active against a wide range of aerobic Gram-negative bacteria.
1.5.3 Penems
These synthetic compounds differ from the penams by the presence of a double bond
between C2 and C3.
1.5.4 Carbapenams
The carbapenams differ from the penams in the substitution of a CH2 group for sulphur in
the five-membered ring (Figure 1.7).
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1.5.5 Carbapenems
This class of bicyclic p-lactams is characterised by an extremely broad-spectrum of
activity against both aerobic and anaerobic bacteria. The first of these compounds,
thienamycin, was discovered in 1978 as a natural product of Streptomyces cattleyci
(Kahan et al., 1979). Unfortunately, it was also found to be extremely unstable and
therefore was not clinically developed. However, subsequent work resulted in the
N-formimidoyl derivative of thienamycin, imipenem, which proved to be far more stable
than thienamycin but retained its broad-spectrum of activity (Birnbaum et al., 1985).
Unfortunately, imipenem is hydrolysed by a dehydropeptidase enzyme located in the
brush border of the mammalian kidney and consequently must be administered in
combination with the enzyme inhibitor cilastatin which prevents both renal metabolism
and nephrotoxicity (Kahan et al., 1983).
1.5.5.1 Structure of the carbapenems
The nuclear structure of the carbapenems differs from the penam nucleus of penicillins in
having a carbon atom instead of a sulphur at position 1 (Figure 1.7). They also have an
unsaturated bond between C2 and C3 in the thiazolidine ring. An important aspect of the
carbapenems is found in the stereochemistry of the side-chain linked to the (3-lactam ring.
In contrast to the penicillins and cephalosporins, where this group is in the cis (P)
configuration, in the carbapenems, it is in the trans (a) configuration which confers
striking resistance to the majority of P-lactamases.
Since the development of imipenem, subsequent research has resulted in derivatives
which are more stable than their counterpart (Hikida et al., 1991; Kurihara et al., 1992).
Meropenem is one such compound. It has the same configuration as imipenem, both
have low molecular weights, are zwitterionic and penetrate bacteria readily (Trias and
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Nikaido, 1990a). However, meropenem offers several advantages in that it possesses a
methyl group in position 1 which confers stability to renal dehydropeptidase I (Figure
1.7). It also has a unique side-chain in position 2, resulting in improved activity against
P. aeruginosa and other Gram-negative bacteria (Moellering et al., 1989).


















1.6 Mode of action of the P-lactams
1.6.1 The bacterial cell wall - target of the P-lactams
The activity of the P-lactams demonstrates rather eloquently Paul Ehrlich's principle of
'selective toxicity' in that they act on a structurally unique feature found in both
Gram-negative and Gram-positive bacteria that is absent from mammalian cells. This
feature is the cell wali which provides the organism with a chemical and physical barrier
against substances that may damage the cell. The major component of the cell wall is the
polymer peptidoglycan which plays a vital role in providing rigidity and strength to this
structure. P-lactam antibiotics act by interfering with the biosynthesis of peptidoglycan,




1.6.2 Structure of the cell wall
The cell wall of Gram-negative bacteria differs in structure from that of Gram-positive
bacteria. Essentially, they each possess peptidoglycan, but the wall of Gram-positive
organisms is a thicker, less complex structure consisting of a network of cross-linked
peptidoglycan interspersed with teichoic acid and teichuronic acid polymers, the amounts
ofwhich vary between species (Neidhardt et al., 1990a).
Gram-negative bacteria have a much thinner peptidoglycan layer, which is surrounded by
a lipid bilayer outer membrane. This extremely efficient barrier consists of
lipopolysaccharide, protein and phospholipid, all ofwhich prevents many hydrophilic and
some hydrophobic molecules from penetrating the cell. Nutrients required by the cell are
able to gain entry through this barrier via protein molecules called porins that are located
within the outer membrane (Neidhardt et al., 1990a). These channels are also utilised by
the hydrophilic p-lactam antibiotics to gain access to their target enzymes located within
the periplasmic space (Nikaido, 1993). Differential activity of the p-lactams is dependant
on their ability to move through the porin channels, which in turn is determined by their
size and physicochemical structure (Livermore, 1987a).
Peptidoglycan is composed of linear chains of alternating P 1-4 linked N-acetyl
glucosamine and N-acetylmuramic acid residues that are crossed-linked via oligopeptide
bridges attached to the muramic acid residues (Neidhardt et al., 1990b). Assembly
consists of the synthesis of pentapeptide precursors in the cytoplasm that are
subsequently transported across the cell membrane where they are added to the existing
peptidoglycan chain. There are a number of enzymes involved in the final cross-linking
process (Barnikel et al., 1983). Transpeptidases catalyse the formation of a peptide bond
between the carboxyl of the penultimate D-alanine of one pentapeptide, and the amino
group of the middle amino acid of another pentapeptide. The energy for this reaction is
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provided by the loss of the second pentapeptides's terminal D-alanine which is catalysed
by carboxypeptidases (Barnikel et al., 1983).
1.6.3 Penicillin-binding proteins
Both transpeptidases and carboxypeptidases, along with endopeptidases (which cleave
peptide bonds formed between pentapeptides), are the targets of (3-lactam antibiotics
(Waxman and Strominger, 1983). They are also collectively known as penicillin-binding
proteins (PBPs) since they are able to efficiently bind penicillin (Georgopapadakou and
Liu, 1980). PBPs la, lb, 2 and 3 of Gram-negatives have essential functions in
peptidoglycan synthesis (Zimmerman, 1980).
Numbered in descending order according to their molecular weight, their numbers vary
between species (Georgopapadakou and Liu, 1980). P-lactams exert their effect by
acting as substrate analogues for the PBPs. The amide group (0=C-N) of the (3-lactam
ring is similar in conformation to the carboxy terminal of the D-alanyl-D-alanine. The
PBPs thus effectively recognise the antibiotic as they would their normal substrate,
allowing it to interfere with cell wall formation by commandeering the active-site cavity
(Tipper and Strominger, 1965).
A common feature shared among the PBPs is a C-terminal transpeptidase domain with a
conserved active-site serine residue that is acylated by the P-lactams resulting in the
formation of a stable covalent ester, and inactivation of the enzyme (Ghuysen, 1988).
The effect of this interaction on the cell depends on the enzyme involved. Penicillin
binding proteins 1, 2 and 3 are transpeptidases to which most P-lactams bind (Spratt,
1977).
25
1.7 Bacterial resistance to antibiotics
1.7.1 The origins of resistance
Antibiotic resistance has evolved in parallel with the advent of antimicrobial
chemotherapy, the first |3-lactamase was identified before the widespread use of penicillin
(Abraham and Chain, 1940). Given the fact that many antibiotics in use today were
discovered in soil micro-organisms, it is hardly surprising that bacteria have developed a
remarkable ability of acquiring resistance to them.
There is much evidence to suggest that the most likely sources of resistance genes found
in clinical isolates are from the soil micro-organisms which produce many of the
antibiotics in use today (Benveniste and Davis, 1973; Thompson and Gray, 1983).
However, there are other potential sources, for example, modification of genes encoding
essential metabolic enzymes, also known as 'housekeeping' genes (Shaw et al., 1992;
Rather etal., 1993).
1.7.2 The role of antibiotics in producer organisms
A number of theories exist which attempt to explain the function of antibiotics in
producer micro-organisms. One such theory is that they have a regulatory role during the
transition from vegetative cell to spore in sporulating organisms (reviewed by Demain,
1974). A competition hypothesis also exists, which describes a functional role in the
survival of producing organisms, thus offering a competitive advantage to the cell (Brian,
1957). It has even been suggested that antibiotics act as bacterial pheromones in
promoting the transfer of plasmids between different bacteria (Mazodier and Davies,
1991). What is known is that antibiotics are secondary metabolites that are produced
after the logarithmic growth phase of the organism, and that the enzymes involved in
antibiotic biosynthesis are repressed during this growth period (Demain, 1974).
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1.7.3 Self-defence mechanisms in antibiotic-producing micro-organisms - the
origins of bacterial resistance?
Bacteria that produce potentially toxic antibiotics utilise a number of survival strategies to
avoid self intoxication. A number of organisms modify the intracellular target to which
the antibiotic normally binds; for example, Streptomyces erythraeus produces the
macrolide erythromycin, which inhibits bacterial protein synthesis by binding to 50S
ribosomal subunits. By methylation of its own 23 S rRNA, S. erythraeus avoids the
effects of the antibiotic (Teraoka and Tanaka, 1974). A similar methylase has been
identified as the cause of resistance to erythromycin and other macrolides in
Staphylococcus aureus and certain streptococci (Weisblum et al., 1979), suggesting that
a common evolutionary origin exists for the genes encoding these enzymes.
There are a number of producer organisms that possess the ability to inactivate their
antibiotic products within the cell; for example, the streptomycin-producing strains of
Streptomyces griseus and S. bikiniensis (Miller and Walker, 1969). During their
exponential growth phase, they are normally sensitive to the drug, but once in the
stationary phase, when streptomycin is actively being produced, they develop a high level
of resistance. This is achieved by phosphorylation of the antibiotic to an inactive
6-phosphoryl derivative, by an enzyme, aminoglycoside 6-phosphotransferase (APH (6)),
which is present in the cell at high levels during antibiotic production. Once the antibiotic
reaches the cell membrane, a process of dephosphorylation occurs thereby ensuring that
the drug is excreted in its active form (Nomi et al., 1967).
Evidence now exists to support the hypothesis that the genes encoding phosphorylating
enzymes present in clinical strains of aminoglycoside-resistant bacteria, have significant
sequence homology with those present in producer bacteria (Thompson and Gray, 1983).
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1.7.4 Selective pressure and antibiotic resistance
It is universally accepted that the use of antimicrobial agents, both in clinical medicine and
as food supplements in animal populations, exerts a strong selective force for the
emergence of bacterial resistance (Tenover and McGowan, 1996; Spika et al., 1987).
Particular areas within the hospital setting, for example, intensive therapy units, where
bacteria are constantly being exposed to a fluctuating antibiotic environment, allow for
the selection of resistant variants that are maintained and transferred within these areas
(Saunders, 1981).
Intensively farmed animals, for example, poultry and pigs, act as a reservoir of
antibiotic-resistant bacteria (Linton, 1986). If the foodstuff is contaminated during
slaughter, these resistant bacteria pose a potential threat to human health via a number of
routes (Piddock, 1996). There is evidence to suggest that an increased use of antibiotics
as growth promotors and as treatment for infections in these animals, correlates with a
similar rise in the number of isolated antibiotic-resistant strains (Levy et al., 1987).
In addition to these factors, there are other selective pressures at play, both intrinsic to
the bacteria and to the patient, which contribute to the complexity of the resistance
problem (Toltzis, 1995).
1.8 Acquisition of resistance genes - the genetic vehicles of bacterial
resistance




Intrinsic or 'natural' resistance as it is often referred to, is found to some extent in most
bacterial species (Costerton & Cheng, 1975; Li et al., 1994a; Li et al., 1994b). It is a
term usually used to describe the inherent features of a species or genus that are
responsible for preventing access of the antibiotic to the interior targets of the cell
(Nikaido & Nakae, 1979). It can pose a therapeutic problem for infections caused by
certain bacteria such as Acinetobacter species (Fass & Barnishan, 1980) and
P. aeruginosa (Yoshimura & Nikaido, 1982), both of which are multi-resistant pathogens
that are frequently isolated from ITUs.
More recently, multidrug efflux pumps that are capable of pumping a wide range of
compounds including antibiotics, out of the cell, have been highlighted as playing an
increasingly important role in the intrinsic mechanisms of antibiotic resistance in many
bacteria (Nikaido, 1996).
1.8.2 Acquired resistance
In contrast to intrinsic resistance where all the cells within a given population express the
resistance phenotype, acquired resistance occurs when resistant strains emerge from
previously sensitive bacterial populations, usually after exposure to antibiotics (Tenover
and McGowan, 1996). It can occur as a result of mutations to the existing genome
(Heisig et al., 1993), or when genetic information is transferred between bacterial cells by
the mechanisms of transduction, transformation and conjugation (Mazodier and Davies,
1991).
Transduction involves the transfer of DNA between bacterial cells via a bacteriophage
vector, and may be restricted to related species due to the specificity involved in cell
invasion by the phage (Mazodier and Davies, 1991). Transformation is an important
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mechanism of DNA transfer in a few bacteria and involves the incorporation of short
DNA fragments by homologous recombination in the recipient cell (Spratt et al., 1992).
Conjugation requires physical contact between two cells and is the mechanism of
self-transfer utilised by plasmids and transposons; two genetic elements that play an
important role in the transfer of resistance genes between bacteria (Watanabe, 1963;
Courvalin and Carlier, 1986).
1.8.3 The vectors of acquired resistance
1.8.3.1 Plasmids
Plasmids are circular, extrachromosomal genetic elements that are able to replicate
independantly of the chromosome and encode a number of functions (Lederberg, 1952).
They began to attract a great deal of interest following the discovery of plasmid-mediated
antibiotic resistance in Japan in the late 1950s, and the demonstration of transferable
multiple drug resistance (Watanabe, 1963). At around the same time, it was discovered
that penicillinase synthesis by S. aureus was a plasmid-mediated characteristic (Novick,
1963). Indeed, a large number of P-lactamases are now known to be plasmid-encoded,
and this is undoubtedly the main reason why this mechanism of P-lactam resistance is a
major contributor to the antibiotic resistance problem (Bush et al., 1995).
Plasmids owe much of their success as vehicles of antibiotic resistance, to a number of
factors:
1. They allow the genes that they carry to evolve independantly of the chromosome, and
are therefore free of the genetic constraints that this entails.
2. They offer a high degree of mobility so that genes can be passed vertically from
mother cells to progeny but can also be acquired horizontally from other bacteria.
3. They are also frequently vectors of other genetic determinants (transposable
elements) involved in antibiotic resistance.
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1.8.3.2 Transposable elements
The discovery of insertion sequences, transposons and more recently, integrons, has gone
a long way to help explain many of the mechanisms by which bacteria acquire (and lose)
resistance genes. Bacteria of the pre-antibiotic era contained plasmids very similar to
those which now carry resistance genes (Hughes and Datta, 1983). Indeed, it is now
known that transposable elements have been instrumental in the evolution of antibiotic
resistance in bringing about important rearrangements in bacterial DNA (Saunders,
1984). A common feature of transposable elements is their ability to insert (transpose)
into different sites on the same, or on different DNA molecules without the need for
homology between the element and the sites of insertion. Thus, the recipient replicon can
be in another microorganism (Bennett and Howe, 1990).
1.8.3.2.1 Insertion sequences and transposons
Insertion sequences (ISs) were first identified in mutants ofE. coli, in which the mutation
was due to the insertion of small pieces of DNA, rather than a classical deletion or point
mutation (Jordon et al., 1968). Similar elements were subsequently discovered (Fiant et
al., 1972), and are now known to be normal components ofmost bacterial chromosomes
and plasmids (Galas and Chandler, 1989). ISs have been implicated in antibiotic
resistance by creating novel promoters for antimicrobial resistance genes (Podglajen et
al., 1994).
There are several classes of transposons grouped according to their method of
transposition and their gene composition (Berg, 1989; Sherratt, 1989; Phillips and
Novick, 1979; Clewell and Gawron-Burke, 1986). Many carry antibiotic resistance genes
in addition to those required for transposition (Saunders, 1984). Unlike plasmids,
transposons are unable to replicate independantly and so must be maintained within a
functional replicon that subsequently acts as a vector in transferring the transposon into a
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new host. If the vector is unable to replicate within the host, the transposon can still exist
by transposing itself to the host chromosome or resident plasmid (Saunders, 1981).
1.8.3.2.2 Integrons
It is now known that a considerable number of antibiotic resistance genes found in
Gram-negative bacteria are part of small, mobile elements called gene cassettes (Recchia
and Hall, 1995), which are normally integrated by site-specific recombination in another
element commonly associated with them, called an integron (Stokes and Hall, 1989).
Together, these elements form an extremely efficient natural cloning and expression
system that is utilised by bacteria to disseminate resistance genes.
To date, there are over 40 cassettes that are known to contain antibiotic resistance genes,
including those which confer resistance to the (3-lactams (Recchia and Hall, 1995). An
important feature of this recombination system is that integration of the gene cassette
within the integron is reversible, and therefore captured genes can be released and
subsequently recaptured by another integron (Collis and Hall, 1992). This can result in
the formation of a large number of different integrons each containing a set of 1 or more
cassettes.
There are 3 classes of integrons known to date (Recchia and Hall, 1995; Tietze et al,
1987; Young et al., 1994; Arakawa et al., 1995). The most prevalent integrons found in
Gram-negative clinical isolates belong to class 1 which have contributed greatly to the
emergence ofmulti-resistant Gram-negative bacteria (Martinez-Freijo et al., 1998).
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1.9 Mechanisms of resistance to the P-lactams
There are essentially 4 main mechanisms that bacteria utilise to evade the action of
(5-lactam antibiotics:
1. Changes in outer membrane permeability
2. Efflux pumps
3. Modification ofPBPs
4. Production of P-lactamases
1.9.1 Outer membrane permeability
The presence of porin channels in the outer membrane of Gram-negative bacteria
facilitates the transmembrane diffusion of hydrophilic molecules, including the P-lactams.
(Yoshimura and Nikaido, 1985). However, mutations resulting in the loss of specific
porins can result in an increase in resistance to the P-lactams. This is evident with
Psendomoncis aeruginosa, a pathogen renowned for its intrinsic resistance to a wide
range of antibiotics (Yoshimura and Nikaido, 1982). Indeed, the overall outer membrane
permeability of this organism is between 12 to 100-fold lower than that of E. coli
(Nikaido and Hancock, 1986).
Increased resistance to the P-lactams has also been attributed to a decrease in the number
of porins produced by some bacteria (Yamazaki et al., 1989), and the production of
porins with small channels (Sato and Nakae, 1991). Acinetobacter spp. have improved
on this by producing a decreased number of small-sized porins (Sato and Nakae, 1991).
Loss of porin expression in clinical isolates of Klebsiella pneumoniae from patients
undergoing antibiotic therapy has been attributed to the insertion of ISs (Hernandez et
al., 1999).
33
Reduced permeability alone is usually insufficient to prevent antibiotic influx and
subsequently, it generally occurs in combination with a second mechanism to produce this
effect (Nikaido, 1981). In the case of (3-lactams, this additional mechanism is usually the
production of a P-lactamase (Hancock and Bell, 1988), although there is now evidence
that active efflux systems also play an important role.
1.9.2 Efflux pumps
Studies suggest that the outer membrane and specific multidrug efflux pumps of
Gram-negative bacteria act together to lower both the cytoplasmic and periplasmic
concentrations of P-lactams, including the carbapenems (Li et al., 1994b; Masuda et al.,
1995; Kohler et al., 1999). Many of these systems are multidrug efflux pumps because
they have extremely broad specificities and are capable of pumping out a wide range of
compounds (Nikaido, 1994).
1.9.3 Alterations in PBPs
This mechanism of resistance is more common in Gram-positive bacteria (Brown and
Reynolds, 1980), and in certain fastidious Gram-negatives such as Haemophilus
influenzae (Serfass et al., 1986). It is generally not regarded as a primary resistance
mechanism in other Gram-negative bacteria that have more efficient mechanisms at their
disposal. It is likely that in bacteria in which this resistance mechanism occurs, the
development of p-lactam resistance is due to multiple amino acid substitutions, each
resulting in a relatively small decrease in affinity of the PBP for the P-lactam antibiotic(s),
and as this may potentially alter the stability of the enzyme, 'restabilizing' amino acid
substitutions may also occur (Hedge and Spratt, 1985). Reduced affinity of specific
PBPs has been documented for Pseudomonas aeruginosa (Gotoh et al., 1990) and for
Acinetobacter baumannii (Gehrlein et al., 1991). P-lactam resistance can also occur as a
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result of the production of additional PBPs, as seen with PBP2' (Cookson and Phillips,
1990) and PBP2B (Komatsuzawa et al., 1999) of methicillin resistant S. aureus, or due
to overproduction of a PBP possessing slow enzyme-P-lactam kinetics (Fontana et al.,
1983).
1.9.4 Production of P-lactamases
By far the most successful mechanism of antibiotic resistance at the disposal of bacteria is
the production of P-lactamases, enzymes that can cleave the amide bond of the P-lactam
ring thus rendering inactive a vast number of these antibiotics (Medeiros, 1984).
P-lactamases are produced both by Gram-negative and Gram-positive bacteria, and their
impact on antimicrobial efficacy has been immense. Although the advent of P-lactamase
inhibitors and extended-spectrum P-lactams have appeared to restrain the effects of many
of these enzymes, the bacterial response has been to modify existing P-lactamases or to
produce novel, more efficient ones. This unrelenting challenge on antimicrobial therapy
appears to be far from exhausted.
1.10 The evolution of P-lactamases
The hypothesis that p-lactamases have evolved from PBPs is now generally accepted as a
result of sequence-based analyses, and structural and enzymatic information that has
provided an understanding of this evolutionary process. We now know that P-lactamases
and PBPs share several highly conserved amino acid sequences (Massova and
Mobashery, 1998). As a primary defensive response to antibiotics produced by other soil
bacteria, it is thought that non-producing bacteria excreted their PBPs that were bound to
the antibiotic, acting in effect as a detoxification mechanism. Over time, they developed
into enzymes that were capable of hydrolysing the P-lactam, thus providing these bacteria
with a distinct survival advantage (Kelly et al., 1986). This evolutionary process
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continues today, the only difference being that the selective pressure is now the heavy use
of antibiotics in the hospital setting.
1.10.1 Structure and mechanism of action
P-lactamases can be divided into 2 broad categories based on the structure of their
active-site. The first category comprises those with a serine amino acid at this site, and
can be further subdivided into molecular classes A, C and D on the basis of sequence
similarity (Bush et al., 1995). The second category comprises the small but rapidly
growing group of class B P-lactamases, or metallo-enzymes, so called because they utilise
1 or 2 zinc ions to disrupt the P-lactam ring rather than the serine ester mechanism of
serine-based P-lactamases (Valladares et al., 1997; Carfi el1 al., 1998).
1.10.2 Structure of the serine P-lactamases
X-ray studies have revealed structural analogies between the DD-peptidase PBP of
Streptomyces R61 (S. R61) and several class A and C P-lactamases (Kelly et al., 1986;
Lobkovsky et al., 1993). Essentially, these enzymes consist of 2 structural domains (the
a and a/p domains), with the active-site located in a groove between the two. Class C
P-lactamases and the S. R61 PBP have additional loops and secondary structures away
from the active site on the surface of the a domain (Matagne et al., 1998). The
active-site is located at the N-terminus of the first hydrophobic helix (the a-2 helix) of
this domain.
There are a number of conserved sequences at the active-sites of serine p-lactamases that
play a role in substrate recognition and catalysis. The Ser-Xaa-Xaa-Lys (Xaa is any
amino acid) motif contains the active-site serine residue. The side chain of the lysine
residue points onto the active-site, and the amino group of this side chain is thought to be
involved in the catalytic process (Knox and Moews, 1991).
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The second element is referred to as the SDN loop in class A (3-lactamases and almost
always consists of Ser-Xaa-Asn (serine-any amino acid-asparagine) in these enzymes and
most PBPs (Bush, 1997). In class C and D 3-lactamases, and a few PBPs, the serine
residue is replaced by Tyr (tyrosine). This motif is found in the a domain and forms one
side of the active-site cavity (Bush, 1997).
The third element is called the KTG triad (Joris et al., 1988), is highly conserved and
forms the opposite wall of the cavity. In the majority of enzymes, it consists of the
sequence Lys-Thr-Gly (lysine-threonine-glycine), but Lys may be replaced by His
(histidine) or Arg (arginine) in a few rare cases, and Thr by Ser in some class A
(3-lactamases (Matagne et al., 1998).
There is a fourth structure which is highly conserved in all class A |3-lactamases but is
altered in other active-site enzymes (Bulychev et al., 1997). In class A enzymes, it is
found on a 16-19 residues loop known as the Q-loop. In most cases, this contains the
sequence Glu l66-Xaa-Glu-Leu-Asn 170 where Glutamic acid at position 166 and
Asparagine at position 170 are essential in the positioning of one of the conserved water
molecules which are involved in the deacylation step of the enzyme-|3-lactam reaction,
close to the active site (Herzberg and Moult, 1987).
1.10.3 The serine ester mechanism of class A, C and D P-lactamases
P-lactam hydrolysis begins with the non-covalent association of the P-lactamase and the
P-lactam (Figure 1.8 ). The carbonyl group of the 3-lactam ring is attacked by a free
hydroxyl on the side chain of the serine residue (Ser-70 in class A and D, and Ser-64 in
class C) at the active-site of the enzyme to yield a covalent acyl ester. The ester is
hydrolysed, freeing the enzyme from the hydrolysed substrate. Additional residues are
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known to play an important role in the formation of the acyl-enzyme intermediate, and in
the regeneration of the free enzyme (Massova and Mobashery, 1998).
Figure 1.8 Mechanism of (3-lactam hydrolysis utilised by serine
active-site P-lactamases
serine residue at































1.10.4 Classification of P-lactamases
The classification of Sawai in 1968 discriminated penicillinases from cephalosporinases
based on their response to antisera (Sawai et al., 1968). As more information on enzyme
function became available and with the discovery of new P-lactamases, other
classification schemes evolved (Richmond and Sykes, 1973; Sykes and Matthew, 1976;
Mitsuhashi and Inoue, 1981; Bush, 1989a; Bush, 1989b, Bush, 1989c). Amber was the
first to propose a molecular classification scheme (Ambler, 1980) which is still the most
straightforward.
1.10.4 1 The Ambler classification scheme
When Ambler first proposed a molecular structure classification, only four P-lactamase
amino acid sequences were known (Ambler, 1980). On that basis, there are now four
molecular classes to which P-lactamases are assigned based on the similarity of their
amino acid sequences (Jaurin and Grundstrom, 1981; Huovinen and Jacoby, 1991;
Ouellete et al., 1987). Classes A, C, and D contain the serine active-site p-lactamases
and represent the majority of known enzymes. Class A enzymes share considerable
homology and include TEM-1 and SHV-1, which are two of the most prevalent
P-lactamases found in Enterobacteriaceae (Wiedemann et al., 1989). Many class A
P-lactamases are encoded by genes on plasmids or transposons, and are produced by both
Gram-positive and Gram-negative bacteria (Bush et al., 1995). Fewer class C
P-lactamases have been found associated with transmissible elements, and they are only
produced by Gram-negative bacteria (Bush et al., 1995). Class B comprises the
metallo-P-lactamases which require a bivalent metal ion (usually zinc) for their activity,
and class D are a group of enzymes which are capable of hydrolysing oxacillin (Dale et
al., 1985) that appear to have evolutionary links with high molecular-weight class C
PBPs (Massova and Mobashery, 1998).
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1.10.4.2 The Bush classification scheme
The most recent scheme of Bush attempts to correlate both the phenotypic and the
molecular properties of known P-lactamases (Bush et al., 1995). It refrains from using
the location of the gene encoding the P-lactamase as a primary classification factor,
reflecting the ability of a large number of these genes to move between chromosome and
plasmid. There are four main functional groups within this classification scheme.
Group 1
Chromosomal cephalosporinases of this group are often referred to as AmpC-type
P-lactamases that are intrinsically resistant to P-lactamase inhibitors and are ubiquitous in
most enterobacteria. The amount and mode of expression of these enzymes vary between
genera (Sanders and Sanders, 1988). Some of the genes encoding these enzymes have
migrated onto plasmids in Klebsiella pneumoniae and Escherichia coli clinical isolates
(Sanders and Sanders, 1992). Of concern is the recent report of a plasmid-mediated
AmpC p-lactamase (ACT-1) in K. pneumoniae which, in combination with loss of an
outer membrane protein resulted in resistance to imipenem (Bradford et al., 1997).
Group 2
The P-lactamases of this group belong to molecular classes A or D and are generally
inhibited by active-site-directed inhibitors. They hydrolyse a diverse range of substrates
which is acknowledged by the definition of subgroups for these enzymes.
Extended-spectrum P-lactamases that are derived from the TEM and SHV enzymes
(group 2b) constitute group 2be, and those that have a reduced affinity for P-lactamase
inhibitors comprise the 2br group. The main criterion for group 2d is the preferential
hydrolysis of cloxacillin or oxacillin (hydrolysis rate of greater than 50% than that for
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benzylpenicillin) (Bush et al., 1995). Likewise, (5-lactamases that hydrolyse carbenicillin
at a rate of greater than 60% compared with that for benzylpenicillin have been allocated
to group 2c. Group 2f comprises the active-site serine carbapenemases. Many of the
genes that encode these (3-lactamases are found on plasmids.
Group 3
The metallo-3-lactamases of this group are not inhibited by classical P-lactamase
inhibitors with the exception of EDTA, a metal chelator and p-chloromercuribenzoate
(p-CMB), an amino-acid modifier.
Group 4
Penicillinases that are not inhibited by the suicide inactivator clavulanic acid, have been
placed in this group. The LCR-1 P-lactamase from P. aeruginosa was originally a
member of group 4 (Bush, 1989c) however, sequence data has subsequently revealed its
homology with class D OXA enzymes (Couture et al., 1992) with the result that it has
been relocated to group 2d (Bush et al., 1995).
Bush and colleagues have endeavoured to produce a "workable, and potentially useful,
compilation of P-lactamase characteristics" however, as they concede, "no functional
classification will ever be completely satisfactory" (Bush et al., 1995). As more sequence
data is revealed about 3-lactamases, and enzyme variants emerge with altered substrate
and inhibitor profiles as a result of point mutations of their genes, it is likely that the
composition of the classification groups described here will alter accordingly.
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1.11 Mechanisms of resistance to the carbapenems
The advent of the carbapenems was embraced with a sense of great expectation in that at
last, a class of (3-lactams now existed that seemed capable of evading many of the
resistance mechanisms which have compromised the use of other (3-lactams. However,
cases of resistant clinical isolates have begun to emerge and initially, resistance
mechanisms other than the production of [^-lactamases were considered solely
responsible. Impermeability mechanisms have been shown to play a role in a number of
Gram-negative bacteria (Buschner et al., 1987; Pagani et al., 1990; Mehtar et al., 1991),
as has PBP modification (Neuwirth et al., 1995; Gehrlein et al., 1991), although the
importance of the latter appears to be of little consequence in Gram-negative bacteria due
to the ability of the carbapenems to target the vulnerable site of PBP2 (Hashizume et al.,
1984).
There are now an increasing number of reports that attribute carbapenem resistance to
[3-lactamase activity. In many of these cases, a change in outer membrane permeability is
also required, but there is now a growing number of so called 'efficient carbapenemases'
that appear to be able to cause carbapenem resistance on their own.
1.11.1 Outer membrane impermeability and Bush group 1 (3-lactamase
production
There is a specific porin protein, OprD, in P. aeruginosa that is used by the organism to
bring dipeptides into the cell (Hancock and Bell, 1988). The zwitterionic carbapenems
are sufficiently similar in structure to these dipeptides that they are also able to enter the
cell by this route via the same binding site (Huang and Hancock, 1993; Trias and
Nikaido, 1990a). However, imipenem resistance has occurred in this organism as a result
of loss of this porin (Buschner et al., 1987). It has subsequently been reported that this
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mechanism can function only when a chromosomal (3-lactamase is expressed (Livermore,
1992). Many of these particular (3-lactamases have been demonstrated to hydrolyse the
carbapenems albeit at a very slow rate (Livermore and Yang, 1987b). OprD-deficient
clinical isolates of P. aeruginosa with derepressed production of their chromosomal
(3-lactamase have been found to be four-fold more resistant to imipenem than
OprD-deficient isolates that only produced basal levels of the enzyme (Satake et al.,
1991).
Expression of chromosomal (3-lactamase does not appear to have a role in meropenem
resistance in laboratory mutants lacking OprD (Livermore, 1992). Similar findings have
been demonstrated in Enterobacter cloacae (Cornaglia et al., 1995). Interestingly,
P. aeruginosa mutants overexpressing the MexAB-OprM efflux pump have demonstrated
an increase in meropenem resistance but not in imipenem resistance (Masuda and Ohya,
1992). Studies have revealed that meropenem (but not imipenem) is a substrate of this
pump in P. aeruginosa, and it has been suggested that differences in the
physicoproperties of the two antibiotics may explain this observation (Kohler et al.,
1999). Alternative ports of entry have also been suggested for meropenem in
P. aeruginosa (Perez, F. J. et al., 1996).
The interplay of overexpression of group 1 (3-lactamases and outer membrane
impermeability appears to be the main mechanism of carbapenem resistance in
Enterobacter spp. (Hopkins and Towner, 1990; Chow and Shlaes, 1991; Raimondi et al.,
1991; Lee et al., 1991; De Champs et al., 1993; Cornaglia et al., 1995). It has also been
reported in Citrobacter freundii (Marinardi el al., 1997), in Proteus mirabilis (Mehtar et
al., 1991), and in Providencia rettgeri (Raimondi et al., 1991). The decrease in
permeability is thought to slow the rate of entry of the carbapenem sufficiently enough to
permit the large amount of (3-lactamase present in the periplasmic space to inactivate the
drug before it reaches its target site on the cytoplasmic membrane (Raimondi et al.,
1991). More recently, there has been a report of carbapenem resistance in a clinical
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isolate of E. co/i associated with production of a plasmid-determined molecular class C
P-lactamase in combination with loss of an outer membrane protein (Stapleton et al.,
1999). In addition, the production of an extended-spectrum P-lactamase SHV-2, along
with the loss of an outer membrane protein, has been reported as a mechanism of
imipenem resistance in a clinical isolate of K. pneumoniae (Mackenzie et al., 1997). This
observation has subsequently been described in another clinical isolate of the same species
but has been attributed to an increased inoculum effect (Martinez-Martinez et al., 1999).
1.11.2 Efficient carbapenemases
The molecular class B metallo-P-lactamases and some serine active-site P-lactamases are
both able to hydrolyse the carbapenems, and are often referred to as carbapenemases.
1.11.2.1 The metallo-P-lactamases
The chromosomally-encoded zinc-dependant P-lactamase from Bacillus cereus was the
first metallo-P-lactamase to be reported (Sabath and Abraham, 1966). A number of
similarly encoded metallo-P-lactamases subsequently emerged in Pseudomonas (now
Stenotrophomonas) maltophilia (Saino et al., 1982), Aeromonas hydrophila (Shannon et
al., 1986), Bacteroidesfragilis (Cuchural et al., 1986), Legionella gormanii (Fujii et al.,
1986) and Flavobacterium odoratum (Sato et al., 1985). Although these enzymes were
greeted with interest, they were considered to be of little clinical significance since they
were recovered from single isolates. However, there have since been numerous reports
of other metallo-enzymes from these and other species (Rasmussen and Bush, 1997;
Stunt et al., 1998; Walsh et al., 1996; Woodford et al., 1998). Of greater concern, are
the reports of plasmid-mediated metallo-P-lactamases. The first of these, from
P. aeruginosa, was reported in 1991 (Watanabe et al., 1991), followed closely the
following year by the report of a transferable metallo-enzyme from B. fragilis (Bandoh et
al., 1992). They have subsequently been joined by a plethora of
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extra-chromosomally-encoded metallo-enzymes (Cardoso et al., 1999; Bellais et al.,
1999; Rasmussen and Bush, 1997; Lauretti et al., 1999).
From a clinical viewpoint, 1MP-1 is considered to be the most threatening
metallo-(3-lactamase, since it has succeeded in becoming established in several species of
enterobacteria and in P. aeruginosa in Japan. It was originally isolated in Japan from a
clinical strain of Serratia marcescens, and was found to be chromosomally-encoded,
conferring resistance to imipenem and broad-spectrum (3-lactams (Osano et al., 1994). It
shares similar kinetic properties and identical sequence with the metallo-enzyme described
by Watanabe et aim 1991, with the result that the two are now considered to be the same
(Iyobe et al., 1996).
The acquisition of IMP-1 does not necessarily coincide with the emergence of high-level
carbapenem resistance (Senda et al., 1996). An additional factor, most likely
impermeability, has been suggested for resistance to occur in some cases (Minami et al.,
1993).
An alarming development has been the discovery of the gene encoding IMP-1 (b/amp) on
an integron-like element (Arakawa et al., 1995). In addition, the integrons carrying
blajMP also possess the aminoglycoside acetyltransferase gene (aac(6')-Ib), so that
cross-resistance can also occur to amikacin, tobramycin and netilmicin (Arakawa et al.,
1995). Fears of this facilitating the spread of the IMP-1 gene to other bacteria, both
within and outside of Japan are now being realised. It has already been found, amongst
others in clinical isolates of E. coli, K. pneumoniae, C. freundii, and Burkholderia
cepacia (Kurokawa et al., 1999), and appears to be disseminating, with reports of
IMP-1-producing clinical isolates in Singapore (Koh et al., 1999). An IMP-l-like
P-lactamase has recently been discovered in Italy from a clinical isolate of Acinetobacter
baumannii (Cornaglia et al., 1999).
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There is no doubt that the heavy use of carbapenems and other antibiotics in Japan has
exerted a strong selective pressure that has brought about the emergence of strains
producing IMP-1 and other related metallo-p-lactamases (Livermore, 1997), and that a
reduction in the use of these antibiotics results in a concomitant decrease in the number of
strains which produce such enzymes (Senda et al., 1996). However, there is still the
possibility that silent genes remain in these bacteria, as observed in B. frcigilis (Podglajen
et al., 1992), that can be switched on following a return of antibiotic pressure.
1.11.2.2 Serine active-site carbapenemases
Serine active-site P-lactamases that are capable of hydrolysing the carbapenems are a
relatively recent addition to this type of resistance. The first, Sme-1, was isolated from
two S. mcircescens strains collected in London in 1982 (Yang et al., 1990). The second,
IMI-1, emerged two years later in two E. cloacae isolates from a hospital in southern
California (Rasmussen et al., 1996), and a third, NMC-A, was isolated from a single
E. cloacae collected in Paris in 1990 (Nordmann et al., 1993). Interestingly, both IMI-1
and Sme-1 were discovered before the marketing of imipenem. Although all three
P-lactamases are chromosomally-encoded, they are not typical for their host species
therefore, it can be assumed that they have been acquired and that the genes encoding
them have become integrated into the chromosome (Yang et al., 1990; Rasmussen
et al., 1996; Nordmann et al., 1993). Consequently, the possibility exists in the future
that the genes encoding these p-lactamases may once again find their way onto
transposable elements if there is sufficient selection pressure.
Serine active-site carbapenemases differ from metallo-P-lactamases in a number of ways.
The most obvious is in their classification. Sme-1, IMI-1 and NMC-A are all molecular
class A enzymes, and belong to Bush group 2f (Bush et al., 1995). They also display a
greater resistance to imipenem than meropenem, unlike the metallo-P-lactamases which
produce similar resistance to both. The class A carbapenemases are also resistant to
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aztreonam but not the third-generation cephalosporins, and are inhibited by clavulanic
acid. Metallo-P-lactamases are not active against aztreonam, nor are they inhibited by
clavulanic acid (Livermore, 1997).
In contrast with the expression of metallo-P-lactamase genes which can be either
inducible in response to the presence of a P-lactam, or non-inducible (Rasmussen and
Bush, 1997), expression of the genes encoding all three class A carbapenem-hydrolysing
P-lactamases is inducible and is under the control of LysR-like regulatory proteins, the
genes of which are found immediately upstream of their respective P-lactamase genes
(Naas and Nordmann, 1994; Naas et al., 1995; Rasmussen et al., 1996). All three
P-lactamases have now been sequenced. Sme-1 is about 70% identical to IMI-1 and
NMC-A, which both share 95% identity (Naas et al., 1995; Naas and Nordmann, 1994;
Rasmussen et al., 1996). To date, Sme-1 and NMC-A have not been found outwith their
producer isolates. However, more recently, Sme-type carbapenem-hydrolysing
P-lactamases have been reported in the USA from geographically diverse isolates of
S. marcescens which share similar substrate profiles with Sme-1, and which differ from
the parent enzyme by a single amino-acid change (Queenan et al., 1999).
The carbapenemase story has however, taken a rather diverse twist with Acinetobacter
spp. recently, with an increase in the incidence of carbapenem-hydrolysing P-lactamases
that are not zinc dependant. In particular, many of those reported are not class A
enzymes but instead appear to be oxacillin-hydrolysing P-lactamases of molecular class
D
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1.11.2.3 Proposed mechanism of carbapenem hydrolysis by serine active-site
P-lactamases
Site-directed mutagenesis studies with Sme-1 have identified a possible role of the
amino-acid serine at position 237 (Ser-237) in the hydrolysis of imipenem (Sougakoff et
al., 1999). This residue is located near the highly conserved KTG motif in the active-site
of class A P-lactamases, which plays an important role in substrate binding. By replacing
the serine with an alanine (Ser-237-Ala mutant), this particular study demonstrated a
subsequent 5-fold decrease in imipenem hydrolysis. The mutant retained activity against
aztreonam, and it was confirmed therefore that Ser-237 has no specific role in the
hydrolysis of the monobactams or the oxyiminocephalosporins. Sougakoff and
colleagues have suggested that Ser-237 allows a better positioning of imipenem or its
acylated intermediate within the active-site of Sme-1. However, the mutant was found to
retain a low but nonetheless significant activity against imipenem, which suggests the
involvement of other residues at the active-site, that are needed for the efficient
hydrolysis of imipenem by this enzyme.
Other studies have provided possible candidates for this role. The asparagine residue at
position 132 (Asn-132) is displaced at the active-site of NMC-A, and it has been
proposed that this subtle relocation enlarges the substrate-binding site to accommodate
the C-6 side chain of carbapenems, allowing the turnover process to take place (Swaren
et al., 1998).
Another important difference observed between the group 2f carbapenemases and other
class A P-lactamases is the replacement of arginine with alanine at position 244
(Arg-244-Ala). Arginine at this position is thought to interact with the C-3 carboxylate
group of the substrate after acylation (Jelsch et al., 1993). An alanine residue in its place
may therefore alter this interaction and lead to a faster substrate turnover rate for the
group 2f enzymes (Rasmussen and Bush, 1997). Interestingly, mutations at position 244
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(among others) of TEM-1 and TEM-2 result in derivatives of these enzymes that are
resistant to inhibitors such as clavulanic acid and sulbactam (Bush and Jacoby, 1997;
Canica etal., 1997).
A histidine to tyrosine change at position 105 (His-105-Tyr), and a tyrosine in place of a
leucine at position 207 (Leu-207-Tyr) in the three group 2f P-lactamases may also
contribute to a more effective hydrolysis rate of the carbapenems (Rasmussen and Bush,
1997). In addition, a glucose residue at position 104 in most other class A P-lactamases
is found at position 103 in Sme-1, IMI-1 and NMC-A, which may place the catalytic
water molecule in a more desirable position for carbapenem hydrolysis (Rasmussen and
Bush, 1997).
1.12 The clinical consequences of carbapenem resistance
The selective pressure exerted by the use of broad-spectrum antibiotics in the hospital
setting has resulted in a gradual shift in the pattern of pathogens that are now being
isolated from patients. This is particularly evident in the intensive therapy units (ITUs)
where the already difficult situation of treating immuno-compromised patients is further
complicated by conditions specific to these units for example, invasive monitoring and the
ventilation of patients.
Enterobacteriaceae remain major pathogens in ITUs in Europe (Vincent et al., 1995), and
the increased incidence of P-lactam resistance has provided a major obstacle for the
successful treatment of infections caused by these bacteria (Nordmann, 1998). There has
also been a resurgence in infections caused by Gram-positive bacteria that have
developed resistance to many of the antibiotics which have been until now the mainstay of
successful therapy (Cookson and Phillips, 1990; Hiramatsu et al., 1997; French, 1998).
Undoubtedly the most alarming trend is the emergence of previously clinically
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insignificant bacteria as major causes of ITU-related infections. Many of these
'opportunistic' pathogens demonstrate multi-resistance (Simpson el al., 1993; Denton
and Kerr, 1998), and have subsequently added the carbapenems to their substrate range
which have traditionally been the treatment of choice for these infections. Acinetobacter
spp. are among this elite group of predominantly nonfermenting Gram-negative bacteria
(Quinn, 1998), and are now considered a major pathogen in ITUs ( Bergogne-Berezin
and Towner, 1996).
1.13 Acinetobacter - A taxonomic history
Acinetobacter spp. are Gram-negative coccobacilli that are strictly aerobic, non-motile,
catalase-positive and oxidase-negative, and are distributed widely in nature. They are
able to grow at a wide range of temperatures, and have a DNA G+C content of between
39 - 47%.
The on-going taxonomy of the genus Acinetobacter is complex and can be somewhat
confusing. They were originally described by Beijerinck in 1911 under the name of
Micrococcus calco-aceticus (Beijerinck, 1911). Since then, they have been included in a
number of other genera including Bacterium (anitratrum) (Schaub et al., 1948), Herellea
{vaginolo) and Mima (polymorpha) (Debord, 1939), Achromobacter, Alcaligenes and
Neisseria (Juni, 1972). Two microbiologists working in France introduced the name of
Acinetobacter for a heterogeneous group of non-motile, Gram-negative, oxidase-positive
(Moraxella) and oxidase-negative organisms (Brisou and Prevot, 1954) that were readily
identifiable by their lack of pigmentation (Ingram and Shewan, 1960).
In 1971, the Subcommittee on the Taxonomy ofMoraxella and Allied Bacteria proposed
that the oxidase-negative members alone should comprise the genus Acinetobacter
(Lessel, 1971), following the studies by Baumann and colleagues which clearly
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demonstrated that they differed from oxidase-positive strains (Baumann et al., 1968).
The revamped genus was included in the family Neisseriaceae, and consisted of one
species (A. calcoaceticus) which comprised two subspecies, or varieties (var. anitratus
and var. Iwoffii) (Juni, 1984).
In 1986, Bouvet and Grimont identified 12 genomic species by DNA-DNA hybridization
(Bouvet and Grimont, 1986). The genus is now in the new family Moraxellaceae, which
also comprises the genera Moraxella, Psychrobacter and related organisms (Rossau et
al., 1991), and there are subsequently over 19 genomic species, of which 7 have been
allocated species names (calcoaceticus, baumannii, haemolyticus, junii, johnsonii,
hvoffii, and radioresistens). However, discrepancies remain in the numbering schemes
employed by individual laboratories (Bergogne-Berezin and Towner, 1996). A
phenotypic group (A. calcoaceticus-A. baumannii, or Acb complex) has been proposed
for genomic species 1 and 2, along with the unnamed DNA groups 3 and 13 sensu
Tjernberg and Ursing (TU), which share DNA homology values of 67-78% (Tjernberg
and Ursing, 1989).
1.14 Nosocomial infections caused by Acinetobacter spp.
Acinetobacter spp. are opportunistic pathogens associated with septicaemia, endocarditis,
meningitis, wound and urinary tract infections and, in particular, are responsible for
outbreaks of nosocomial pneumonia in ventilated ITU patients (Bowton, 1999). The
most commonly isolated species from these infections is A. baumannii
(Bergogne-Berezin and Joly-Guillou, 1991), although other species have also been
associated with serious infections (Meiki and Sramek, 1992; de Beaufort et al., 1999).
Acinetobacter spp. are frequently isolated from infections along with other pathogens,
particularly in the case of bacteraemia (Bergogne-Berezin and Towner, 1996) or infected
wounds (Amsel and Horrilleno, 1985), and as a result, it is often difficult to distinguish
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between true infection and colonisation (Struelens et al., 1993). However, ITU patients
presenting with an Acinetokcicter infection commonly incur complications that may be
potentially life-threatening (Rodriguez-Bano, 1999). Acquisition of A. banmcinnii is
often associated with an increased length of hospital stay and an increased mortality rate
in ITU patients with proven infection (Garcia-Garmendia et al., 1999).
A survey ofGram-negative aerobes isolated in ITUs in the USA between 1990 and 1993
reported that Acinetobacter spp. accounted for 5.3% of these organisms (Itokazu et
al., 1996). More recently, a similar study of ITUs in 5 European countries between 1994
and 1995 reported that Acinetobacter spp. were among the most frequently isolated
aerobic Gram-negative bacilli (2-10%) after E. coli, P. aeruginosa, Enterobacter spp.
and Klebsiella spp., with the highest numbers isolated from ITUs in France. In addition,
Acinetobacter spp. were among those organisms that demonstrated the highest incidence
of resistance in all 5 countries (Hanberger et al., 1999).
1.14.1 Risk factors associated with Acinetobacter infections
The susceptibility of the patient is a major risk factor in the acquisition of
Acinetobacter-related infections. ITU patients are at most risk since they are frequently
ventilated, have been exposed to broad-spectrum antibiotic therapy, or have undergone
invasive procedures (Gomez et al., 1999). The elderly and neonates are also high risk
groups (Bergogne-Berezin and Towner, 1996; de Beaufort et al., 1999). The severity of
an underlying disease has also been identified as an important factor in the acquisition of
A. baumannii infections (Bergogne-Berezin and Towner, 1996), and an increase in
mortality rate is often associated with infections caused by multi-resistant A. baumannii
(Gomez et al., 1999).
Acinetobacter spp. can be found as part of the normal flora of the human skin, especially
the axillae, groin and toe webs (Somerville and Noble, 1970). However, they are also
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found to a lesser degree in the respiratory tract of healthy adults (Rosenthal and Tager,
1975). Carriage is higher in hospitalised patients than in healthy, non-hospitalised
individuals (Joly-Guillou and Brun-Buison, 1996), and subsequently, a high colonisation
rate of the respiratory tract is thought to be associated with outbreaks involving
mechanically-ventilated ITU patients (Buxton et al., 1978, Koljalc et a/., 1999). Contact
between hospital staff and patients colonised with A. baumannii is an important factor in
the spread and maintenance of infection outbreaks (Getschell-White et al., 1989).
Acinetobacter spp. are not considered to be highly virulent organisms, although they do
possess characteristics common to other Gram-negative bacteria that no doubt enhance
their virulence (Joly-Guillou and Brun-Buisson, 1996). They are however renowned for
their ability to survive in the environment in dry conditions for prolonged periods.
Environmental contamination during ITU outbreaks can be extensive and is usually in the
vicinity of infected or colonised patients (Allen and Green, 1987). Contaminated bedding
material and various equipment act as important reservoirs for the dissemination of
Acinetobacter spp. (Joly-Guillou and Brun-Buisson, 1996). More recently, it has been
suggested that vegetables may be a natural habitat of A. baumannii and may therefore
provide a route by which this species is introduced into the hospital setting (Berlau et al.,
1999). Acinetobacter spp. are also able to survive exposure to certain disinfectants that
are used routinely in hospitals, especially if the recommended concentration is not used
(Berry et al., 1990).
1.15 The resistance profile ofAcinetobacter spp.
The ability of Acinetobacter spp. to develop antibiotic resistance extremely rapidly may
have originated from their exposure to antibiotics in nature from soil antibiotic-producing
micro-organisms. In combination with the widespread use of antibiotics in the hospital
setting, this has resulted in the establishment of Acinetobacter as an increasingly
important nosocomial pathogen with a reputation for being extremely difficult to treat.
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In the 1950s and 1960s before selective pressure by broad-spectrum antibiotics had
become established in hospitals, Acinetobacter spp. were generally resistant to penicillin
and chloramphenicol, susceptible to the tetracyclines, and demonstrated variable
susceptibility to streptomycin, erythromycin and sulphonamides, depending on the species
(Bergogne-Berezin, 1996). However, by the 1970s, increasing rates of resistance were
observed, a trend that has continued ever since. Many acinetobacters are now resistant to
the majority of the most commonly used antibiotics including the aminopenicillins,
ureidopenicillins, narrow- and expanded-spectrum cephalosporins, and tetracyclines
(Bergogne-Berezin and Towner, 1996). They have also added many of the newer
antibiotics to this substrate range, with resistance rates to the fluoroquinolones,
broad-spectrum cephalosporins, tobramycin and amikacin on the increase (Seifert et al.,
1993; Vila et al., 1993; Acar and Goldstein, 1997). Generally, species other than
A. baumannii are more susceptible to antibiotics, and are less associated with nosocomial
infections (Traub and Spohr, 1989; Bergogne-Berezin and Joly-Guillou, 1985).
Until recently, the carbapenems have been effective antibiotics against multi-resistant
Acinetobacter spp. (Seifert et al., 1993; Vila et at., 1993). However, imipenem
resistance is now being reported with increasing frequency, particularly in A. baumannii
strains (Go et al., 1994; Tankovic et al., 1994; Itokazu et al., 1996; Hanberger et al.,
1999).
1.15.1 Antibiotic resistance mechanisms ofAcinetobacter baumannii
Multiple antibiotic resistance in A. baumannii clinical isolates is due to a number of
mechanisms at the disposal of this species (Table 1.1). Resistance to the carbapenems
however, has generated considerable interest and concern recently, primarily due to an
increasing number of reports describing P-lactamase-mediated resistance to this antibiotic
class.
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1.15.2 Mechanisms of carbapenem resistance
A decrease in outer membrane permeability remains the main mechanism of resistance
to this class in the majority of clinical strains. The outer membrane of Acinetobacter
is less permeable than that of P. aeruginosa, an organism renowned for its ability to
confer resistance by restricting the passage of antibiotics through its outer membrane
porins (Yoshimura and Nikaido, 1982). Sato and Nakae demonstrated that the
amount of porins present in an A. calcoaceticus strain was less than 5% of the total
outer membrane protein compared with 60% in E. coli, and that diffusion rates of the
carbapenems across the outer membrane were less than 2% ofE. coli, suggesting that
the inefficient permeability of the A. calcoaceticus outer membrane is due to the
presence of a small number of small-sized porins (Sato and Nakae, 1991). These
findings are in agreement with more recent studies involving imipenem-resistant
A. baumanmi isolates (Clark, 1996).
The PBPs of Acinetobacter spp. are unlike those of E. coli or P. aeruginosa and
have instead a higher degree of similarity with those of the genus Bacteroides
(Piddock and Wise, 1986). Studies investigating the roles of PBPs and carbapenem
resistance in this genus are somewhat lacking however, Gehrlein and colleagues have
reported an alteration of PBPs in clinical isolates of A. baumannii as a mechanism of
imipenem resistance (Gehrlein et al., 1991).
In 1985, a strain of A. baumannii that demonstrated resistance to imipenem was
isolated from a blood culture at the Royal Infirmary of Edinburgh. When the
|3-lactamase content of this strain was examined, an unidentified enzyme was
discovered in addition to a chromosomal cephalosporinase. Further studies revealed
that this (3-lactamase hydrolysed imipenem and azlocillin, which was surprising since
imipenem had not been in use in the hospital at this time. The P-lactamase was
subsequently named ARI-1 (Acinetobacter resistant to imipenem) (Paton et al.,
1993).
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Although initial conjugation studies failed to demonstrate the transfer or mobilisation
of the ARI-1 gene, Scaife and colleagues later demonstrated that it was indeed
plasmid-encoded by successfully transferring the gene from its original host to an
A. junii recipient, with visualisation of the same plasmid in both donor and recipient
strains (Scaife et al., 1995). An unusual characteristic of ARI-1 is that it appears to
be a serine active-site enzyme rather than a metallo-P-lactamase (Paton et al., 1993).
There have so far only been isolated reports ofmetallo-P-lactamases in Acinetobacter
(Perez, A. N. et al., 1996; Cornaglia et al., 1999; Da Silva and Peixe, 1999;
Afzal-Shah etal., 1999a).
Although the discovery ofARI-1 initially caused concern, it has not been found in any
other clinical strains to date. However, a number of other P-lactamases have since
been reported which have been linked to imipenem resistance (Table 1.1 ). The
worrying trend is that the majority of these enzymes are similar to ARI-1 in that they
are not metallo-P-lactamases but are instead serine active-site enzymes.
The geographical distribution of these carbapenemases is also rather worrying.
Acinetobacter clinical isolates isolated from a burns unit in London in 1996
demonstrated reduced susceptibilities to both imipenem and meropenem, and
subsequent studies revealed the presence of carbapenemase activity in these strains
(Weinbren et al., 1998). Subsequent reports are emerging of similar findings in
isolates from Argentina, Belgium, Hong Kong, Kuwait, Singapore and Spain
(Afzal-Shah et al., 1998).
These findings are complicated further by the discovery of an oxacillin-hydrolysing
P-lactamase from a clinical isolate ofA. baumannii that has been linked to imipenem
resistance (Hornstein et al., 1997). Moreover, this does not appear to be a one-off
report since similar P-lactamases have subsequently been identified in strains from
Argentina (Afzal-Shah et al., 1999b), and Spain (Bou and Martinez-Beltran, 1999),
and sequencing of the ARI-1 gene has revealed that this too is a molecular class D
p-lactamase (Donald et al., 2000). These enzymes appear to represent the next
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evolutionary stage in bacterial antibiotic resistance, since this class has never before
been associated with carbapenem resistance.
AIMS OF THIS THESIS
The main aims of this thesis were:
• To determine the extent of antibiotic resistance, in particular carbapenem
resistance, in clinical isolates ofAcinetobacter spp. collected world-wide.
• To identify and characterise the mechanism(s) of carbapenem resistance in
resistant isolates.
• To investigate the role of fluoroquinolones in the treatment of multi-resistant
Acinetobacter spp. and their mechanisms of resistance.
• To determine the efficacy of sulbactam as a potential therapeutic alternative






Table 2.1 contains clinical isolates ofAcinetobacter species investigated in this study.
Standard bacterial strains and standard P-lactamase-producing strains are listed in
table 2.2. The API 20NE identification system (Biomerieux, France) was used for
species identification.
2.2 Storage of strains
Bacterial strains were inoculated onto MacConkey agar plates and incubated at 37°C
overnight. Cryovials (Alpha Laboratories, Eastleigh, Hampshire) containing 900 pi of
nutrient broth (Oxoid, Basingstoke, Hampshire) were inoculated with 1 colony from
the plates, the suspension was vortexed and incubated at 37°C overnight. A 100 pi
volume of 50% sterile glycerol was added to each cryovial to give a final
concentration of 5%. The vials were mixed by vortexing and stored at -70°C.
2.3 Culture media
Unless otherwise stated, all media was sterilised by autoclaving at 15 lbs psi for 15
minutes.
2.3.1 Solid media
Nutrient agar, IsoSensitest (1ST) agar and MacConkey agar were all obtained from
Oxoid. They were prepared according to the manufacturer's instructions and
sterilised as described (section 2.3). The agar was allowed to cool to 50°C before
being poured into sterile petri dishes (Sterilin Ltd, Stone, Staffordshire) and allowed
to set. The plates were then stored at 4°C.
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Table 2.1 Clinical isolates ofAcinetobacter species and their sources
REFERENCE NUMBER SOURCE
779,780, 781, 782, 783, 784, 785, 786, 787, 788, Dr. C. Bantar, Dr. J. Smayevsky,
789, 790, 791, 883, 884, 885, 886, 887 Buenos Aires, Argentina
806, 807, 808, 809 Dr. J. Vila, Barcelona, Spain
811, 812, 813, 814, 815 ,816 Dr. J. Ling, Hong Kong
820 ,821, 822, 823, 824, 825, 826, 827, 829, 830, Professors Z. Gulay & D. Gur,
831, 832, 833, 834, 836, 837, 838, 839, 840, 841, Ankara, Turkey
843, 844, 847, 848, 849, 850,
860, 861, 862, 863, 864, 865, 866, 867, 868, 872, Dr. R. Lin, Singapore
873
2.3.2 Liquid media
Nutrient broth and 1ST broth from Oxoid were prepared according to the
manufacturer's instructions and sterilised as previously described. Luria Bertani (LB)
Broth was prepared by dissolving 10 g of tryptone (Difco Laboratories, Detroit,
Michegan), 5 g of yeast extract (Difco), and 1 g of glucose (Sigma Chemicals, Poole,
Dorset) in 900 ml of distilled water. The pH was adjusted to pH 7.0 with IN NaOH
(Sigma), the volume was adjusted to 1 litre with distilled water, and then sterilised as
previously described.
2.4 Reagents
All reagents were obtained from Sigma Chemicals unless otherwise stated.
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Table 2.2 Standard strains and (3-lactamase-producing strains
Strain Characteristics Source/Reference
E. coli NCTC 10418
P. aeruginosa NCTC 10662





A. baumannii 6B92 bla\n\-\ Paton etal., 1993
S. maltophilia ULA-511 blaL1 Felici etal., 1993
E. coli K-12 J62-2 blatem-1 S. G. B. Amyes*
E. coli J53-2 blasHv-i S. G. B. Amyes*
E. coli K12 blasm-3 S. G. B. Amyes*
E. coli K12 blasuv-5 S. G. B. Amyes*
E. coli K12 blaoxa-2 S. G. B. Amyes*
P. aeruginosaMl8 blajMp Dr Y. Arakawa
S. marcescens S6 blaSme-l Yang etal., 1990
E. cloacae NOR-1 bla^wc-K Nordman et al., 1993
Acinetobacter sp. BD413-2 ura\ SmR, Rif^ Juni and Janick, 1969
Acinetobacter &p. BD413-2
transconjugant
bla^si.\ Wendy Scaife, Dundee
University
*personal culture collection
2.5 Antimicrobial susceptibility testing
2.5.1 Antimicrobial agents
Table 2.3 lists the antibiotics and their suppliers. All compounds were dissolved in the
recommended diluents of the Working Party on Antibiotic Sensitivity Testing of the
British Society for Antimicrobial Chemotherapy (1991).
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Table 2.3 Antimicrobials and suppliers
Antimicrobial Supplier




Ciprofloxacin, Moxifloxacin Bayer UK
BRL 42715, Clavulanic acid, Nitrocephin SmithKline Beecham Pharmaceuticals
Ceftazidime, Grepafloxacin GlaxoWellcome
Imipenem Merck Sharp & Dohme
Meropenem Zeneca Pharmaceuticals
Rifampicin Marion Merrell Ltd
Sparfloxacin Dainippon, Japan
Tazobactam Lederle
Trovafloxacin, Sulbactam Pfizer Inc
Gentamicin David Bull Laboratories,
Warwick
2.5.2 Minimum Inhibitory Concentrations (MICs)
The minimum inhibitory concentrations of antibiotics were determined according to
the guidelines of the Working Party on Antibiotic Sensitivity Testing (1991, 1998a).
Bacterial strains were grown overnight at 37°C in 1ST broth and diluted in 0.9% saline
to give 107 colony-forming units per ml (cfu/ml). A Denley multipoint inoculator
(Denley, Surrey) was used to inoculate 1 p.1 of the diluted suspension onto agar plates
containing serially diluted antibiotics to give a final inoculum of 104 cfu/spot. The
recommended NCTC strains were included as controls (Working Party on Antibiotic
Sensitivity Testing, 1991).
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MIC values were defined as the lowest concentration of antibiotic that inhibited
visible bacterial growth after overnight incubation.
2.5.3 Disc sensitivity testing
This was performed and interpreted by Stoke's method (Holt and Brown, 1989) on
1ST agar. Antibiotic discs were supplied by Mast Laboratories Ltd, Liverpool.
2.5.4 Dose response curve
Bacterial cultures were challenged with increasing doses of antibiotic and the effect of
this on viability was determined. A 10 ml volume of 1ST broth was inoculated with
the strain of interest and incubated overnight at 37°C. The broth was diluted 1:50 in
0.9% saline and incubated with shaking (200 osc/min) at 37°C for 3 hours. A series
of 10 ml volumes of 1ST broth was prepared, each containing a doubling dilution of
the antibiotic, to give a range of 1-128 mg/L. An additional broth without antibiotic
was used as a control to obtain an initial viable count. Each broth was inoculated
with 100 pi of the diluted broth culture, including the antibiotic-free broth, of which
100 pi was removed and inoculated onto a MacConkey agar plate which was
incubated overnight at 37°C. The broths were incubated for 3 hours with shaking
(200 osc/min) at 37°C after which they were diluted in 0.9% saline and placed on ice.
Dilutions were inoculated onto MacConkey agar plates. The plates were incubated
overnight at 37°C and the percentage viability determined by relating the viable counts
to the initial count, which was taken as 100%.
2.5.5 Determination of combined bacteriostatic action by chequerboard
titration
Dilutions of antibiotics were incorporated into 1ST agar plates to give a series of
antibiotic combinations. Final concentrations for imipenem were 4, 8, 12, and
16 mg/L, and for sulbactam were 0.5, 1, 1.5, 2, 12, 18, 24, and 32 mg/L. Plates were
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also prepared which contained each antibiotic dilution alone, to verify MIC values of
the antibiotics. Representative strains were grown overnight in 1ST broth at 37°C.
The broths were diluted in 0.9% saline and the plates inoculated with the diluted
cultures as previously described (section 2.5.2). After overnight incubation, the MIC
values of each antibiotic combination were recorded. The combined activity was
expressed as the summed fractional inhibitory concentration (X TIC) which was
calculated as follows:
X FIC = MIC drug A in combination + MIC drua B in combination
MIC drug A MIC drug B
Synergy is indicated by a value of <0.7, addition by a value between 0.71-1.29 and
antagonism by a value of>1.3.
2.5.6 Time-kill assays
Representative strains were grown in 1ST broth overnight at 37°C. The overnight
culture was diluted 1:50 in 1ST broth and incubated for 3 hours at 37°C with shaking
(200 osc/min). MacConkey agar plates were inoculated with appropriate dilutions of
the log phase culture and incubated overnight at 37°C to obtain the viable count.
A series of tubes were prepared containing 1ST broth with appropriate antibiotic
combinations to which aliquots of each log phase culture were added. The tubes were
incubated at 37°C for a period of 5 hours. At 1 hour intervals during this period,
aliquots were removed from each tube and diluted in 0.9% saline. Each dilution was
used to inoculate MacConkey agar plates which were incubated overnight at 37°C.
Viable counts were determined after overnight incubation.
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2.6 Preparation of (3-lactamases
2.6.1 Small-scale preparation
Bacterial strains were inoculated onto nutrient agar slopes and incubated overnight at
37°C. The slopes were washed with 1 ml of 50 mM sodium phosphate buffer, pH 7.0
and the cell suspensions were transferred into bijou bottles. Cells were subjected to
ultrasonication (MSE Soniprep 150, MSE Instruments, Crawley) for 3 x 30 seconds
at an amplitude of 8 microns with constant cooling, and with a 1 minute cooling
period between each sonication. The cell lysate was cleared by centrifugation (MSE
Microcentaur centrifuge) at high speed (13 000 x g) for 10 minutes at 4°C. The
cell-free (3-lactamase extracts were stored at -20°C until required.
2.6.2 Large-scale preparation
The bacterial strain under investigation was grown in 10 ml of sterile nutrient broth
overnight with shaking (200 osc/min) at 37°C. A 1ml volume of the overnight broth
was added to 100 ml of pre-warmed nutrient broth in a 250 ml flask and incubated
overnight as previously described. Cells were harvested by centrifiigation at 6084 x g
(GS3 rotor, Sorvall® R.C-5B, Du Pont) for 15 minutes at 4°C. The cell pellet was
washed with 10 ml of 50 mM sodium phosphate buffer pH 7 0 and the suspension
centrifuged (H1000B rotor, Sorvall RT 6000D, Du Pont) at 1521 x g for 15 minutes
at 4°C. The pellet was resuspended in 4 ml of buffer and the P-lactamase content
released by ultrasonication and stored as previously described (section 2.6.1).
2.6.3 Induction of p-lactamases
The bacterial strain was grown overnight in 10 ml of nutrient broth as described in
section 2.6.2. This broth was added to 100 ml of pre-warmed nutrient broth in a
250 ml flask and incubated at 37°C with shaking (200 osc/min) for 90 minutes. At
this stage, imipenem was added at lA the strain's MIC as a P-lactamase inducer
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(Reid, 1986). After incubation for a further 2 hours, the cells were harvested, washed
and sonicated as previously described (section 2.6.2).
2.6.4 Preparation of P-lactamases for anion exchange column
The bacterial strain was grown in 10 ml of LB broth overnight with shaking (200
osc/min) at 37°C. The broth was added to 1 L of pre-warmed LB broth in a 2 L flask
and incubated overnight as previously described, and the culture was divided into 4 x
250 ml and centrifuged (GS3 rotor, Sorvall® RC-5B) at 6084 x g at 4°C. The cells
were washed and resuspended in 2 x 20 ml of 50 mM Tris-HCl buffer pH 8.2, and
centrifuged as previously described. The cell pellets were subsequently resuspended
in 2 x 5 ml of buffer and subjected to ultrasonication as previously described (section
2.6.1). The cell lysate was centrifuged (70.38 rotor, Sorvall Ultracentrifuge OTD
65B, Du Pont) at 32,000 x g for 1 hour at 4°C, and the supernatant containing
P-lactamase was removed and filtered by syringe through a 0.22 pm Durapore
membrane filter (13 mm diameter, Millipore). The extract was stored at 4°C until
ready to be applied to the column.
2.6.5 Detection of P-lactamase activity by the nitrocephin spot assay
A 30 pi volume of P-lactamase preparation was added to 100 pi of nitrocephin
(50 mg/L) in a microtitre plate. The colour change of the solution from yellow to red
indicated P-lactamase activity, and the time in seconds for this change to take place
was recorded.
2.7 Analytical isoelectric focusing (IEF)
P-lactamases were identified by IEF as described by Matthew et al. (1975). The
extracts were focused on a horizontal thin layer polyacrylamide gel containing
ampholines with a range of pH 3.5-10.
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2.7.1 Gel casting
Two glass plates were separated by rubber tubing placed along their perimeters, and
clamped together to form a casting chamber into which the gel solution was poured.
Prior to assembly, one of the glass plates was coated with a binding solution (0.5%
w/v gelatine, 0.5% w/v chromium potassium sulphate dodecahydrate), and dried at
55°C. This promoted adhesion of the gel to the glass. The other plate was siliconised
to permit easy separation of the polymerized gel.
Table 2.4 lists the components of the gel in the order they were added. Once the gel
solution had been poured between the glass plates, it was left to polymerise for at
least 4 hours.
Table 2.4 Composition of an IEF gel
Material Volume added (ml) Final concentration




100 g acrylamide plus 2.7 g
methylene bisacrylamide (BDH) in
300 ml distilled water
9.0
acrylamide - 75 g/L
bisacrylamide - 2 g/L
Riboflavin (20 mg/L) 4.0 2 mg/L
5% (v/v)TEMED* 0.2 0.005% (v/v)
*Tetramethyl-ethylenediamine
2.7.2 Loading IEF gels
The volume (pi) of P-lactamase preparation that was equivalent to its nitrocephin spot
test time, was applied to the gel surface close to the anode. A maximum of 15 pi of
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preparation was added per lane, P-lactamase preparations of known isoelectric points
(pis) were also applied to the gel in order to quantify the gradient.
2.7.3 Running conditions
Focusing was performed at 4°C, 500V (limiting), 1W (constant) and 20mA (limiting)
for 18 hours.
2.7.4 Pre-poured polyacrylamide gels
When a large number of P-lactamase extracts were to be analysed at one time,
pre-poured gels (Ampholine® PAGplate, Pharmacia Biotech, Uppsala, Sweden)
containing 2% (v/v) of broad range ampholines, pH 3.5-9.5 were used. The gel was
electrophoresed on a LKB 2217 Ultraphore Electrophoresis Unit (Pharmacia Biotech)
according to the manufacturer's instructions.
2.7.5 Visualisation of (3-lactamases after electrophoresis
P-lactamase activity was detected by soaking a piece of filter paper (Whatman® No. 1,
Whatman International Ltd, Maidstone) in nitrocephin solution (50 mg/L) and
overlaying the surface of the gel. The focused P-lactamases appeared as red bands on
a yellow background. Stained gels were photographed with a Polaroid camera using
a Tiffen green filter.
2.7.6 Inhibitor overlays
To detect P-lactamase inhibition, filter paper (Whatman® No. 1) was soaked in the
required concentration of inhibitor solution and laid over the gel surface. The gel plus
filter paper was incubated at 37°C for 5 minutes before the filter paper was removed
and the gel stained as described (section 2.7.5).
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2.8 Microbiological assays
2.8.1 Method of Paton et al., 1993.
This method as described by Paton et al (1993) was employed to detect P-lactamase
activity in extracts prepared as described in sections 2.6.1 and 2.6.2. The indicator
organism, S. aureus NCTC 6571 was grown in 1ST broth at 37°C overnight and
diluted in 0.9% saline to give an optical density of 0.2 at 550nm. The suspension was
spread onto an 1ST agar plate. An antibiotic disc containing the choice antibiotic was
placed in the centre of the plate. Filter paper discs containing 10 pi of (3-lactamase
extract either neat, or diluted 1:2, 1:4, or 1:8 in 50 mM sodium phosphate buffer pH
7.0, were placed at the periphery of the expected zone of inhibition (determined by
incubating a plate with indicator organism and antibiotic disc only). After overnight
incubation at 37"C, any growth of the indicator organism observed around the filter
paper discs was recorded.
2.8.2 Modified microbiological method
In order to quantify the hydrolysis of imipenem by (3-lactamase preparations
demonstrated by the microbiological assay (section 2.8.1), a modification of this
method was developed, p-lactamase preparations were incubated with antibiotic over
a period of 1 Vi hours. The concentration of imipenem remaining at several time
points within this period was subsequently determined from a standard graph from
which the rate of imipenem hydrolysis could be determined.
2.8.2.1 Preparation of standard curve of imipenem concentration against
diameter of inhibition zones
Molten 1ST agar was pipetted into 2 large (140 mm diameter) petri dishes (60 ml per
petri) and allowed to set. A 10 ml volume of 1ST broth was inoculated with a
standard strain of S. aureus (NCTC 6571) and incubated overnight at 37°C. The
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following day, the broth was standardised with 0.9% saline to give an optical density
of 0.2 at 550nm. The 1ST agar plates were subsequently inoculated with the
standardised culture and the surfaces were allowed to dry at room temperature.
Using a glass tube that had been sterilised in absolute alcohol, 3 holes were made in
the agar of each plate, and the cut agar was removed. A series of doubling dilutions
of imipenem was prepared (range 10~3 M to 0.312 x 10~6 M) in 50 mM sodium
phosphate buffer pH 7.5. Aliquots of 20 pi of each dilution were then added to the
appropriately labelled wells and the plates incubated overnight at 37°C. The following
day, the zones of inhibition were measured and recorded. The procedure was
repeated twice and the mean value of each zone size was plotted against imipenem
concentrations on a semi-logarithmic scale.
2.8.2.2 Determination of the rate of hydrolysis of imipenem by crude
3-lactamase extracts
A 250 pi volume of crude P-lactamase extract was placed in a sterile Eppendorf tube
to which 25 pi of imipenem 10"4 M was added to give a final antibiotic concentration
of 10° M. After mixing, a 25 pi volume was immediately transferred to a fresh
Eppendorf and incubated at 70°C for 4 minutes to inactivate the 3-lactamase. (The
time period and temperature for complete enzyme inactivation without degradation of
antibiotic were determined by incubating enzyme/antibiotic solutions at varying
temperatures over a period of 15 minutes). The sample was subsequently placed on
ice. The remaining enzyme/antibiotic solution was incubated at 37°C and after
15 minutes, another 25 pi aliquot was removed and incubated at 70°C for 4 minutes
before being placed on ice. This procedure was repeated at 15 minute intervals over a
1 Vi hour period. At the end of this time, the wells in the inoculated 1ST agar plates
were filled with 20 pi of the appropriate inactivated enzyme/antibiotic solutions.
Following overnight incubation at 37°C, the zones of inhibition were measured and
recorded. The relative concentrations of antibiotic remaining after each 15 minute
period during the 1 Vz hours were determined by plotting the zone sizes on the
standard graph. The concentrations obtained from this graph were subsequently
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plotted against time. The initial rate of hydrolysis was measured as nmoles of
imipenem hydrolysed/min. Specific activities were determined by calculating the
protein concentration of (3-lactamase extract by the method of Waddell (1956) as
described in section 2.12.2.
2.8.2.3 Determination of antibiotic instability
To confirm that the loss of antibiotic activity was due solely to hydrolysis by the
P-lactamase extract rather than to instability of the substrate, aliquots of a solution of
imipenem (1CT5 M) were incubated under the same conditions as the test solution and
added to the wells in appropriately labelled 1ST agar plates which had been seeded
with the S. aureus standard strain. The plates were incubated overnight at 37°C, after
which time the zone sizes were measured and any loss of activity as a result of
substrate instability was taken into account when calculating the rate of hydrolysis.
2.9 Conjugation studies
For both methods employed, donor (test strain) and recipient (Acinetobacter sp.
BD413-2) strains were grown independently in 4.5 ml of nutrient broth and incubated
overnight statically at optimum temperature. Matings were performed at 25°C and
37°C. Controls of each strain were prepared by inoculating 0.1 ml volumes of each
broth onto separate nutrient agar plates containing 4 mg/L of imipenem (to select
donor colonies) and 50 mg/L of rifampicin (recipient-selective). In addition, a total
viable count of the donor strain was performed by the technique of Miles and Misra
(1938). Both control plates and viable count plates were incubated at the same
temperatures as the mating mixtures.
2.9.1 Broth matings
Broth matings were performed as described by Amyes and Gould (1984). A 0.1 ml
volume of donor broth and 1.0 ml volume of recipient broth were added to 4.5 ml of
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pre-warmed nutrient broth, and incubated statically overnight at the designated
temperature. The mating mixture was vortexed to separate the conjugating pairs and
serially diluted in 0.9% saline. A 100 pi aliquot of each dilution was spread onto
antibiotic-containing nutrient agar plates selective for transconjugants (4 mg/L
imipenem and 50 mg/L rifampicin). The plates were incubated at the optimum
temperature overnight or until colonies were visible.
2.9.2 Membrane filter matings
Membrane filter matings were performed by the method of Willets (1988). Donor
and recipient strains were grown in 10 ml of nutrient broth overnight at the
appropriate temperature. After incubation, 0.2 ml of donor culture and 1.8 ml of
recipient culture were mixed together. The mixture was filtered through a 0.2 pm
pore cellulose acetate filter (Whatman), using a sterile 5 ml disposable tip and pipette.
Sterile forceps were used to place the filter onto a prewarmed nutrient agar plate
(cells uppermost), which was incubated at the designated temperature for 2 hours.
The filter was immersed in 2 ml of nutrient both which was subsequently vortexed to
resuspend the cells. Appropriate dilutions of the suspension were plated onto
selective plates and incubated for a suitable duration at the optimum temperature.
2.10 Plasmid elimination by ethidium bromide
To determine whether the genes of imipenem-hydrolysing |3-lactamases were
plasmid-encoded, strains were treated with ethidium bromide, which preferentially
inhibits plasmid synthesis (Bouanchaud et al., 1969). The bacterial culture was grown
overnight at 37°C in 10 ml of nutrient broth. The culture was diluted 1:100 in 0.9%
saline. Tubes of nutrient broth containing serial dilutions of ethidium bromide were
prepared. The range of dilutions was dependant on the tolerance of the strain to
ethidium bromide. If this was not known, the MIC was determined (section 2.5.2),
and the range was altered accordingly to include this value. The tubes were each
inoculated with 20 pi of diluted culture and incubated overnight at 37°C.
73
The tube that contained the highest concentration of ethidium bromide and
demonstrated visible bacterial growth was diluted 1:100 in 0.9% saline (to obtain
single colonies), and 100 pi of this suspension was inoculated onto 2 or 3 nutrient
agar plates. The plates were incubated overnight at 37°C. After incubation, a series
of 4.5 ml volumes of 0.9% saline were inoculated with between 40 and 50 distinct
colonies from the plates. Nutrient agar plates containing a sub-inhibitory
concentration of imipenem were inoculated with 10 pi of each saline suspension.
Control plates (no antibiotic) were also inoculated with the same volume. Following
overnight incubation at 37°C, the control plates were checked for bacterial growth.
The corresponding antibiotic plates were subsequently checked and those that showed
no visible growth were recorded. Loss of imipenem resistance was verified by
determining the MIC values (section 2.5.2) for colonies that had failed to grow on the
imipenem-containing plates. P-lactamase extracts were prepared from colonies that
demonstrated a reduction in MIC value, and analysed by IEF (section 2.7).
2.11 Purification of ^-lactamases by anion-exchange and gel filtration
by Fast Protein Liquid Chromatography (FPLC®) system
2.11.1 Partial purification of 3-lactamases by MonoQ HR 5/5
anion-exchange
Crude 3-lactamase extract was prepared as described in section 2.6.4 and a 8 ml
volume of this applied to a MonoQ anion-exchange column employing the FPLC*
system (Pharmacia). The column was run at a flow rate of 0.5 ml/min, and protein
was eluted in a 1 mM NaCl gradient (prepared in 50 mM Tris-HCl pH 8.2). Fractions
were collected in 1 ml volumes using an LKB 2070 Ultrorac II fraction collector
(Pharmacia), and were assayed with nitrocephin (section 2.6.5) to determine
P-lactamase activity. The presence of specific 3-lactamases in positive fractions was
determined by IEF. Fractions containing the P-lactamase of interest were pooled and
applied to a gel filtration column.
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2.11.2 (3-lactamase purification by Superdex 75 Hiload 26/60™ gel
filtration
A 7 ml volume of pooled fractions collected from the anion-exchange column was
applied to a Pharmacia FPLC Superdex 75 Hiload™ 26/60 gel filtration column
(capacity volume of approximately 80 ml). The column was run at a flow rate of
1.5 ml/min, and fractions were collected in 3 ml volumes which were subsequently
assayed for (3-lactamase activity as previously described. Isoelectric focusing was
performed on positive fractions to determine whether separation of (3-lactamases had
been successful.
2.11.3 Concentration of purified P-lactamases
Fractions collected from the gel filtration column that contained the P-lactamase of
interest were pooled together and concentrated using a VectaSpin Micro centrifuge
tube filter (Whatman) according to the manufacturer's instructions.
2.12 (3-lactamase assays
2.12.1 Substrate hydrolysis assays
Spectrophotometry analysis of P-lactamase hydrolytic activity of a range of p-laetam
antibiotics was performed using a double beam UV/V Lambda 2 spectrophotometer
(Perkin-Elmer). Assays were performed using 10mm path length cuvettes (Hellma) in
50 mM sodium phosphate buffer pH 7.0 at 37°C for a period of 5 minutes at the
wavelength (X) of maximal absorbance for each P-lactam (Table 2.5).
All substrates were freshly prepared prior to use. Penicillins and carbapenems were
assayed at 10° M, and cephalosporins and nitrocephin at 10"4 M (final
concentrations). Enzyme samples were kept on ice until ready to be used. Only the
initial linear phase of the reaction was used to calculate the change in absorbance rate,
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and all rates were related back to that obtained for a standard substrate (ampicillin),
the value of which was set at 100.













(3-lactamase activity was calculated as the amount of substrate hydrolysed (pinoles)
per minute per ml of enzyme sample by the following formula as described by Payne
and Farmer (1998).
AAbs min 1 x Vr/1000 x 1/Ve
AX X to-6
AAbs min"1 = rate of absorbance change Vr = volume of the reaction (ml)
AX = molar extinction coefficient of hydrolysis* Ve = volume of enzyme added
*The molar extinction coefficient was determined by measuring the absorbance of a
known concentration of ^-lactam at its optimal wavelength (Table 2.5).
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These values were inserted into Beer Lambert's equation to obtain the molar
extinction coefficient:
A = e c 1
where A = absorbance, e = molar extinction coefficient, c = concentration of P-lactam
measured, 1 = cuvette path length (cm)
2.12.2 Specific activities
The specific P-lactamase activity was calculated by determining the protein
concentration of P-lactamase sample (mg/ml) by the method of Waddell (1956). The
sample was diluted 1:1000 in 50 mM phosphate buffer pH 7.0 and the absorbance
measured at 215 nm and 225 nm. The difference in absorbance between the two
measurements was multiplied by the correction factor (168) determined by a
calibration curve with this spectrophotometer. Specific activity was expressed as
nmoles of substrate hydrolysed min"1 mg"1 protein.
2.12.3 Determination of Vmax and Km values
Values were determined by linear regression analysis of Lineweaver-Burk plots of the
initial velocity data obtained at different substrate concentrations (Lineweaver and
Burk, 1934). The assayed range of penicillins and carbapenems was 0.25-4 mM, and
0.025-0.4 mM for cephalosporins. Vmax is defined as the velocity of reaction
produced by a given enzyme concentration in vast excess of substrate. Ktn is the
Michaelis constant for a substrate, and is the substrate concentration that gives half
the maximum velocity. Values were obtained by plotting the reciprocal of substrate
concentrations against the reciprocal of the rate of hydrolysis.
2.12.4 Inhibition assays
The 1D50 value is defined as the concentration of inhibitor required to reduce the
hydrolytic activity of the P-lactamase by 50%. The P-lactamase was incubated with a
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range of inhibitor concentrations for 10 minutes at 37°C. A reporter substrate
(nitrocephin at 100 pM) was subsequently added and the initial rate of hydrolysis
determined as previously described. The ID50 values were determined by plotting the
percentage inhibition against logio concentration of inhibitor. The concentration of
inhibitor that gave 50% inhibition was calculated from this graph.
2.13 Determination of P-lactamase molecular mass (Mr) by Sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
Samples were mixed with an equal volume of SDS-PAGE sample buffer (stock = 4 ml
distilled water, 1 ml 0.5 M Tris-HCl, pH 6.8, 800 pi glycerol, 1.6 ml 10% (w/v) SDS,
400 pi P-mercaptoethanol, 200 pi 1% bromophenol blue), heated at 100°C for 5
minutes, and kept on ice until required for gel loading. A 35 pi volume of each
sample was loaded into the wells of a 4-15% linear gradient Tris-HCl Ready-Gel (Bio
Rad) in duplicate so that each half of the gel contained each sample. Low range
molecular weight markers (Bio Rad) were added to a well on one side of the gel only.
The gel was inserted into a minigel electrophoresis apparatus (Miniprotean" II,
Bio Rad) and electrophoresis was carried out at 200 V for approximately 30 minutes
or until the dye in the sample buffer had reached the end of the gel.
The gel was removed from its casing and cut in two using a scalpel. One gel halfwas
immersed in the non-ionic detergent, Triton X-100 (1% v/v in 50 mM Tris-HCl
pH 7.5) for 4 hours at 37°C to renature the [3-lactamases. The gel was then immersed
in nitrocephin (50 mg/L) until bands were visualised. The positions of the bands
(from the bottom of each well) and the gel length were measured (mm) and recorded.
The other gel half containing the molecular weight standards was stained in
Coomassie Blue (40% v/v methanol, 10% v/v acetic acid, 0.25% w/v Coomassie blue
R-250) with gentle shaking for % to one hour. The gel was transferred to a destaining
solution (40% v/v methanol, 10% v/v acetic acid in distilled water) and destained with
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gentle shaking for approximately 4 hours, or until the background became clear.
Destaining solution was replaced with fresh solution several times during this period.
As this procedure results in shrinkage, the gel was subsequently immersed in 20%
(v/v) glycerol until it resumed its original length.
2.14 N-terminal amino-acid sequencing of purified (3-Iactamase
All electrophoresis and electroblotting reagents were prepared in ultra pure
pyrogen-free water (MilliQPF, Millipore). Stains were filtered (Whatman " No. 1
filter paper) before use.
2.14.1 Native-PAGE of purified P-lactamase
A 10% polyacrylamide gel was prepared as follows:
15 ml of acrylamide (Phigel 2 29:1 acrylamide:bisacrylamide, Fisher Scientific)
25 ml MilliQ water
20 ml 0.25 mM tris/glycine pH 8.8
80pl TEMED
A small amount of ammonium persulphate was added with the tip of a spatula to the
above solution and mixed gently, avoiding the addition of air which affects the gel
matrix. The solution was poured into the preassembled gel apparatus (Protean II xi
Cell, Bio Rad). A 10 well comb was inserted, and the gel allowed to polymerise for at
least 45 minutes.
Samples were prepared by adding 8 pi each of bromophenol blue and 25% (w/v)
sucrose to 65 pi of purified p-lactamase and mixing gently.
The top chamber of the electrophoresis unit was filled with 0.1 M Tris/glycine pH 8 .8
containing 0.002 M thioglycolic acid, and the bottom chamber with 0.1 M
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Tris/glycine pH 8.8. Samples were loaded and electrophoresis was carried out at
250V for approximately 7 hours, or until adequate separation of protein bands had
been achieved.
After the gel had been removed from the electrophoresis apparatus, it was immersed
in nitrocephin (50 mg/L) and the positions of (3-lactamase bands were measured as
previously described (section 2.13). The gel was subsequently stained with
Coomassie blue (0.025% w/v Coomassie blue R-250, 25% v/v isopropanol, 10% v/v
acetic acid) overnight at 37°C, followed by destaining (16.5% v/v methanol, 5% v/v
acetic acid) with gently agitation until a relatively clear background was obtained.
The stained gel was photographed and the protein band(s) of interest (that
corresponded to those visualised by the activity stain) were noted.
2.14.2 Protein immobilisation
Proteins were transferred from the polyacrylamide gel onto a PVDF membrane
(ProBlot™, Applied Biosystems).
A piece of membrane was cut to the size of the gel and immersed in 100% methanol
for a few seconds. The membrane and the gel were subsequently equilibrated by
placing them in a glass dish containing electrophoresis buffer (25 mM Trizma base,
190 mM glycine, 20% v/v methanol) for 10 minutes. A Trans-BlotElectrophoretic
Transfer Cell (Bio Rad) was assembled as described by the manufacturer.
Electroblotting was carried out at 30 V overnight, after which the apparatus was
disassembled and the membrane removed from the transblotting sandwich.
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2.14.3 Protein detection
The membrane was stained (0.1% w/v Coomassie blue R-250, 50% v/v methanol,
1% v/v acetic acid in MilliQ water, filtered) for 30 minutes, followed by 2 x 5 minutes
destaining (50% v/v methanol) and 2x5 minutes washing in MilliQ water. The
membrane was placed between 2 sheets of filter paper (Whatman " No. 1) and allowed
to dry overnight.
2.14.4 N-terminal amino-acid sequencing
N-terminal amino-acid sequencing of the protein bands of interest was performed by
Edman degradation (Hayes et al., 1989) on an Applied Biosystems Procise
Sequencer.
2.15 Protein separation by Reversed-Phase High-Performance
Liquid Chromatography (RPHPLC)
The concentrated pooled fractions from the Superdex 75 column were subjected to
reversed-phase HPLC in an attempt to separate their protein content. A 200 pi
aliquot of the fractions was passed through a ABI 130 A Microbore HPLC system.
Solvents and running conditions used were as follows:
Cartridge: Aquapore RP300 C8 (7 pm particle size, 30 mm x 2.1 mm)
Solvent A: 0.1% Trifluoroacetic acid (TFA) in 0.1% TFA in water
Solvent B: 0.08% TFA in 70% acetonitrile
Running conditions - Gradient: linear 10-20% solvent B over 45 minutes
Flow rate: 200 pl/min
Chart speed: 2 mm/min
Wavelength: 220 nm
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Protein peaks were collected manually in sterile Eppendorfs, and centrifuged under
vacuum with cooling for approximately 4 hours, or until most of the solvent had
evaporated.
2.15.1 Native-PAGE of protein peaks collected from RPHPLC
Samples were diluted 1:3 in sample buffer and loaded on a 15% single gradient
Tris-HCl Ready Gel (Bio Rad). Electrophoresis was carried out as previously
described (section 2.13) and the gels were stained by silver stain (Pharmacia Biotech)
according to the manufacturer's instructions.
2.16 Preparation of DNA
2.16.1 Plasmid DNA extraction by alkaline lysis
The method used was a modification of the method described by Birnboim and Doly
(1979).
The bacterial strain was grown in 2 x 10 ml LB broths overnight at 37°C with
agitation (200 osc/min). The culture was transferred into 1.5 ml Eppendorfs and
centrifuged at 13 000 x g for 5 minutes. The supernatant from each Eppendorf was
removed by vacuum and discarded. The pellets were resuspended in 100 pi of
Solution I (25 mM Tris-HCl pH 8.0, 50 mM glucose, 10 mM Na2EDTA) by
vortexing to completely resuspend the cells. A 100 pi volume of freshly prepared
lysozyme (4 mg/ml in Solution 1) was added to each Eppendorf and mixed by
inverting, before placing on ice for 5 minutes. A 400 pi volume of freshly prepared
Solution II (0.2 M NaOH, 1% SDS w/v) was subsequently added to each tube. The
contents were mixed by inverting the Eppendorfs until the solution became
translucent. Following a period of 5 minutes on ice, 300 pi of Solution III (3 M
sodium acetate, pH 4.8) was added to each Eppendorf, the contents were mixed by
inversion and the Eppendorfs returned to ice for a further 20 minutes. The resulting
precipitates were pelleted by centrifugation at 13 000 x g for 15 minutes, after which
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the supernatant from each tube was pooled and transferred in 750 pi aliquots into
fresh Eppendorf tubes.
An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added to each
tube and the contents inverted for 2 minutes before being centrifuged at 13 000 x g
for 5 minutes. The clear top layer above the interface was removed from each tube,
pooled together and aliquoted in 750 pi amounts into fresh Eppendorf tubes. Ice-cold
propan-2-ol (450 pi) was subsequently added to each tube, the contents mixed by
inversion and stored on ice for 30 minutes, after which they were centrifuged at
13 000 x g for 10 minutes. The propanol was removed by vacuum and 1 ml of 70%
(v/v) ethanol (room temperature) was added to each Eppendorf and the contents
mixed by inverting several times. The tubes were centrifuged at 13 000 x g for 5
minutes and the supernatant removed by a vacuum pump and discarded. The tubes
were re-centrifuged at the same speed for a few seconds and any remaining ethanol
removed again by a vacuum pump. The DNA pellets were allowed to dry at room
temperature for at least 45 minutes. TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM
Na2EDTA) (50 pi) was added to one of the Eppendorfs to resuspend the DNA. The
contents of this tube were subsequently added to the second Eppendorf, and the
resuspension procedure repeated until all the DNA had been pooled together. The
DNA was stored at -20°C.
2.16.2 Extraction of chromosomal DNA
Genomic DNA was extracted using the Puregene" DNA Isolation Kit (Gentra
Systems) according to the manufacturer's instructions.
2.16.3 Rapid estimation ofDNA yield
The concentration of DNA prepared as described in sections 2.16.1 and 2.16.2 was
estimated by the ethidium bromide dot quantitation method as described in Unit 2.6 in
Current Protocols in Molecular Biology (Moore et al., 1995).
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2.17 Agarose gel electrophoresis
Electrophoresis was performed for the analysis of DNA (sections 2.16.1 and 2.16.2),
and to identify DNA fragments after enzyme restriction. This was usually performed
in 1% agarose gels.
2.17.1 Preparation of agarose gel
Electrophoresis grade agarose (Gibco BRL, Life Technologies, Paisley) was added to
1 x TAE buffer (10 x TAE stock: 400 mM tris-acetic acid pH 8.0, 20 mM Na2EDTA)
to give the required gel concentration (typically 1-2%). The agarose was dissolved
completely by heating in a microwave in 20 second bursts with gentle swirling
between heating. The agarose was allowed to cool to approximately 55°C before
carefully pouring into the gel casting tray into which a gel comb had been inserted
The gel was allowed to set completely before the comb was removed.
2.17.2 Sample loading and running conditions
The agarose gel was submerged in a horizontal electrophoresis tank (Mini-Protean" II
Sub-Cell, Bio Rad) which had been filled with 1 x TAE buffer so that the gel was
covered to a depth of about 1 mm. DNA samples (typically 10 pi) were mixed with
3 pi of 10 x loading buffer (10 x stock: 0.25% w/v bromophenol blue, 0.25% w/v
xylene cyanol, 40% w/v sucrose), and loaded into the wells with a pipette. DNA
molecular weight standards (either X Hind III fragments or 100 bp ladder, both from
Gibco BRL), were also loaded at a concentration of approximately 0.5 pg/lane.
Electrophoresis was performed at 100 V (constant). The power was turned off when
the bromophenol blue tracking dye in the loading buffer (which migrates at
approximately the same speed as DNA of size 0.5 kb) had migrated approximately %
the length of the gel.
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2.17.3 Staining and visualisation of DNA
Gels were immersed in ethidium bromide solution (0.5 mg/L) for between 10-30
minutes depending on the concentration of DNA being analysed. If necessary,
destaining was carried out with gentle agitation in distilled water to remove excess
ethidium bromide and reduce background fluorescence. DNA was visualised by
placing the gels on a UV transilluminator (UV Products) and photographed.
2.18 Restriction endonuclease digestion of DNA
The following components were pipetted into a clean Eppendorf tube:
x (0.1 DNA (0.1-4 pg DNA in distilled water or TE buffer)
2 pi lOx restriction endonuclease buffer (supplied with enzyme)
1-5 U restriction enzyme
x pi sterile distilled water (to give a total reaction volume of
20 pi)
The contents were mixed by pulsing in a microcentrifuge for a few seconds, and
incubated in a water bath at the recommended temperature for the enzyme used
(typically 37°C) for a minimum of 2 hours. The reaction was stopped by the addition
of 0.5 pi of 0.5 M Na2EDTA. DNA fragments were electrophoresed and visualised
as previously described (section 2.17).
2.19 Transformation of plasmid DNA into Acinetobacter sp. BD413-2
Transformation was carried out by the method of Cruze et al (1979). The naturally
competent strain, Acinetobacter sp. BD313-2 was grown overnight in 10 ml of LB
broth at 28°C with agitation (200 osc/min). The overnight broth (20 pi) was
inoculated into 20 ml of pre-warmed LB broth held in a 100 ml conical flask, and
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incubated at 28°C with agitation until the OD550 was between 0.3 and 0.4 (indicative
of mid-exponential growth phase). This culture (200 pi) was added to a sterile
Eppendorf to which the plasmid DNA had been added (approximately 50 ng in 50 pi
of sterile distilled water). The tube was incubated for 1 hour at 28°C with vigorous
shaking (300 osc/min), after which transformants were selected by inoculating 100 pi
of appropriately diluted culture onto selective media (32 mg/L rifampicin and 1 mg/L
imipenem). The plates were incubated at 28"C until colonies were visible.
2.20 DNA amplification by the Polymerase Chain Reaction (PCR)
2.20.1 Reaction volumes
PCR reactions were performed in total volumes of 100 pi. Approximately 25 ng of
template DNA was used per reaction. Table 2.6 lists the reaction components which
were added in that order to the DNA, in a sterile 0.5 ml thin-walled PCR tube
(Advanced Biotechnologies). Negative controls were also included, which comprised
a) all components minus template DNA, and b) all components minus primers. Once
all the components had been added to the tubes, the contents were mixed by pulsing
in a microcentrifuge for a few seconds and overlaid with 50 pi of sterile mineral oil to
prevent evaporation during the reaction.
2.20.2 Primer design
Primers were either designed with Primer 3 software
(http://www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi), or the sequences were
taken from previously published work. All primers were synthesized by Oswell DNA
Services (Southampton University, Southampton). Table 2.7 lists primers used for
PCR amplifications.
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2.20.3 PCR cycling parameters
PCR tubes containing the PCR reaction mixtures were placed in a Cyclogene Thermal
Cycler (Techne Ltd, Cambridge). The specific cycling parameters are given in Table
2.8. Primer annealing and extension temperatures varied depending on the GC
content and length of the primers.
Table 2.6 PCR reaction components
Component Stock concentration Volume added (pi) Final
concentration
10 x Taq Buffer* 100 mM Tris-HCl/ 10 lOmM /50 mM
500 mM KC1
MgCI2* 25 mM 10 2.5mM
dNTPs** 2 mM 10 0.2 mM
Primer 1 10 pmol/pl 1 10 pmol
Primer 2 10 pmol/pl 1 10 pmol
Sterile water make volume up to
100 pi
Taq DNA 5 U/pl 5 pi of 1:10 dilution 2.5 U
polymerase
*Supplied by Promega UK; **2 mM 4dNTP stock - 2 mM of each dNTP (Boehringer
Mannheim, Sussex) in TE buffer pH 7.5. Stored at -20°C in 0.5 ml aliquots
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2.20.4 Visualisation of PCR products
PCR product was carefully removed from the tube with a pipette inserted through the
oil layer. DNA was electrophoresed on a 1% agarose gel and visualised as previously
described (sections 2.17.2 and 2.17.3).
Table 2.7 Oligonucleotide primers used for PCR amplifications
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Table 2.8 Primer-specific cycling parameters
Primer pair DNA denaturation: primer Final extension cycle
annealing: extension
SHV-5' & SHV-3' 94°C - 5 min
Followed by:
95°C - 30 sec -
68°C - 30 sec
72°C - 50 sec „
1 cycle
| 30 cycles
72°C - 5 min
OXA-A & OXA-B 94°C - 1 min 7
60°C - 1 min '
72°C - 3 min v.^ 30 cycles
72°C - 5 min
Helen 3 & Helen 4 95°C - 5 min ~
60°C - 30 sec
72°C - 1 min _
Followed by:
95°C - 15 sec"
60°C - 30 sec 1
72°C - 1 min _
| 1 cycle
| 30 cycles
72°C - 5 min
GyrAl & GyrA2 96°C - 30 sec 0
55°C - 30 sec j
72°C - 2 min J
• 30 cycles
72°C - 5 min
ParCl & ParC2 96°C - 30 sec -j
61°C - 30 sec (
72°C - 2 min J^ 30 cycles
72°C - 5 min
IntA and IntB
Cassl and Cass2
94°C - 1 min 1
55°C - 1 min /■
72°C - 3 min J
■ 30 cycles
72°C - 10 min
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2.20.5 Purification of PCR products
Purification was performed using the QIAquick PCR Purification Kit (Qiagen, West
Sussex) according to the manufacturer's instructions.
2.20.6 Sequencing of PCR products
Sequencing of purified PCR products was performed by the dideoxy method on an
ABI Prism automated sequencer (Perkin-Elmer).
2.21 DNA:DNA hybridisation
2.21.1 DNA dot blotting
A piece of positively charged nylon membrane (Hybond™-N", Amersham Life
Science) was cut to an appropriate size and a grid of 0.5 cm x 0.5 cm squares marked
on the surface with a blunt pencil. The membrane was submerged in distilled water
for 10 minutes. Sample DNA was pipetted into sterile eppendorf tubes to which 1 M
NaOH and 200 mM EDTA, pH 8.2 were added to give a final concentration of 0.4 M
NaOH/10 mM EDTA. The samples were boiled at 100°C for 10 minutes to denature
the DNA, after which they were placed on ice. The wetted membrane was placed
over the top of a petri dish so that most of the membrane surface was freely
suspended. The DNA samples were centrifuged for 5 seconds and pipetted onto the
grid in 3 pi volumes which were allowed to dry before repeating the process. A total
of 9 pi of each DNA sample was applied to the membrane. The top right corner of
the membrane was cut to mark the orientation of the grid. The membrane was then
rinsed briefly in 2 x SSC (1:10 dilution of 20 x stock: 3 M NaCl, 0.3 M
Na3citrate.2H20, pH adjusted to 7.0 with 1 M HC1) and allowed to air dry.
90
2.21.2 Southern blotting using an alkali buffer
Restricted DNA was transferred from agarose gels and covalently linked to a
Hybond™ -N+ membrane by an alkaline transfer buffer as described in Unit 2.9 of
Current Protocols in Molecular Biology (Brown, 1995).
DNA samples were first restricted with an appropriate restriction endonuclease as
previously described (section 2.18), and subjected to electrophoresis on a 1% agarose
gel (section 2.17). Transfer of restricted DNA was carried out for a minimum of 2
hours with 0.4 M NaOH as the transfer solution. If dot blotted DNA was to be
incorporated onto the same membrane, this was carried out after the membrane had
been recovered from the alkaline transfer. The membrane was subsequently rinsed in
2x SSC and placed between 2 pieces of 3MM filter paper (Whatman '') to air dry.
2.21.3 Labelling of DNA probes
Table 2.9 lists the probes used in this study. PCR-amplified DNA was purified as
described in section 2.20.5, and the DNA concentration estimated as described in
section 2.16.3. An aliquot was diluted to approximately 25 mg/L and denatured by
boiling at 100°C for 5 minutes, then chilled on ice. The DNA fragments (50 ng of
DNA) were labelled with fluorescein-11-dUTP by the ECL Random Prime Labelling
System (Amersham Life Science) and stored at -20°C until required.
Oligonucleotides were labelled at their 3'-end with FI-dUTP by the ECL
3'-OHgolabelling System (Amersham Life Science). Approximately 100 x 10"12 moles
of oligonucleotide was labelled per reaction.
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(TGG AGA ACC AGA AAA CGG AT)
ARI-NB degenerate Conserved sequence of blaow genes
(YTC IAC CCA ICC IAC CCA CC)
ARI-2N degenerate N-terminal sequence ofARI-2 protein
(GIA ARA ARA AYA CIG CIC CIG
CIG)
2.21.4 Hybridisation procedure
Hybridisations with labelled probes were performed using either the ECL Random
Prime Detection System or the ECL 3'-01igolabelling and Detection System
depending on the probe type. The reaction stages requiring temperatures other than
room temperature were performed in a hybridisation incubator (Techne Hybridiser
HB-1D, Techne Ltd, Cambridge). For room temperature stages, membranes were
transferred to plastic boxes which were gently agitated (Mk V Orbital Shaker, LH
Engineering). A 20 ml volume of hybridisation buffer was used per membrane and
labelled probes were added at a concentration of approximately 20 ng/ml for gene
probes, and 10 ng/ml for oligonucleotide probes. Degenerate oligonucleotide probes
were used at a higher concentration of approximately 20 ng/ml.
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2.21.5 Post-hybridisation washes
The following stringency washes ( typically in 100 ml volumes) were carried out for




1x15 minutes at 50°C with 1 x SSC, 0.1% SDS
1x15 minutes at 60°C with 1 x SSC, 0.1% SDS
1x15 minutes at 60°C with 1 x SSC, 0.1% SDS





2x5 minutes at room temperature with 5 x SSC,
0.1% SDS
2x5 minutes at room temperature with 5 x SSC,
0.1% SDS followed by 1 x 15 minutes at 42°C with
1 x SSC, 0.1% SDS
2.21.6 Signal detection
Hybridisation signals were generated and detected as described in the appropriate
detection systems. Autoradiography film (Hyperfilm™ -ECL, Amersham Life
Science) was exposed initially for 30 min, and extended up to 5 hours depending on
the strength of the signal after the initial period.
2.21.7 Reprobing blots
Membranes were wrapped (wet) in SaranWrap and stored at -20°C after ECL
detection, making sure that they did not dry out. When reprobing was required,
membranes were rinsed in 5 x SSC for 5 minutes before a solution of 0.1% (w/v) SDS
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(which had been brought to the boil) at approximately 5 ml/cm2 membrane was
poured over them. The blots were left at room temperature for 2 hours and rinsed in
5 x SSC for 5 minutes. If reprobing was not to be carried out immediately, the
membranes were wrapped wet in SaranWrap and stored at 4°C.
2.22 Analysis of Restriction Fragment Length Polymorphism (RFLP)
patterns by Pulsed-Field Gel Electrophoresis (PFGE)
Restricted genomic DNA fragments were separated on a Contour-clamped
Homogenous Electric Field (CHEF) electrophoresis system (CHEF-II, Bio Rad)
according to the manufacturer's instructions.
2.22.1 Preparation of unsheared genomic DNA in plugs
Strains were inoculated into 10 ml of nutrient broth containing 0.5% yeast extract
(Oxoid) and incubated at 37°C overnight with agitation (200 osc/min). The cells were
harvested by centrifugation at 1521 xg(H 1000B rotor, Sorvall RT 6000D, Sorvall)
for 10 minutes at 4°C. After the supernatant had been discarded, the cell density of
each broth was standardised by resuspension in SE Buffer (100 mM NaCl, 25 mM
Na2EDTA, pH 7.5) to give a value of 1.0 OD at 590nm (Lambda 2
spectrophotometer, Perkin-Elmer).
Low melting agarose (Bio Rad) was added to SE buffer (a volume of 500 p.1 of buffer
per strain) to give a final agarose concentration of 2%. The solution was boiled at
100°C for 30 minutes and allowed to cool to 55°C. The standardised cultures
(500 p.1) were pipetted into sterile eppendorfs, and 500 p.1 of the molten agarose was
subsequently added to each one. The tubes were mixed well by inverting several
times and kept molten at 55°C. Plug moulds (Bio Rad) were wiped with ethanol and
sealed with tape at the bottom. Each culture/agarose mixture was carefully pipetted
into each mould to give a total of 5 plugs per strain. The moulds were then allowed
to set at 4°C for approximately 15 minutes, after which time the tape was removed
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from the bottom and the plugs carefully transferred into sterile bijou bottles by
pushing them through from the top of the mould with a sterile pipette tip.
2.22.2 Lysis of DNA in agarose plugs
A 2 ml volume of lysis buffer (1% N-lauroylsarcosine, 50 mM Na2EDTA, pH 9.5)
containing 0.5 mg/ml of Proteinase K was added to each bijou and plugs were
incubated at 56°C overnight in a shaking waterbath (Gallenkamp). After incubation,
the lysis buffer was removed and replaced with fresh buffer containing the same
concentration of Proteinase K, followed by another overnight incubation at 56°C.
This procedure was repeated and after removal of the lysis buffer, the plugs were
washed in 2 ml of TE buffer (10 mM Tris-HCl, 10 mM Na2EDTA, pH 7.5) for 30
minutes at 4°C. The wash stage was repeated a further 2 times with fresh TE buffer
used each time. The plugs were subsequently stored in TE buffer at 4°C until ready
for use. (Plugs were stored under these conditions for several months with no DNA
degradation if the TE buffer was replaced approximately every 6 weeks).
2.22.3 Digestion ofDNA in agarose plugs
DNA plugs were transferred into a sterile petri dish where an appropriate portion
(equivalent to the size of the well former being used) was cut using a sterile scalpel
blade. Each plug piece was carefully transferred to a sterile bijou into which 4 ml of
1 x KGB buffer (2 x stock: 200 mM potassium glutamate, 50 mM tris-acetate pH 7.5,
20 mM magnesium acetate, 100 ug/ml bovine serum albumine fraction V, 1 mM
(3-mercaptoethanol in Milliq) had been added. The bijoux were incubated at 4°C for
2-3 hours with at least 2 changes of 1 x KGB buffer during this period.
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The buffer was removed and the DNA plugs transferred to sterile Eppendorfs to
which the following components were added in that order:
47 pi ofMilliQ water
50 pi 2 x KGB buffer
1 pi lmg/ml BSA (Promega UK)
2 pi lOU/ul Apa 1 restriction endonuclease (Promega UK)
The contents were mixed well by gently tapping the sides of the Eppendorf several
times. The DNA was subsequently digested for 16 hours at 25°C, after which the
restriction mixture was removed and the plug pieces carefully transferred to sterile
20 ml universal containers. MilliQ water (approximately 10 ml) was added to each
universal to wash the DNA plugs. The universals were kept at 4°C for 1 hour, with at
least 1 change of distilled water during this period. Plugs were stored at 4°C until the
gel was ready to be loaded.
2.22.4 Preparation of agarose gel
The gel casting tray was wiped with absolute alcohol and assembled according to the
manufacturer's instructions (Bio Rad). Tris-Borate-EDTA (TBE) buffer (Sigma) was
diluted 1:10 to give a final concentration of x 0.5 in a 2 L volume. A 100 ml volume
of this dilution was aliquoted into a sterile 250 ml Duran bottle (Schott), into which
PFGE-grade agarose (Bio Rad) was added (final agarose concentration of 1%). The
agarose solution was boiled at 100°C for 30 minutes and then allowed to cool to
approximately 55°C. The cooled agarose (leaving approximately 2 ml in the bottle)
was carefully poured into the assembled casting tray and allowed to set for at least 45
minutes, with the remaining 2 ml kept molten at 55°C. The rest of the diluted buffer
was added to the electrophoresis cell (Bio Rad), and allowed to circulate with cooling
until it reached the required temperature.
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2.22.5 Loading of PFGE gel
Once the comb had been carefully removed from the gel, the plugs containing
restricted DNA were carefully inserted into the appropriate wells using a sterile
disposable plastic loop (Technical Service Consultants Ltd), ensuring that no air
bubbles were introduced. DNA Size Standards (A. ladder range 48.5-970 kbp,
Bio Rad) were also loaded into a well approximately half way along the gel. The
wells (including those with no DNA plugs) were filled with the molten agarose and
the gel was kept at 4°C until the agarose had set.
2.22.6 Running conditions
The gel was removed from the casting tray and placed in the electrophoresis cell. Gel
running conditions were as follows:
Initial pulse time 1 sec Run time 20 hours
Final pulse time 35 sec Voltage 200 V (6V/cm)
Ratio 1.0 Temperatue 14°C
2.22.7 Gel staining and visualisation of RFLP patterns
The gel was carefully removed from the electrophoresis cell and transferred to a
container to which 200 ml of ethidium bromide solution (0.5 mg/L) had been added.
Staining was carried out with gentle agitation for approximately 30-45 minutes,
followed by 2 x 15 minute washes in distilled water.
RFLP patterns were visualised on a UV transilluminator and photographed with a
Polaroid camera fitted with a Tiffen orange filter.
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2.22.8 Analysis ofRFLP patterns
The relatedness of patterns was compared by the GelCompar v.3.10 computer
program (Applied Maths, Kortrijk, Belgium). Photographs of RFLP patterns were
scanned (ScanJet 4c, Hewlett Packard), and the files exported into the GelCompar
program which generated a matrix of similarity coefficients between all pairs of strains
using the Dice coefficient. Patterns were also analysed manually using the criteria of
Tenover and Arbeit (1995).
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CHAPTER 3
DETERMINATION OF RESISTANCE MECHANISMS IN




A total of 18 clinical isolates were collected from 3 hospitals in Buenos Aires,
Argentina, all of which were reported to have reduced susceptibilities to imipenem
(Table 3.1). One of the hospitals (CEMIC) isolated 5 imipenem-resistant strains
within a 1 year period from October 1993 to November 1994. A year later, another 4
resistant strains were isolated, followed by an additional 4 in 1998. Three
imipenem-resistant strains were also isolated from another teaching hospital in 1994,
and another 2 from a geriatric hospital in the same year. Species identification by the
API 20NE system indicated that the majority of isolates belonged to the A. baumannii
complex.
3.2 Antimicrobial susceptibility testing
Table 3.2 lists the MIC values of a range of antibiotics tested against these isolates. A
high percentage of isolates were resistant to all of the antibiotics tested, with 100%
resistance demonstrated to amoxycillin, the (3-lactam/inhibitor combination of
amoxycillin and clavulanic acid, to ciprofloxacin, and to each of the cephalosporins
tested.
The majority of isolates (89%) had MIC values of imipenem above the recommended
breakpoint compared with 16% that had MIC values above the breakpoint for
meropenem. However, nearly 78% of those that were 'susceptible' to meropenem
had MIC values equal to the breakpoint. Gentamicin was the most effective antibiotic
tested, with 50% of the isolates remaining susceptible. One isolate (number 789) had
a similar resistance profile to the other strains; however, this strain was susceptible to
both carbapenems (Table 3.2).
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Table 3.1 Species identification and clinical details of Acinetobacter
isolates from Buenos Aires, Argentina
Isolate Identification Date of Isolation Hospital Source
779 A. baumannii 02/10/93 CEMIC Catheter site
780 A. baumannii 13/03/94 CEMIC Catheter site
781 A. baumannii 02/05/94 CEMIC BAL
782 A. baumannii 03/11/94 CEMIC BAL
783 A. baumannii 21/07/95 CEMIC BAL
784 A. baumannii 22/07/94 CEMIC Catheter site
785 A. baumannii 1994 Hospital de Clinicas BAL
786 A. baumannii 1994 Hospital de Clinicas BAL
787 A. junii 1994 Hospital de Clinicas Soft tissue
788 A. baumannii 21/08/94 Sanatorio Greyton Urine
789 A. baumannii 1994 Sanatorio Greyton BAL
790 A. baumannii 07/10/95 CEMIC BAL
791 A. baumannii 16/10/95 CEMIC BAL
883 A. baumannii 1995 CEMIC BAL
884 A baumannii 07/98-08/98 CEMIC BAL
885 A. baumannii 07/98-08/98 CEMIC BAL
886 A. baumannii 07/98-08/98 CEMIC BAL
887 A. baumannii 07/98-08/98 CEMIC Catheter &
blood culture
Abbreviations:
Teaching hospitals; CEMIC (Centro de Educacion Medica e Investigaciones
Clinicas), Hospital de Clinicas; Geriatric hospital, Sanatorio Greyton; BAL, bronchial
alveolar lavage
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CLD CTX CAZ IMP MER CIP GENT
779 >128 128 >128 64 4 8 4 >16 0.5
780 >128 128 >128 64 4 8 4 >16 0.5
781 >128 >128 >128 64 4 8 4 >16 0.5
782 >128 128 >128 64 4 8 4 >16 8
783 >128 >128 >128 32 4 16 8 >16 1
784 >128 >128 >128 32 4 16 4 >16 2
785 >128 >128 >128 32 4 32 4 >16 2
786 >128 >128 >128 64 4 8 4 >16 >64
787 >128 >128 >128 32 4 16 4 >16 1
788 >128 128 >128 64 4 8 8 >16 >64
789 >128 32 >128 >128 >128 0.25 0.5 >16 >64
790 >128 >128 >128 64 128 16 4 >16 >64
791 >128 >128 >128 32 4 32 8 >16 >64
883 >128 >128 >128 64 64 4 4 >16 >128
884 >128 >128 >128 >128 >128 8 4 >16 0.12
885 >128 >128 >128 >128 >128 8 4 >16 0.12
886 >128 >12.8 >128 >128 >128 8 4 >16 0.12
887 >128 >128 >128 >128 >128 8 4 >16 0.25
Abbreviations: AMOX; Amoxycillin, CO-AMOX; Co-amoxiclavulanic acid, CLD;
Cephaloridine, CTX; Cefotaxime, CAZ; Ceftazidime, IMP; Imipenem, MER;
Meropenem, CIP; Ciprofloxacin, GENT; Gentamicin. Recommended breakpoints
(mg/L) (Working Party on Antibiotic Sensitivity Testing, 1991 and 1998a): AMOX,
CO-AMOX; 8, CLD, CAZ; 2, IMP, MER; 4, GENT, CTX, CIP; 1.
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3.3 IEF analysis of carbapenem-resistant isolates
Crude small-scale P-lactamase extracts of strains with MIC values of 4 mg/L or above
of imipenem were prepared and analysed by isoelectric focusing. The
carbapenem-sensitive isolate (789) was also analysed by this method. The presence of
3 P-lactamases was revealed in the majority of imipenem-resistant strains (Figure 3.1
and Table 3.3). The first of these co-focused with a TEM-1 control at pi 5.4. The
second focused at high pis (>8.0) that were reminiscent of the chromosomal
cephalosporinases described by Hood and Amyes (1991).
Two unknown P-lactamase bands focused together at pis 6.5 and 7.0, the latter being
the predominant band. These bands did not resemble any of the known P-lactamases
that had been included as reference bands on the gel (Figure 3.1). Both the unknown
bands and the high bands of pi >8.0 were present in all isolates. The TEM-1-like band
of pi 5.4 was present in 11 of the 17 strains (Table 3.3). A TEM-l-like band was also
detected in the imipenem-sensitive isolate 789, along with a band of pi >8.0 however,
the bands of pis 6.5 and 7.0 were not present in this isolate.
The P-lactamase extract of a representative strain (790) that contained all 3
P-lactamases was subsequently loaded onto another IEF gel and electrophoresed
under the same conditions. The gel was then overlaid with inhibitor solutions to
detect loss of p-lactamase activity. This method, although not quantitative, provided
additional evidence for the presumptive identity of these enzymes.
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Figure 3.1 IEF gel of representative strain 790 demonstrating
P-lactamases present in clinical isolates ofAcinetobacter from
Argentina
1 2 3 4 5 6
Lane Strain P-lactamase(s)
1 E. cloacae NOR-1 NMC-A (pi 6.9)
2 S. marcescens S6 Sme-1 (pi 9.7)
3 A. baumannii 6B 92 ARI-1 (pi 6.65)
4 P. aeruginosaMl 8 Imp-1 (pi >9.5)
5 E.coliJ62-2 TEM-1 (pi 5.4)
6 A. baumannii 790 pis 5.4, 6.5, 7.0, >8.0
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Table 3.3 Distribution of (3-lactamase bands in clinical isolates of
Acinetobacter spp.
Carbapenem MICs (mg/L)
Isolate Imipenem Meropenem P-lactamase bands (pi)
779 8 4 7.0 (main band), >8.0
780 8 4 7.0, >8.0
781 8 4 7.0, >8.0
782 8 4 7.0 >8.0
783 16 8 5.4, 7.0, >8.0
784 16 4 5.4, 7.0, >8.0
785 32 4 5.4, 7.0, >8.0
786 8 4 5.4, 7.0, >8.0
787 16 4 5.4, 7.0, >8.0
788 8 8 7.0, >8.0
789 0.25 0.5 5.4, >8.0
790 16 4 5.4, 7.0, >8.0
791 32 8 5.4, 7.0, >8.0
883 4 4 7.0, >8.0
884 8 4 5.4, 7.0, >8.0
885 8 4 5.4, 7.0, >8.0
886 8 4 5.4, 7.0, >8.0
887 8 4 5.4, 7.0, >8.0
3.3.1 Inhibitor overlays
Table 3.4 lists the inhibitors and their specific inhibitory activities used in IEF
overlays. Although not an inhibitor per se, imipenem was included primarily to detect
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whether the P-lactamases were able to bind to this (3-lactam which, if found bound to
the active-site, would give an indication that it was a potential substrate.
Table 3.4 Characteristics of inhibitors and concentrations used as
overlays of IEF gels
Inhibitor Concentration Inhibitory affect
BRL 42715 100 pM Serine active-site P-lactamases
EDTA 1 mM Metal ion chelator - inhibits metallo-P-lactamases
Clavulanic acid 1 mM Class A but not class C P-lactamases (some
class D P-lactamases)
tmipenem 100 pM -
The activity of a standard TEM-1 P-lactamase (a class A serine active-site enzyme)
that was run as a positive control was inhibited by clavulanic acid and BRL 42715,
but not by EDTA, as expected (Figures 3.2 and 3.3). The P-lactamase extract of the
LI metallo-enzyme produced by S. maltophilia was also included and, as expected, its
activity was inhibited by EDTA only. Partial inhibition of this enzyme was detected
with imipenem. The TEM-1-like band of pi 5.4 in strain 790 was inhibited by
clavulanic acid and BRL 42715, but not by EDTA, indicating that this P-lactamase
was indeed TEM-derived. Imipenem had no effect on its activity, which suggested
that the carbapenem is not a substrate of this enzyme.
The bands of pi >8.0 focused rather weakly and therefore the inhibitory effects were
difficult to read. However, they appeared to be inhibited by BRL 42715, and partially
inhibited by imipenem, but not by EDTA. The bands of pi 6.5 and 7.0 were not
inhibited by EDTA, indicating that this P-lactamase was not a metallo-enzyme. This
was further substantiated by the inhibition of both bands by BRL 42715, an inhibitor
of serine active-site P-lactamases. P-lactamase activity was also inhibited by
imipenem, and partially inhibited by clavulanic acid. Although the latter result was
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inconclusive, the possibility that this enzyme was a class A could not be ailed out at
this stage. Inhibition by imipenem suggested that the enzyme was able to bind this
P-lactam, and suggested its possible role as a mechanism of carbapenem resistance in
those isolates that possessed this P-lactamase. Interestingly, the inhibitor profile of
this P-lactamase was very similar to that of the serine active-site carbapenemase
ARI-1 produced by strain 6B92 (Figures 3.2 and 3.3), which further supported this
hypothesis.
3.4. Microbiological assays
P-lactamase extracts from all isolates that were resistant to imipenem were subjected
to the microbiological assay using imipenem and meropenem antibiotic discs (both
10pg), to determine whether carbapenem inactivation occurred as a result of
P-lactamase activity. The ARI-1 carbapenemase was included as a positive control,
and the TEM-1 P-lactamase as a negative control. Loss of imipenem activity
(indicated by a reduction in the zone diameter around the discs containing the
P-lactamase dilutions), and meropenem activity (to a lesser extent) was demonstrated
with all 17 imipenem-resistant isolates and with ARI-1, but not with TEM-1 or isolate
789, the carbapenem-sensitive isolate (Figure 3.4). This suggested that the
P-lactamase(s) present in the imipenem-resistant isolates were able to hydrolyse and
inactivate the carbapenems.
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Figure 3.2 IEF demonstrating inhibitor overlays of P-lactamases in
strain 790
EDTA 1 mM Clavulanic 1 mM Control lanes
acid
Lane Strain P-lactamase
1 A. baumannii 6B92* ARI-1
2 A. baumannii 790* pi 5.4,6.5,7.0, >8.0
3 S. maltophiliaULA-511 LI
4 E. coli J62-2 TEM-1
5 As lane 1
6 As lane 2
7 As lane 3
8 As lane 4
9 As lane 1
10 As lane 2
11 As lane 3
12 As lane 4
*pl >8.0 P-lactamases not visible in this photograph
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Figure 3.3 IEF demonstrating inhibitor overlays of (3-lactamases in
strain 790
1 2 3 4 5 6 7 8 9 10 11 12
Control lanes Imipenem 100 pM BRL 42715 100 pM
Lane Strain (3-lactamase(s)
1 A. baumannii790 pi 5.4, 6.5, 7.0, >8.0
2 A. baumannii 6B 92 ARI-1
3 S. maltophiliaULA-511 LI
4 E. coh J62-2 TEM-1
5 As lane 1
6 As lane 2
7 As lane 3
8 As lane 4
9 As lane 1
10 As lane 2
11 As lane 3
12 As lane 4
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Figure 3.4 Microbiological assay demonstrating carbapenem
inactivation by crude P-lactamase extracts
IMIPENEM MEROPENEM
Strain 790 (representative strain)
Strain 6B 92 (ARI-1)
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3.5 Induction studies of (3-lactamases
Large-scale (3-lactamase preparations of strain 790 and 6B 92 were prepared from
broth cultures grown in the presence of imipenem at Vi their respective MIC values.
Aliquots of the broths were removed and the MIC values of imipenem determined.
The crude preparations were subjected to spectrophotometric analysis to determine
the hydrolysis rates of both nitrocephin and imipenem before and after induction.
These results are summarised in Table 3.5. There was no increase in MIC value
detected after the induction of either strain. Both induced strains had identical MIC
values to the non-induced cultures (16 mg/L for 790 and 8 mg/L for 6B 92). In
addition, spectrophotometric analysis did not demonstrate a significant difference in
the hydrolysis rates of nitrocephin for induced and non-induced cultures (Table 3.5).
Table 3.5 MIC values and rates of hydrolysis of induced and
non-induced cultures of strains 790 and 6B 92
Strain Imipenem Rate of hydrolysis (nmoles hvdrolvsed min 1 mg 1
MIC protein)
(mg/L) Nitrocephin Pre-incubation Imipenem
(10 4 M) imipenem (10 3 M)
790 16 8.39 0.32 ND (<0.1)
790 induced 16 11.33 0.68 ND (<0.1)
6B 92 8 62.43 0.33 ND (<0.1)
6B 92 induced 8 67.76 0.68 ND (<0.1)
S. maltophilia
ULA-511 (LI)
NT NT 8.36 16.09
ND = not detected; NT = not tested
ill
Direct hydrolysis of imipenem could not be detected by this method with both strains.
The crude P-lactamase extract of an LI-producing strain was therefore assayed as a
control to confirm that this was not as a result of inactivation of the imipenem.
The P-lactamase extracts were then incubated with imipenem for 10 minutes at 37°C
before determining the hydrolysis rates for nitrocephin. There was a dramatic
decrease in these rates with the P-lactamase extracts from both induced and
non-induced cultures of 790 and 6B 92. With strain 790, hydrolysis rates decreased
by 85% and 96% for induced and non-induced cultures respectively. Strain 6B 92
demonstrated a 99% reduction in nitrocephin hydrolysis with both induced and
non-induced cultures. Pre-incubation with imipenem and the P-lactamase extract of
the LI producer resulted in a decrease of nitrocephin hydrolysis of 48%. Although
direct imipenem hydrolysis could not be detected with the P-lactamase extracts of
strains 790 and 6B 92, the pre-incubation assays with imipenem suggested that
binding to imipenem had occurred, resulting in a loss of available enzyme and a
subsequent decrease in the rate of nitrocephin hydrolysis.
3.6 Modified microbiological assay of crude extracts from strain 790
and strain 6B92
The crude P-lactamase extract of strain 790 did not appear to hydrolyse imipenem
spectrophotometrically over a 5 minute period. Therefore the microbiological assay
was adapted to determine whether slow hydrolysis occurred over a longer period of
time. Crude P-lactamase extracts of strain 790 and 6B 92 were subjected to the assay
as previously described. The rate of imipenem hydrolysis by strain 790 was
0.75 nmoles hydrolysed min mlof sample and the specific activity was calculated
as 0.055 nmoles hydrolysed min mg of protein. Crude extract from strain 6B 92
which produces the ARI-1 carbapenemase, hydrolysed imipenem at a rate of
0.5 nmoles hydrolysed min ml"1 of sample. The specific activity was calculated as
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0.043 nmoles hydrolysed min _1 mg of protein. Thus, crude (3-lactamase extracts
from both strains hydrolysed imipenem slowly at comparable rates.
3.7 Elimination of plasmid-determined resistance by treatment with
ethidium bromide
The results of the microbiological assays suggested that carbapenem resistance in
strain 790 and indeed in the other carbapenem-resistant isolates, may be associated
with (3-lactamase activity. Strain 790 was therefore subjected to treatment with
ethidium bromide to investigate this hypothesis further. Strain 6B 92 which produces
the plasmid-encoded ARI-1 (3-lactamase, was included as a positive control.
Following treatment, 14/38 (36.8%) of colonies of strain 790 failed to grow on 1ST
agar plates containing a sub-inhibitory concentration of imipenem, which suggested
that they had been cured of imipenem resistance.
A similar cure rate was obtained with colonies of 6B 92 (16/39, or 41%).
Antimicrobial susceptibility tests of strain 790 cured colonies confirmed that the MIC
value of imipenem had decreased to a susceptible level (Table 3.6). None of the other
P-lactams tested had been affected by curing, as indicated by similar MIC values for
both cured and parent colonies. These findings suggested that the genetic determinant
responsible for carbapenem resistance was associated with a plasmid.
113
Table 3.6 MIC values of cured and parent colonies of strain 790
following treatment with ethidium bromide
MIC values (mg/L)









3.7.1 Analysis of the P-lactamase content of cured strain 790 by IEF
Crude P-lactamase extracts of several of the cured colonies were subjected to
isoelectric focusing to ascertain whether loss of carbapenem resistance was associated
with the loss of the unknown p-lactamase. All the assayed extracts had lost the
P-lactamase bands at pi 6.5 and 7.0 (Figure 3.5), which provided strong evidence that
this p-lactamase was indeed associated with plasmid-mediated carbapenemase
activity. Both the TEM-1 P-lactamase and the cephalosporinase were still present in
the extract from the cured colonies.
3.7.2 Microbiological assays of cured colonies of strain 790
To determine whether carbapenem inactivation was diminished after loss of the
p-lactamase of pi 7.0, a crude p-lactamase extract of cured strain 790 was subjected
to the microbiological and the modified microbiological assays. The extract failed to
inactivate both carbapenems as determined by no reduction in the zone of inhibition
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around the discs (Figure 3.5). In addition, there was an 11-fold decrease in the rate of
imipenem hydrolysis with the P-lactamase extract of the cured strain compared with
the parent (0.067 compared with 0.75 nmoles hydrolysed min"1 ml"1 of sample). There
was also a corresponding reduction in the specific activity, calculated at 0.005
compared with 0.055 nmoles hydrolysed min"1 mg"1 of protein. These results provided
further evidence that the P-lactamase of pi 7.0 lost after treatment with ethidium
bromide was indeed associated with carbapenem resistance.
3.7.3 The effect of BRL 42715 on the MIC values of the carbapenems in
strain 790
It now appeared that there was a novel carbapenemase present in the 17 isolates from
Argentina. The curing results did not rule out the possibility however, that changes in
outer membrane permeability or alterations in PBPs could still be contributing factors
to carbapenem resistance. This was investigated by combining the serine active-site
inhibitor BRL 42715 with both carbapenems in susceptibility tests (Table 3.7).
The results demonstrated a significant decrease in the MIC values of the
imipenem/inhibitor combination obtained with the parent strain to a level comparable
with the imipenem MIC value for the cured strain. There was not as significant a
decrease in the MIC value ofmeropenem in the presence of the inhibitor. These results
provided further support for the existing evidence that p-lactamase activity, and not
changes in outer membrane permeability, was the major factor responsible for imipenem
resistance. Furthermore, there was no significant change in MIC values observed with
the cured strain, indicating that carbapenemase activity was not associated with the
TEM or cephalosporinase present in this strain. The P-lactamase of pi 6.5 and 7.0 was
subsequently designated ARI-2.
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Figure 3.5 IEF gel and microbiological assay of crude (3-lactamase
extracts from parent and cured colonies of strain 790
plpff
* pi >8.0
Loss of bands at pi
6.5 and 7.0
pi 5 .4 (TEM-1)
mmm
Parent Cured
Parent - carbapenem inactivation Cured - no inactivation
(imipenem shown)
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Table 3.7 MIC values of the carbapenems alone and in combination
with BRL 42715
MIC values (mg/L)
Strain Imp Imp/BRL Mero Mero/BRL
790 parent 16 0.25 8 4
790 cured 0.5 0.25 1 1
Abbreviations: Imp; Imipenem, Imp/BRL; imipenem/BRL 42715 (4 mg/L fixed
concentration), Mero; Meropenem, Mero/BRL; Meropenem/BRL 42715 (4 mg/L)
3.8 Partial purification of the ARI-2 (3-lactamase
In order to ascertain the kinetic properties of ARI-2, anion-exchange and gel filtration
chromatography were employed in an attempt to separate this enzyme from the other
(3-lactamases present in strain 790. A large-scale (3-lactamase preparation of this strain
was passed through a Mono Q anion-exchange column and fractions that displayed
(3-lactamase activity by the nitrocephin spot test were pooled and analysed by IEF
(Figure 3.6). The ARI-2 and TEM-1 (3-lactamases were detected in the first 13 ml
volume eluted from the column before the NaCl gradient had been applied. These
fractions also contained the cephalosporinase, although most of this (3-lactamase
remained bound to the column and was subsequently eluted in fractions 23-26 at
approximately 125 mM NaCl.
Fractions 1-13 were applied to a Superdex 75 gel filtration column, and fractions were
assayed for (3-lactamase activity as previously described. Activity was demonstrated in
pooled fractions 11-20 and in 29-40, which were both subjected to isoelectric focusing
to determine their (3-lactamase content. Both TEM-1 and ARI-2 were detected in
fractions 29-40 (Figure 3.6). As the cephalosporinase was not present in these
fractions, it was assumed that it would be present in fractions 11-20 however, this was
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not apparent by IEF even though these fractions demonstrated (3-lactamase activity by
the nitrocephin spot test.
Figure 3.6 IEF of fractions collected from anion-exchange and gel
filtration chromatography columns






1 1-13 from anion-exchange (unbound)
2 23-26 from anion-exchange (bound)
3 Strain 790 crude (3-lactamase extract
4 Empty lane
5 11 -20 from gel filtration
6 29-40 from gel filtration
3.8.1 Estimation of the molecular weight ofARI-2 by SDS-PAGE
Fractions 29-40 collected from the gel filtration column were subjected to SDS-PAGE
to determine the molecular weight of the ARI-2 (3-lactamase. As this procedure
resulted in protein denaturation, the portion of the gel that contained the fractions was
subjected to treatment with the non-ionic detergent Triton X-100 after electrophoresis,
which returns protein molecules to their original conformation. The gel could then be
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stained with nitrocephin to visualise the P-lactamases. Two diffused P-lactamase bands
were visualised in close proximity to each other in fractions 29-40, which corresponded
to those detected in the sample of crude extract that was included as reference (Figure
3.7). The molecular weights of these bands were determined by plotting a graph of the
molecular weight of standard proteins (that had been electrophoresed on the other half
of the gel and stained with Coomassie blue) against their migration distances through
the gel. The molecular weights of the TEM-1 and ARI-2 p-lactamase bands were
subsequently extrapolated from the graph. The molecular weight of the lower band
was estimated as 29.8 kDa, and the band above it as 35.5 kDa. Surprisingly, a third,
less prominent band which had not been detected by IEF, was also visible in these
fractions, and which corresponded to the third P-lactamase band in the crude extract.
The estimated molecular weight of this band was 53 kDa, and it was assumed to be the
high molecular weight cephalosporinase. The band of 29.8 kDa was similar in weight
to TEM-1, therefore the remaining band of 35.5 kDa was the ARI-2 P-lactamase.
As Figure 3.7 demonstrates, the TEM and ARI-2 P-lactamases proved to be close in
molecular weight, which was probably the main reason why several attempts to
separate them by chromatographic means had proved unsuccessful. In an attempt to
circumnavigate this problem, the other 16 isolates were once again analysed to
determine whether any of them expressed the ARi-2 P-lactamase to a comparable high
level as strain 790, but also lacked the TEM P-lactamase. Strain 788 met these criteria
and was subsequently used for further purification studies.
3.8.2 Partial purification ofARI-2 from strain 788
A 5 ml volume of a large-scale crude P-lactamase extract from strain 788 was passed
through the Mono Q anion-exchange column as previously described. Fractions 2-9
contained predominantly the ARI-2 p-lactamase, but also some of the
cephalosporinase. The majority of the latter enzyme, however, had bound to the
column and was eluted in fractions 28-36 at approximately 120 mM NaCl. Fractions
2-9 were subsequently pooled and applied to the Superdex 75 gel filtration column.
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Figure 3.7 Nitrocephin activity stain of SDS-PAGE gel of fractions




1 Fractions 29-34 Red arrow indicates position of 3rd band
2 Empty lane - *activity band due to carryover from lane 1
3 Crude P-lactamase extract from strain 790
IEF analysis of fractions collected from the column revealed that fractions 29-34 (which
equated with eluate volumes of 123 ml and 131 ml) contained only the ARI-2
P-lactamase. Fractions 58-61 (eluate volumes of 167 ml and 172 ml) contained the
cephalosporinase (Figure 3 .8).
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Figure 3.8 IEF gel of fractions collected from Superdex 75 gel
filtration column
ARI-2
Lane 1; Fractions 29-34, lane 2; fractions 58-61, lane 3; crude P-lactamase extract of
strain 788
3.9 Biochemical characterisation of ARI-2
The ARI-2 P-lactamase in fractions 29-34 was concentrated as previously described
(section 2.11.3), and the rates of hydrolysis of a range of substrates, by the P-lactamase
were determined by spectrophotometry. The specific activities were determined as
previously described (section 2.12.2). Vmax and Km values were calculated from
Lineweaver-Burk plots of initial velocity data. Ampicillin was the best substrate
(specific activity of 36 nmoles hydrolysed min"1 mg"1 of protein compared with 1.9
nmoles of cephaloridine hydrolysed min"1 mg"1 of protein), which indicated that ARI-2
was predominantly a penicillinase. None of the cephalosporinases were hydrolysed,
with the exception of cephaloridine. Interestingly, imipenem hydrolysis was detected
with the purified enzyme extract. Although hydrolysis was slow, the enzyme had the
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highest affinity for this substrate (km value of 11 pM). No hydrolysis ofmeropenem was
detected. Slow hydrolysis of both oxacillin and cloxacillin was also observed.







V d▼ max Kme RelativeVmax/
Km
Ampicillin 1923 100 36 1498.5 24 100
Cephaloridine 104 5.4 1.9 149.2 77 0.03
Cefuroxime ND (<0.1) - - - - -
Cefotaxime ND (<0.1) - - - - -
Ceftazidime ND (<0.1) - - - - -
Imipenem 125 6.5 4 46.8 11 0.068
Meropenem ND (<0.1) - - - - -
Oxacillin 61 3.2 1.3 484.1 531 0.015
Cloxacillin 64 3.3 1.2 31.9 129 0.004
a
- nmoles of substrate hydrolysed min ml 1 of enzyme solution
b
- relative to ampicillin (100%)
c
- nmoles of substrate hydrolysed min mg of protein
d
- nmoles min ml"1
e- pM
ND = not detected
3.9.1 Inhibitor studies
Purified ARI-2 was pre-incubated for 10 minutes at 37°C with varying concentrations
of inhibitor. Table 3.9 shows the concentration of each inhibitor required for 50%
inhibition of enzyme activity (ID5o).
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Table 3.9 ID50 values of inhibitors using nitrocephin (lOOpM) as
reporter substrate





Sodium chloride 3.2 mM
Imipenem 2.5
Meropenem 0.004
The metal ion chelator EDTA (10 mM) did not affect the activity of ARI-2, indicating
that it was not a metallo-enzyme. Unfortunately, BRL 42715 was not available when
these inhibitor studies were performed however, the IEF overlay of ARI-2 with this
inhibitor (100 pM) completely inhibited its activity which, in addition to the lack of
inhibition by EDTA, confirmed that it was a serine active-site (3-lactamase (section
3.3.2). Sulbactam proved to be a more efficient inhibitor of en2yme activity than
clavulanic acid. The class C inhibitor cloxacillin was not a good inhibitor of enzyme
activity.
Enzyme activity was inhibited by chloride ions (ID5o value of 3.2 mM sodium chloride).
Both imipenem and meropenem achieved 50% inhibition at 2.5 pM and 0.004 pM
respectively, which indicated high affinity ofARI-2 for the carbapenems.
3.10 Attempts to visualise the plasmid carrying the blaari-2 gene
Plasmid DNA from both parent and cured colonies of strain 790 were subjected to
restriction endonuclease digestion with Hind III enzyme as described in section 2.18.
Following restriction, visualisation of fragments along with unrestricted plasmid DNA
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demonstrated the presence of a DNA band in the parent strain that was not visible in
the cured strain (Figure 3.9). This suggested that elimination of this plasmid was
associated with a concurrent reduction in carbapenem MIC values to susceptible levels,
and loss of the ARI-2 P-lactamase.
From the migration distances of the fragments, the plasmid visualised in strain 790 was
estimated to be approximately 40 kb, although this was probably an underestimate since
many of the fragments were difficult to visualise. However, when the plasmid was
viewed alongside the />/aARi-i-containing pUK1356 plasmid of the Acinetobacter sp.
transconjugant (Figure 3.12), this estimate compared favourably with the latter, which
is approximately 58 kb in size.
Figure 3.9 Visualisation of plasmid DNA obtained from parent and
cured colonies of strain 790
1 2 3 4 5
Lane 1; plasmid DNA from strain 790, lane 2; 790 restricted with Hind III, lane 3;
plasmid DNA from cured strain 790, lane 4; cured 790 restricted with Hind III,




3.11 Analysis of the mechanism of plasmid transfer
3.11.1 Conjugation studies
A series of conjugation experiments were performed using the rifampicin-resistant
recipient Acinetobacter sp. BD413-2 in an attempt to determine whether the plasmid
observed in strain 790 was conjugative. For both broth and membrane filter mating
experiments at both mating temperatures, no transconjugant colonies were visible on
nutrient agar plates containing imipenem at 4 mg/L and rifampicin at 50 mg/L.
3.11.2 Transformation ofAcinetobacter sp. BD413-2 with plasmid DNA of
A. baumannii strains 788 and 790
Following the failure to demonstrate conjugative transfer of the plasmid, plasmid DNA
from strains 788 and 790 were used in an attempt to transform a naturally competent
plasmid-ffee strain of Acinetobacter (BD413-2) according to the method described in
section 2.19. For both plasmid DNA preparations, no colonies were visible on the
selective 1ST agar containing 32 mg/L of rifampicin and 1 ml/L of imipenem even after
a prolonged incubation period of 72 hours.
3.12 Investigation of the characteristics of blaxm-i
A series of PGR reactions were employed to investigate whether there were any
homologous DNA regions shared between the gene encoding the ARI-2 gene and other
P-lactamases.
3.12.1 PCR analysis with SHV-specific primers
Interestingly, it had been observed by IEF that the ARI-2 p-lactamase focused at an
identical pi value to that of the SHV-3 P-lactamase (main band of pi 7.0). The
biochemical analysis of ARI-2 had not indicated that it was SHV-derived; however,
125
PCR amplification with SHV-specific primers, and DNA hybridisation with an SHV
gene probe were performed to rule out this possibility. Both experiments revealed no
sequence homology, which demonstrated that ARI-2 was not an SHV P-lactamase.
Attention was subsequently directed towards other P-lactamases.
3.12.2 PCR analysis with OXA-specific primers
The biochemical profile of ARI-2 had revealed that it hydrolysed both oxacillin and
cloxacillin albeit slowly therefore, the possibility existed that it could potentially be
related to the molecular class D P-lactamases. PCR amplification was subsequently
performed with intragenic primers that had been designed from the bla0xA-2\ sequence
of the oxacillin-hydrolysing P-lactamase OXA-21, which shares an identical pi to that
of ARI-2. As the former enzyme had also been found in a clinical isolate of
A. baumannii, the possibility existed that the ARI-2 P-lactamase could be a mutated
form of this enzyme that had acquired the ability to hydrolyse imipenem.
Template DNA from strain 788, and from both parent and cured colonies of strain 790
was included in the reaction. Both OXA-21 and OXA-2 possess the non-silent
mutation Ile-217 to Met (Vila et al., 1997a) therefore, an OXA-2-producing strain
(E. coli K12) was used as a positive control. The imipenem-sensitive strain 789 and a
TEM-1-producing strain (E. coli J62-2) were included as negative controls. Gel
electrophoresis of PCR products revealed the expected band of 550 bp with the
OXA-2-producing strain (Figure 3.10). No bands were visualised with strains 788, 790
or with the negative control strains.
3.12.3 PCR analysis with ARI-1-specific primers
To investigate the degree of homology (if any) between the ARI-1 and ARI-2
p-lactamase genes, template DNA from strains 788 and 790 was subjected to PCR
analysis with ARI-1-specific primers. The primers (Helen 3 and Helen 4) amplified a
fragment of 513 bp within the bla.ua-i gene. Strains 6B 92 and Acinetobacter sp.
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BD413-2 transconjugant were included as positive control strains. A
TEM-1-producing strain (E. coliJ62-2) and the imipenem-sensitive clinical strain 789
were also included as negative controls.
A PCR product of the anticipated size was obtained with both the clinical and
transconjugant strains containing ARI-1 as expected. No products were visualised with
strains 788 and 790, or with either of the negative controls (Figure 3.11).














A. baumannii strain 788
A. baumannii strain 790
Cured strain 790
Empty lane
Strain 789 (imipenem-sensitive) - negative control
E. coli J62-2 (TEM-1 producer) - negative control
E. coli K12 (OXA-2. producer) - positive control
100 bp A, ladder
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1 A. baumannii 6B 92
2 Acinetobacter sp. BD413-2 transconjugant
3 A. baumannii strain 788
4 A. baumannii strain 790
5 A. baumannii strain 789 (imipenem-sensitive)
6 E. coli J62-2 (TEM-1 producer)
7 Primer control (no DNA template)
8 100 bp X ladder
3.12.4 PCR amplification with ARI-l-specific primers utilising reduced
annealing temperatures
A series ofPCR reactions was performed with lower annealing temperatures in order to
reduce primer specificity and encourage their annealing to DNA sequences of lower
homology. If this proved successful, and such DNA sequences were amplified, the
possibility existed that one of the products may have been generated from the template
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DNA of strain 790. If this was the case, there was a chance (although somewhat slim)
that the product would contain the ARI-2 gene.
An annealing temperature range of 50°C-33°C was employed. However, no products
were visualised other than the anticipated product of 513 bp from the ARI-1 -containing
strains.
3.12.5 Hybridisation with intragenic gene probe for
PCR amplification of bla^.\ was performed with template DNA from the
Acinetobacter sp. BD413-2 transconjugant strain using primers Helen 3 and 4 to
amplify the 513 bp fragment within the gene. The PCR product was analysed by gel
electrophoresis (Figure 3.12) to confirm that it was the anticipated size, and purified by
the method described in section 2.20.5. Plasmid DNA obtained from the parent and
cured colonies of strain 790 was restricted with Hind III endonuclease (Figure 3 .11)
and covalently linked to a piece of nylon membrane (section 2.21.2).
Plasmid DNA from the Acinetobacter sp. BD413-2 transconjugant was also included as
a positive control. A negative control in the form of genomic DNA from a
TEM-1-producing E. coli strain (J62-2) was added to the membrane as a dot blot
(section 2.21.1). This was also performed with chromosomal DNA from strain 790.
Following hybridisation with the labelled probe, the membrane was subjected to high,
medium and low stringency washes (section 2.21.5).
After the high stringency wash, the intragenic gene probe hybridised strongly with
restricted DNA fragments and non-restricted plasmid DNA from the transconjugant of
blaAR1-\ as expected (Figure 3.13). No other signals were detected. However, the
plasmid DNA from strain 790 (that corresponded to the plasmid identified as
potentially carrying bla^m^) gave a positive signal after medium (indicated by red arrow
in figure 3.13) and low stringency washes (Figure 3.13) indicating that there was some
degree of homology with the ARI-1 P-lactamase gene. The probe also hybridised
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albeit very weakly, with 2 restricted plasmid DNA fragments from this strain (as
indicated by the arrows in Figure 3.13). No signals were detected with plasmid DNA
from the cured colony of strain 790, or with chromosomal DNA from this strain.
Figure 3.12 Electrophoresis of DNA used in hybridisation with ^/«ari-i
intragenic probe














A. baumannii strain 790 - plasmid DNA
A. baumannii strain 790 - plasmid DNA restricted with Hind III
A. baumannii strain 790 cured - plasmid DNA
A. baumannii strain 790 cured - plasmid DNA restricted with Hind III
X UNAJHind III fragments
Acinetobacter sp. BD413-2 transconjugant plasmid DNA
Acinetobacter sp. BD413-2 transconjugant plasmid DNA restricted with
8
Hind III
X UNAJHind III fragments
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Figure 3.13 Hybridisation of Z>/aARi-2-positive strain 790 with
intragenic gene probe for bldAiu-i
123456 78
High stringency wash
1 2 3 4 5 6 7 8
Medium stringency wash

















Plasmid DNA - strain 790
HindIII restricted plasmid DNA - strain 790
Plasmid DNA - cured strain 790
Hind III restricted plasmid DNA - cured 790
XIHind III fragments
Acinetobacter sp. BD413-2 transconjugant plasmid DNA
Hind III restricted plasmid DNA - BD413-2
X/HindIII fragments
To determine whether a stronger hybridisation signal could be produced after
restriction with endonucleases other than Hind III, plasmid DNA from strain 790 was
restricted with EcoR I, Pst I and HamW 1 and hybridised with the intragenic />/«ari-i
probe. Restricted plasmid DNA from the transconjugant Acinetobacter sp. BD413-2
was again included as a positive control. The membrane was subjected to medium and
high stringency washes. On this occasion however, both the restricted fragments of
plasmid DNA and non-restricted plasmid DNA obtained from strain 790 failed to
hybridise with the intragenic probe, even at low stringency (Figure 3.14). Strong
signals were detected with plasmid DNA from the transconjugant after both stringency
washes, indicating that the hybridisation procedure had been successful.
3.14 Hybridisation of MiARi-2-positive strain 790 with intragenic gene
probe for £/«ari-i following restriction with EcoR I, Pst I and
BamW I
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Low stringency wash Medium stringency wash
Lane Lane
1 BD413-2 transconjugant plasmid DNA 6 790 Plasmid DNA
2 EcoR I restricted BD413-2 7 EcoR I restricted 790
3 Pst I restricted BD413-2 8 Pst I restricted 790
4 BamH I restricted BD413-2 9 BamW I restricted 790
5 X/Hind III fragments 10 X/Hind III fragments
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To confirm this result, the membrane was stripped and reprobed using the same
hybridisation conditions as before. Again, the plasmid DNA from strain 790 failed to
produce a signal. The membrane that had initially demonstrated hybridisation of the
intragenic probe with this DNA preparation (Figure 3.13) was subsequently subjected
to the same hybridisation procedure again to validate the original result. A positive
signal was once again detected with the plasmid DNA from this strain and with the
positive control, indicating that the initial result had been correct.
Different plasmid DNA preparations from strain 790 had been used for each of the
hybridisation experiments therefore, a possible explanation for these opposing results
was that the plasmid DNA used in the first hybridisation could have been contaminated
with chromosomal DNA, and it was this DNA that the probe was hybridising to.
Arguably, a dot blot of chromosomal DNA from the same strain had previously failed
to hybridise with this probe (not shown in Figure 3.13) however, this may have been as
a result of inadequate binding ofDNA to the membrane.
To investigate this hypothesis further, chromosomal and plasmid DNA samples were
extracted from strain 790, restricted and transferred to a piece of membrane.
Hybridisation was carried out with the intragenic probe as before, followed by washes
at low and medium stringencies. Strong signals were detected with plasmid DNA from
the Acinetobacter sp. transconjugant (both restricted and non-restricted) at both
stringencies as expected (Figure 3.15). No signal was detected with plasmid DNA
from strain 790. However, the probe hybridised very weakly with chromosomal DNA
from this strain at low stringency (indicated by the arrow in Figure 3.15). This
appeared to suggest that chromosomal contamination could indeed have produced the
initial result. However, on this occasion, the signal was very much weaker despite the
fact that sufficient chromosomal DNA had been transferred to the membrane.
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Figure 3.15 Hybridisation of chromosomal and plasmid DNA from
£/«ARi-2-positive strain 790 with intragenic gene probe for bla^R 1-1
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Strain 790 plasmid DNA
Strain 790 plasmid/AcoR I
Strain 790 cured plasmid DNA
Strain 790 cured plasmid/AcoR I
GeneRuler DNA fragments
ARI-1 transconjugant plasmid DNA
ARI-1 transconjugant plasmid/AcoR I
A. coli K12 (OXA-2) plasmid DNA




1 Strain 790 chromosomal DNA
2 Strain 790 chromosomal/AcoR 1
3 Strain 790 cured chromosomal DNA
4 Strain 790 cured chromosomal/AcoR I
5 GeneRuler DNA fragments
6 ARI-1 transconjugant plasmid DNA
7 ARI-1 transconjugant plasmid DNA/AcoR 1
8 E. coli K12 (OXA-2) plasmid DNA
9 E. coli K12 (OXA-2) plasmid/AcoR I
10 GeneRuler DNA fragments
Faint signal with chromosomal DNA from strain 790 indicated by red arrow
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If the ARI-2 (^-lactamase gene was now located on the chromosome, as these results
suggested, this was in contrast to the curing experiments performed with strain 790,
which had demonstrated that plasmid elimination had resulted in the concurrent loss of
ARI-2 from the cured strain. This evidence was further supported by visualisation of a
large plasmid in the parent strain that was not present in the cured.
3.12.6 PCR analysis with class 1 integron-specific primers
A possibility existed that &/«ari-2 may be associated with a transposable element that
facilitated its transfer between the chromosome and plasmid. To investigate this
hypothesis, PCR amplification was employed with primers (intA and intB), which were
designed to anneal to the 5' and 3' ends of the intl 1 gene (i.e. the integrase gene
located in the 5' conserved segment of class 1 integrons). Amplification with primers
cass 1 and cass 2 was also performed. This primer pair was designed to amplify the
variable region of class 1 integrons into which cassettes are integrated.
A positive control was employed in the form of template DNA from E. coli J53. This
strain possessed a plasmid (pR388) which contained the dhfrlVo trimethoprim resistance
gene located on one of 2 cassettes within a class 1 integron. Another E. coli J53 strain
containing the plasmid pR483 which has no associated integron structure, was
employed as a negative control.
As expected, PCR amplification with the int primers amplified a PCR product of 892 bp
with pR388, indicating the presence of the intl 1 gene (Figure 3.16). However, no
product was detected with this plasmid using the cass primers when a product of
approximately 1.5 kb was expected. A possible explanation was that the PCR
conditions used were not suitable for amplifying products of that size. Both PCR
reactions failed to amplify DNA from the ARI-2-producing strains 790 (both parent and
cured) and 788. This suggested that there were no class 1 integrons present in these
strains.
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Figure 3.16 PCR amplification of ft/flARi-2-positive strains with class 1
integron-specific primers
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2 Strain 790 cured colonies
3 Strain 788
4 E. coliJ53 (pR388)
5 E. coliJ53 (pR483)
6 GeneRuler DNA ladder
3.12.7 Hybridisation with degenerate probe for conserved sequence of
bla0\\ genes
Chromosomal and plasmid DNA from strain 790 was subjected to hybridisation with a
degenerate oligonucleotide probe (ARI-NB) that had been designed from alignments of
several class D ^-lactamases (Figure 3.17).
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Figure 3.17 Amino acid sequence alignments of conserved sequence in












Degenerate probe designed from conserved sequence is shown in bold.
The labelled probe hybridised strongly with the OXA-2-containing positive control
strain E. coli K12, and less so with plasmid DNA from the Acinetobacter sp.
transconjugant at low, medium and high stringencies (Figure 3.18). No signal was
detected with plasmid DNA from strain 790; however, a faint signal was detected with
the chromosomal DNA from both parent and cured colonies of strain 790.
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1 Strain 790 - chromosomal DNA
2 Strain 190/EcoKI
3 Cured strain 790
4 Cured strain 190/EcoKI
5 GeneRuler DNA ladder
6 BD413-2 transconjugant - plasmid DNA
7 BD413-2/£eoR I
8 E. coliK12 (OXA-2 producer)
9 E. coli K12/EcoR I
10 GeneRuler DNA ladder
Faint signals with strain 790 in lanes 1 and 2, and with cured strain 790 in lane 3 are
indicated by the red arrows.
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3.13 N-terminal amino acid sequencing of the ARI-2 protein
Although the previous hybridisation results had suggested that the bla^a-2 gene
encoded a molecular class D P-lactamase, it was proving difficult to obtain an initial
sequence region that would enable the ARI-2 gene to be sequenced. Consequently, a
different approach was undertaken in an attempt to solve this problem. The
purification procedure with strain 788 had successfully separated ARI-2 from the
higher molecular weight cephalosporinase. It was therefore decided to attempt to
sequence the N-terminal end of the ARI-2 enzyme. The concentrated fractions that
contained the ARI-2 P-lactamase (section 3.8) were subsequently subjected to
electrophoresis on a native PAGE gel, and the proteins immobilised on a Problot
membrane (sections 2.14.1 and 2.14.2). Two protein bands were identified as
potentially being the ARI-2 P-lactamase which were both subjected to N-terminal
amino acid sequencing (section 2.14.4).
A total of 15 amino acids were obtained for band A and 19 for band B (Figure 3.19).
Both sequences were entered into a general protein sequence database for identification
(BLASTP link at http://gc.bcm.tmc.edu:8088/search-launcher/launcher.html). There
was no homology identified between both sequences and with any P-lactamases in the
database. The sequence from band A however, shared 95% amino-acid homology with
a ribosome binding protein which suggested that it was not from the ARI-2 protein
band. The sequence from band B demonstrated no homology with any relevant
proteins in the database. The possibility existed however, that this sequence could be a
signal peptide of the ARI-2 P-lactamase. It was therefore decided to design a
degenerate oligonucleotide from this sequence. This was subsequently labelled and
used in a series of hybridisation reactions with the Z>/tfARi-2-positive strain 790.
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Figure 3.19 Coomassie-stained native PAGE gel of fractions 29-34
from Superdex 75 gel filtration
N-terminal amino acid sequence
A
B
* = either G, T, orM
MINDLKKDSEQRMLK
*LFDFVKGIGKKNTAPAEP
3.13.1 Hybridisation with degenerate probe designed from N-terminal
amino acid sequence of protein band B
The probe failed to hybridise to plasmid and chromosomal DNA from strain 790 even
at low stringency. No signal was detected with the ARI-1 transconjugant.
3.13.2 Further purification and separation of the ARI-2 (3-lactamase by
A final purification step was performed with fractions 29-34 in an attempt to remove
the ARI-2 protein from other non-(3-lactamase proteins that were also present. If this
was successful, the protein could be digested with trypsin followed by sequencing of
several of the resulting peptides in order to obtain some of the internal sequence of the
protein. One of the peptide sequences (chosen at random) could then be used to design
RPHPLC
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a degenerate oligonucleotide, and subsequently used in conjunction with the ARJ-2N
degenerate primer to amplify the region between both sequences, providing that the
chosen peptide sequence was sufficiently distant from the N-terminal itself.
Further purification of ARI-2 was performed by reversed-phase HPLC of fractions
29-34. The protein peaks were collected and subjected to electrophoresis on native
PAGE gels, along with an aliquot of the ARI-2-containing fractions (as reference)
which was stained with nitrocephin to identify the presence of the ARI-2 band.
Unfortunately, the HPLC purification process renders enzymes inactive therefore, the
gels containing the protein peaks could not be stained by this method. However,
staining with Coomassie, and subsequently by the more sensitive silver staining method,
failed to visualise protein bands from the collected peaks. The intensity of the reference
lane was not strong, therefore it was possible that there was insufficient protein in the
HPLC-purified samples for visualisation.
It was unfortunate that despite employing several different approaches, it was not
possible to obtain the sequence of the ARI-2 gene in the time-scale of this work.
However, the initial molecular studies of ARI-2-producing isolates suggested that this




DETERMINATION OF THE PRESENCE OF THE ARI-2
P-LACTAMASE IN CARBAPENEM-RESISTANT CLINICAL




The discovery of the novel carbapenemase, ARI-2 in 17 clinical isolates from
Argentina, raised the possibility that this (3-lactamase may also be responsible for
carbapenem resistance in clinical isolates from other areas worldwide. Consequently,
a number of isolates collected from Hong Kong, Singapore, Spain and Turkey, that
were reported to be resistant to the carbapenems, were investigated.
4.2 Clinical isolates
A total of 36 clinical isolates of Acinetobacter spp. were obtained from the 5
countries. Of these, 4 isolates were from the Hospital Clinic I Provincial in
Barcelona, Spain, 6 were collected from The Prince of Wales Hospital in Hong Kong,
11 were from the KK Women's and Children's Hospital in Singapore, and the
remaining 15 isolates were collected from Izmir, Turkey, the majority of which were
from the Dokuz Eylul University Hospital. The isolates from Spain and Hong Kong
were reported to have MIC values of imipenem of between 2 - >8 mg/L, and those
from Turkey and Singapore were reported to be either of intermediate sensitivity or
resistant by the Stokes method.
4.3 Antimicrobial susceptibility testing
The MIC values of the range of antibiotics tested are summarised in Table 4.1. All
isolates were resistant to amoxycillin, co-amoxiclavulanic acid and cephaloridine, and
the majority were resistant to both cefotaxime and ceftazidime (94% and 97.2%
respectively). Among the 36 isolates, 83% were resistant to the aminoglycoside
gentamicin, and 86% resistant to the fluoroquinolone ciprofloxacin. There was some
variation observed in the MIC values of the carbapenems compared with those
reported by the individual centres. A total of 56% of all isolates were resistant to
imipenem, with the highest percentage of resistance demonstrated in the isolates from
Singapore (82%). Overall, isolates demonstrated lower MIC values of meropenem
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compared with imipenem, with the exception of those from Singapore, of which
100% had MIC values above the breakpoint for meropenem, compared with 82%
above the breakpoint for imipenem. This trend was also observed with the isolates
from Hong Kong, ofwhich 67% were resistant to meropenem compared with 16% to
imipenem.
Table 4.1 MIC values ofA. baumannii clinical isolates from Spain,




Cld Ctx Caz Imp Mero Cip Gen
806 (Sp) >128 128 >128 >256 >256 128 128 >16 64
807(Sp) >128 32 >128 16 8 0.25 0.25 8 32
808 (Sp) >128 >128 >128 16 8 2 4 16 >128
809(Sp) >128 >128 >128 >128 64 8 4 8 64
811 (H) >128 >128 128 >128 128 8 8 4 8
812 (H) >128 >128 64 16 4 4 8 0.25 <0.12
813 (H) >128 >128 64 16 8 4 8 0.25 <0.12
814(H) >128 >128 64 16 8 4 8 0.25 0.25
815 (H) >128 32 >128 128 128 2 4 2 0.5
816 (H) >128 64 >128 0.5 2 0.5 0.06 0.016 0.25
820 (T) 128 64 >128 0.5 8 0.5 0.12 0.03 0.5
821 (T) >128 >128 >128 64 16 4 4 >16 16
822 (T) >128 >128 >128 64 16 8 4 8 16
823 (T) >128 >128 >128 64 16 8 4 >16 16
824 (T) >128 >128 >128 64 16 8 4 8 16
825 (T) >128 16 >128 >128 >128 0.25 0.5 >16 16
826 (T) >128 >128 >128 32 16 8 4 8 16
827 (T) >128 16 >128 >128 >128 0.25 0.5 >16 16
829 (T) >128 >128 >128 32 16 8 4 8 16
830 (T) >128 >128 >128 32 16 8 4 >16 16
869 (T) >128 >128 >128 >128 >128 0.25 1 2 2
870 (T) >128 >128 >128 >128 >128 8 8 8 8
871 (T) >128 >128 >128 128 >128 8 8 2 >128
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Table 4.1 continued
Isolate Amox Co-amox Cld Ctx Caz Imp Mero Cip Gen
875 (T) >128 >128 >128 >128 >128 0.25 2 8 2
876 (T) >128 >128 >128 128 >128 8 4 16 >128
860 (S) >128 >128 >128 >128 >128 8 64 >16 128
861 (S) >128 >128 >128 >128 >128 8 64 >16 >128
862 (S) >128 >128 >128 >128 >128 4 64 >16 >128
863 (S) >128 >128 >128 >128 >128 16 64 >16 >128
864 (S) >128 >128 >128 >128 >128 16 128 >16 >128
865 (S) >128 >128 >128 >128 >128 8 64 >16 >128
866 (S) >128 >128 >128 128 >128 8 64 >16 128
867 (S) >128 >128 >128 >128 >128 8 32 >16 >128
868 (S) >128 >128 >128 >128 >128 16 128 >16 >128
872 (S) >128 >128 >128 >128 >128 4 64 >16 >128
873 (S) >128 >128 >128 >128 >128 8 64 >16 >128
Abbreviations: Sp = Spain; H = Hong Kong; T = Turkey; S = Singapore
Amox; Amoxycillin, Co-amox; Co-amoxiclavulanic acid, Cld; Cephaloridine, Ctx;
Cefotaxime, Caz; Ceftazidime, Imp; Imipenem, Mero; Meropenem, Cip;
Ciprofloxacin, Gen; Gentamicin.
Recommended breakpoints (mg/L) (Working Party on Antibiotic Sensitivity
Testing, 1991 and 1998a); Amox, Co-amox; 8.0, Cld, Caz; 2.0, Imp, Mero; 4.0, Gen,
Ctx, Cip; 1.0
4.4 IEF analysis of imipenem-resistant isolates
Crude small-scale P-lactamase extracts were prepared from isolates that demonstrated
an MIC value of imipenem of > 4 mg/L. Table 4.2 lists the pi values of P-lactamases
that were detected in these isolates.
Identical bands (pi 6.5 and 7.0) to those of the ARI-2 P-lactamase were visualised in
crude extracts from 8 isolates, that comprised 6 isolates from Turkey, and 1 each
from Spain and Hong Kong (Figure 4.1).
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Figure 4.1 IEF gel of crude P-lactamase extracts of isolates from
Spain, Hong Kong and Turkey demonstrating the presence of
bands identical to those ofARI-2






Lane Strain Lane Strain
1 809 (Spain) 7 829 (Turkey)
2 811 (Hong Kong) 8 830 (Turkey)
3 822 (Turkey) 9 790 (ARI-2 producer)
4 823 (Turkey) 10 6B 92 (ARI-1 producer)
5 824 (Turkey) 11 E. coli J62 (TEM-1 producer)
6 826 (Turkey)
The majority of isolates also contained P-lactamase bands of >8.0 that resembled
chromosomal cephalosporinases. A TEM-1-like P-lactamase was visualised in 4
isolates (1 from Elong Kong and 3 from Singapore). In addition, 5 isolates also
demonstrated bands that did not resemble either the ARI-2-like P-lactamase, a
cephalosporinase or the TEM-like P-lactamase (Figure 4.2). The pi value of the band
visualised in isolate 806 from Spain was estimated as 8.65. A single isolate from
Turkey (876) contained a P-lactamase band of pi 7.8, and 3 isolates (812, 813 and
814) from Hong Kong had an identical band of pi 8 .25.
7.0 (main band —* *>
ofARI-2 ^
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Figure 4.2 IEF gel of crude fJ-lactamase extracts of isolates from
Spain, Hong Kong and Turkey demonstrating P-lactamases other
than ARI-2
1 2 3 4 5 6 7 8









Lane Strain and P-Iactamase produced
1 Strain 806 (Spain) - pi 8.65
2 Strain 876 (Turkey) - pi 7.8
3 Strain 812 (Hong Kong) - pi 8.25
4 Strain 813 (Hong Kong) - pi 8.25
5 Strain 814 (Hong Kong) - pi 8.25
6 Strain 790 (Argentina) - pi 7.0 (ARI-2)
7 Strain 6B 92 (Edinburgh) - pi 6.65 (ARI-1)
8 E. coli J62-2 - TEM-1 producer
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Table 4.2 pi values of (3-Iactamase bands present in
imipenem-resistant isolates from Spain, Hong Kong, Turkey and
Singapore





























4.4.1 Inhibitor overlays of IEF gels
Inhibitor overlays were applied to IEF gels containing the focused ARl-2-like
(3-lactamase and the unknown P-lactamases of pis 8.65, 7.8 and 8.25. An identical
inhibitor profile was obtained with the P-lactamases of main pi 7.0 in all 8 isolates
(Table 4.3). The bands were not inhibited by EDTA, indicating that it was not a
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metallo-enzyme. None of the bands were visible after overlays of both imipenem and
BRL 42715, indicating that this enzyme was able to bind imipenem and that it had a
serine residue at its active-site. These results were identical to those obtained with the
17 isolates from Argentina that contained the ARI-2 (3-lactamase (section 3.3.2).
The (3-lactamase of pi 8.25 in isolates 812, 813 and 814 was inhibited by imipenem, as
was the enzyme of pi 7.8 in isolate 876 (Table 4.3). However, the activity of the
(3-lactamase of pi 8 .65 in isolate 806 from Spain was not diminished by imipenem. All
3 (3-lactamases were inhibited by BRL 42715, but not by EDTA.
In the majority of isolates, the cephalosporinase bands of pi >8.0 displayed a similar
inhibitor profile to that of the cephalosporinases visualised in the Argentina isolates, in
that activity was partially lost after the imipenem overlay. However, the
cephalosporinases present in the isolates from Hong Kong were not affected by this
overlay. Interestingly, the (3-lactamase band of pi 8.9 in strain 806 (that also
contained the (3-lactamase ofpi 8 .65) was completely inhibited by imipenem.
The TEM-like enzyme identified in 4 isolates was inhibited by clavulanic acid and by
BRL 42715, but not by EDTA or imipenem. This was in agreement with the inhibitor
overlay results obtained with both the TEM-1 enzyme in the isolates from Argentina,
and with a TEM-1 producer (E. coli J62-2) (section 3.3.2).
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Table 4.3 Inhibitor profiles of ^-lactamases by IEF inhibitor overlays
Isolate P-lactamase BRL 42715 EDTA Imipenem
(Pi) (lOOpM) (ImM) (lOOpM)
809, 811, 822, 823,
824, 826, 829, 830 7.0 + - -
806 8.65 + _ _
8.9 + - +
812, 813, 814 8.25 + - +
876 7.8 + _ +
4.5 Microbiological assays of crude P-lactamase extracts
To determine whether (3-lactamase-mediated inactivation of the carbapenems
occurred with imipenem-resistant isolates that produced the p-lactamases of pis 7.0,
7.8, 8.25 and 8.65, crude p-lactamase extracts were subjected to the microbiological
assay. All isolates that produced the ARI-2-like p-lactamase demonstrated imipenem
inactivation by this method (Figure 4.3). Meropenem inactivation was also detected
but to a lesser extent (Figure 4.3), which was also demonstrated with the
ARI-2-producing strains from Argentina (Figure 3.4). Inactivation of both
carbapenems was demonstrated with isolate 806 that produced the P-lactamase of
pi 8.65 (Figure 4.4), despite the fact that an overlay of imipenem had failed to
eliminate the activity of this enzyme. Isolates 812, 813 and 814 which produced the
P-lactamase of pi 8.25 also demonstrated inactivation of both carbapenems by this
method (Figure 4.4). The crude extract of isolate 876 which produced the enzyme of
pi 7.8 failed to inactivate meropenem. In addition, imipenem inactivation by this
extract was relatively weak (Figure 4.4).
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Figure 4.3 Microbiological assays of crude extracts from isolates
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Figure 4.4 Microbiological assays of crude extracts from isolates
producing ^-lactamases of pi values 7.8, 8.25 and 8.65
Imipenem Meropenem









I»T Representative strain 812
(pi 8.25) from Hong Kong
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Crude (3-lactamase extracts from strains 870 and 873 were also subjected to the
microbiological assay to determine whether the activity of either a cephalosporinase
alone (strain 870 from Turkey), or in combination with TEM-1 (strain 873 from
Singapore) resulted in carbapenem inactivation. However, the extracts failed to
inactivate both imipenem and meropenem (Figure 4.5), indicating that (^-lactamase
activity was not responsible for carbapenem resistance detected in these strains.
Figure 4.5 Microbiological assays of crude extracts from isolates














producing both TEM-1 and
cephalosporinase
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4.6 Analysis of isolates by PFGE
From the preliminary investigations of these carbapenem-resistant isolates, it appeared
that the ARI-2 (3-lactamase was not confined to Buenos Aires, but was also present in
isolates from Turkey, Spain and Hong Kong. To determine whether its dissemination
within a particular area was as a result of clonal spread or from transfer of the blaAm_2
gene between genetically unrelated isolates, DNA restriction fragment length
polymorphism (RFLP) patterns of all ARI-2-producing isolates were analysed.
The RFLP patterns are illustrated in Figures 4.6 and 4.7. Patterns were compared
visually in addition to being analysed by the GelCompar computer system, which
processes digitised images of the RFLP patterns. Data were normalised by the
alignment of molecular size standards that were run in 2 separate lanes in each gel. In
addition, the imipenem-sensitive strain, 789 was also included in each gel. The
program generated a matrix of similarity coefficients between all possible pairs of
strains, leading in turn to a dendrogram (Figure 4.8) in which all patterns were placed
in a horizontal tree with branching dictated by the similarity coefficients. Results were
expressed in terms of percentage correlation values. Clusters of identical or closely
related strains were labelled based on a correlation value cut-off of 80%.
In general, the clusters produced by the GelCompar program correlated well with
visual comparison of the RFLP patterns. Five main clusters were identified, A, B, C,
D and E. Clusters A, B, C and E included isolates from Argentina (Table 4.4).
Cluster A comprised those isolated from the CEMIC teaching hospital between 1993
and 1994, which shared similarities of between 90 and 97%. Cluster B was also
indigenous to this teaching hospital and comprised 4 isolates with identical RFLP
patterns that were collected within a 2 month period in 1998. A similarity value of
60% was obtained when the patterns of clusters A and B were compared.
154
Figure 4.6 PFGE of RFLP patterns of ARI-2-producing isolates from
Buenos Aires, Argentina




















19 789 (imipenem-sensitive isolate)
20 X ladder
155
Figure 4.7 PFGE of RFLP patterns of ARI-2-producing isolates from




2 811 (Hong Kong)
3 822 (Turkey)
4 823 (Turkey)







Figure 4.8 Gel-Compar-generated UPGMA clustering dendrogram




































786 H. de Clinicas -Arg.
788 S. Greyton -Arg
883 CEMIC Argentina
811 Hong Kong
Groups of isolates in bold share identical RFLP patterns
Cluster C included isolates from 2 teaching hospitals in Buenos Aires, and which
shared between 93-97% similarity values. Isolates 784 ( from CEMIC) and 785 (from
Hospital de Clinicas) had identical RFLP patterns. All of the isolates from the Dokuz
Eylul hospital in Turkey, with the exception of 870, the clinical details of which were
unknown, comprised cluster D. Similarity values of between 97% and 100% were
obtained for these isolates. This suggested that clonal spread of carbapenem
resistance had occurred in this particular area.
157












02/10/93 C.E.M.I.C Cath. site A1
780 Buenos Aires 13/03/94 C.E.M.I.C Cath. site A1
781 Buenos Aires 02/05/94 C.E.M.I.C BAL A2
782 Buenos Aires 03/11/94 C.E.M.I.C BAL A3
783 Buenos Aires 21/07/95 C.E.M.I.C BAL C4
784 Buenos Aires 22/07/94 C.E.M.I.C Cath. site C4
785 Buenos Aires 1994 H. de Clinicas BAL C4
786 Buenos Aires 1994 H. de Clinicas BAL El
787 Buenos Aires 1994 H. de Clinicas Soft tissue CI
788 Buenos Aires 21/08/94 Sanatorio
Greyton
Urine El
790 Buenos Aires 07/10/95 C.E.M.I.C BAL C2
791 Buenos Aires 16/10/95 C.E.M.I.C BAL C3
883 Buenos Aires 1995 C.E.M.I.C BAL E2
884 Buenos Aires 7/98-8/98 C.E.M.I.C BAL B
885 Buenos Aires 7/98-8/98 C.E.M.I.C BAL B
886 Buenos Aires 7/98-8/98 C.E.M.I.C BAL B
887 Buenos Aires 7/98-8/98 C.E.M.I.C Cath. site &
blood culture
B
822 Izmir, Turkey 6/96-4/97 Dokuz Eylul/
ITU
Tracheal asp. D2
823 Izmir 6/96-4/97 D. Eylul/
Neurosurgery
Wound D1
824 Izmir 6/96-4/97 D. Eylul/ ITU Tracheal asp. D1





Isolate Geographical Date of Hospital/ward Source RFLP
number origin isolation pattern
829 Izmir 6/96-4/97 D. Eylul/Thoracic
surgery
Tracheal asp. D1
830 Izmir 6/96-4/97 D. Eylul/
Neurosurgery
Spinal fluid D3
870 Unknown Unknown Unknown Unknown H
809 Barcelona,
Spain
Unknown Unknown Unknown F
811 Hong Kong 01/01/96 Prince ofWales
Hospital
Deep wound G
Abbreviations: C.E.M.I.C; Centro de Educacion Medica e Investigaciones Clinicas,
H. de Clinicas; Hospital de Clinicas teaching hospital, Sanatorio Greyton; geriatric
hospital, D. Eylul; Dokuz Eylul University Hospital, Cath. Site; catheter site, BAL;
bronchial alveolar lavage, Tracheal asp; tracheal aspirate
The isolates grouped in cluster E originated from all 3 hospitals in Buenos Aires. As
with cluster C, this group included isolates (786 and 788) from 2 different hospitals,
that had identical RFLP patterns.
The RFLP patterns of the single isolates from Spain and from Hong Kong differed
markedly from each other and from the main clusters.
The appearance of 4 different carbapenem-resistant strains within CEMIC, and 2
within the Hospital de Clinicas, strongly suggested that horizontal transfer of the
ARI-2 gene had occurred between these strains. Interestingly, strains 883 (cluster
E2) and 884 (cluster Bl) which were identified as being unrelated by GelCompar and
visual comparison of RFLPs, were both isolated from the same patient from CEMIC,
the former in 1995 and the latter in 1998.
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CHAPTER 5
THE DIFFERENTIAL ACTIVITY OF FLUOROQUINOLONES




For over a decade, the fluoroquinolones have been used successfully in the treatment
and management of severe nosocomial infections caused by mullti-resistant bacteria,
including Acinetobacter baumannii. However, fluoroquinolone resistance has
emerged in this species (Joly-Guillou and Bergogne-Berezin, 1992), which is of
particular concern given that so many antibiotics, including imipenem, are no longer
guaranteed effective in treating many A. baumannii infections.
Fluoroquinolones exert their antibacterial effect by inhibition of 2 bacterial
topoisomerase enzymes namely DNA gyrase (topoisomerase II) and topoisomerase
IV, that are responsible for the complex reaction ofDNA supercoiling in prokaryotes
(Drlica and Zhao, 1997). The key event in quinolone action involves formation of a
quinolone-enzyme-DNA complex. This is followed by a rapid, reversible inhibition of
DNA synthesis, and at higher drug concentrations, cell death follows as a result of the
release of double-strand DNA breaks from the complex (Drlica and Zhao, 1997).
DNA gyrase is the primary target of the fluoroquinolones in Gram-negative bacteria
(Hooper, 1999).
Resistance to this class of antibiotic is mediated by mutational changes in the genes
encoding the target enzymes, which occur within a region extending between amino
acids 67 and 106, called the quinolone resistance-determining region (QRDR)
(Piddock, 1999). Within gyrA ofE. coli, mutations of serine 83 and aspartic acid 87
result in the greatest reduction in susceptibility (Yoshida et al., 1990). Mutations in
the GyrB sub-unit ofDNA gyrase may also contribute to decreased susceptibility but
they are less common (Nakamura et al., 1989). In addition, other mechanisms that
may be involved in fluoroquinolone resistance include a decrease in outer membrane
proteins (Hooper et al., 1992) or alterations in outer membrane lipopolysaccharides
(Hirai et al. 1986), both of which result in a reduction in the intracellular
accumulation of the antibiotic. Active efflux of quinolones at the inner membrane is
161
also a likely contributor of resistance in both Gram-negative and Gram-positive
bacteria (Nikaido, 1996, Piddock, 1999).
Although there have been several studies reporting resistance rates of Acinetobacter
species against the fluoroquinolones (Fass et al., 1996; Barry and Fuchs, 1997;
Balakrishnan et al., 1999), there is little evidence of the efficacy of these antibiotics
against clinical isolates of imipenem-resistant isolates. The aim of this study therefore,
was to ascertain the activity of seven fluoroquinolones against multi-resistant clinical
isolates collected from Argentina, Spain, Flong Kong and Turkey, which represent
some of the most resistant Acinetobacter strains world wide, and several of which
produce the novel carbapenemase ARI-2.
5.2 Source of clinical isolates
A total of 39 clinical isolates from Argentina, Turkey, Spain and Flong Kong were
tested (Table 5.1). The majority of these were multi-resistant with 58.9%
demonstrating imipenem resistance, of which 86.9% produced the ARI-2 |3-lactamase.
Table 5.1 Source of clinical isolates





5.3 Antimicrobial susceptibility testing
MIC values (range of 0.004-128 mg/L) were determined of all quinolones, with the
exception of levofloxacin, which was tested by the Stokes method.
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Table 5.2 MIC values of fluoroquinolones against multi-resistant




Spar Grepa Trova Norflox
779 64 2 2 16 2 256
780 32 2 2 16 2 256
781 32 2 2 16 2 256
782 32 2 1 8 2 256
783 32 2 2 8 2 256
784 32 4 2 8 2 256
785 16 2 1 8 2 256
786 32 2 2 8 2 256
787 32 2 1 8 2 256
788 32 2 2 8 2 256
789 16 8 4 2 2 256
790 16 2 1 2 2 256
791 16 2 1 2 2 256
806 32 2 4 16 2 256
807 16 2 0.5 2 1 128
808 4 2 1 0.5 0.12 64
809 2 0.12 0.25 0.25 0.12 32
811 8 2 0.25 0.12 0.032 64
812 2 0.25 0.25 0.12 0.016 64
813 0.064 0.008 0.004 0.008 0.004 2
814 0.064 0.008 0.004 0.008 0.004 2
815 2 0.12 0.25 0.12 0.12 16
816 0.008 0.032 0.016 0.008 0.016 0.5
820 0.008 0.032 0.032 0.016 0.016 0.25
821 16 2 1 2 2 256
822 4 0.25 0.12 0.25 0.5 64
823 16 2 2 4 2 256
824 2 0.12 0.12 0.12 0.12 32
825 32 2 2 32 4 256
827 32 2 4 16 2 256
829 2 0.12 0.25 0.12 0.12 16
830 16 2 2 16 2 256
833 32 4 4 32 2 256
834 128 4 16 8 8 256
836 128 4 8 8 8 256
837 128 4 2 8 4 256
838 16 0.5 1 8 2 1
839 0.064 0.12 0.064 0.064 0.032 0.5
850 2 0.12 0.12 0.12 0.12 1
Abbreviations: Cip; Ciprofloxacin, Moxi; Moxifloxacin, Spar; Sparfloxacin, Grepa;
Grepafloxacin, Trova; Trovafloxacin, Norflox; Norfloxacin. Breakpoint; 1.0 mg/L
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Table 5.3 MIC ranges, MIC50 and MIC90 values
Antibiotic MIC range (mg/L) MIC50 MIC90 %
Low High (mg/L) (mg/L) Resistance
Ciprofloxacin 0.008 128 16 64 89.7
Norfloxacin 0.25 256 256 256 87.2
Grepafloxacin 0.008 32 8 16 64.1
Moxifloxacin 0.008 8 2 4 66.7
Sparfloxacin 0.004 16 1 4 43.6
Trovafloxacin 0.004 8 2 4 61.5
Levofloxacin N/A N/A N/A N/A 59










































The isolates varied in their sensitivity to the quinolones tested (Table 5.3 and Figure
5.1). Significant resistance was observed to ciprofloxacin and norfloxacin. The
highest MIC50 and MIC90 values were demonstrated for norfloxacin (256 mg/L for
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both). Comparable values were detected for ciprofloxacin and grepafloxacin. The
most active of the fluoroquinolones were sparfloxacin, trovafloxacin and
moxifloxacin, with the lowest MIC50 and MIC90 values detected for sparfloxacin (1.0
mg/L and 4 mg/L respectively). Overall, the highest resistance levels were
demonstrated by the isolates from Argentina, of which 62% were resistant to all the
quinolones tested. No correlation was observed between carbapenem and
fluoroquinolone resistance.
5.4 Investigation of ciprofloxacin-resistant isolates by PCR
amplification of the QRDR of gyrA
PCR amplification of the QRDR of the gyrA gene was performed with primers
designed from conserved amino acid sequence motifs identified in several diverse
gyrA genes (section 2.20). PCR products were subsequently digested with Hinf I
(section 2.18). The conserved Asp-Ser residues at positions equivalent to 82 and 83
for E. coli form a Hint I restriction site, which is subsequently abolished in isolates
carrying a mutation at codon 83, as indicated by no digestion of the PCR product.
Amplification of the QRDR of the gyrA gene yielded a PCR product of 343 bp in all
isolates (Figure 5.2). Hini I restriction of the PCR products from the isolates with
ciprofloxacin MIC values of 0.008-0.064 mg/L yielded DNA fragments of 291 bp and
52 bp (Figure 5.2), indicating that the Hini I site was intact. Digestion of the PCR
products from isolates with ciprofloxacin MIC values of > 2 mg/L failed to produce
restriction fragments, indicating the loss of the Hini I restriction site at the codons for
amino acids 82-83 (Figure 5.2).
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Figure 5.2 Hinf I restriction of PCR-amplified gyrA QRDR of

















10 GeneRuler DNA fragments
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Sequencing of the PCR products from representative ciprofloxacin-resistant isolates
confirmed the presence of a change at Ser-83 to Leu (C —»-T transversion from codon
TCA) in all isolates with a MIC value of > 2 mg/L (Figure 5.3). No other amino acid
changes were identified. The ciprofloxacin-sensitive isolates with the intact Hinf I site
retained the TCA codon at this position.
Figure 5.3 Comparison of partial DNA sequences (containing the
Ser-83 region) of ciprofloxacin-resistant clinical isolates and the
wild-type A baumannii gyrA gene
76 85
Cip-R isolates AAA TAT CAC CCG CAT GGT GAC TTA GCT GTT
Lys Tyr His Pro His Gly Asp Leu Ala Val
A. baumaniigyrA AAA TAT CAC CCG CAT GGT GAC TCA GCT GTT
Lys Tyr His Pro His Gly Asp Ser Ala Val
Mutation at Ser-83 in ciprofloxacin-resistant isolates is indicated in bold.
The deduced amino acid sequences are given below each nucleotide sequence
5.5 PCR amplification of the QRDR ofparC of
ciprofloxacin-resistant clinical isolates
Investigation of the QRDR of gyrA of clinical isolates had revealed a Ser-83
substitution in isolates with a ciprofloxacin MIC value of 2-128 mg/L. To investigate
whether a mutation in the parC gene could be involved in the variation observed in
the MIC values, PCR amplification of this region was performed with parC-specific
primers (Tables 2.8 and 2.9) which produces a product of 197 bp in size. PCR
products were subsequently digested with Hinf I (section 2.18). A Hinf I restriction
site is present within the QRDR region at the codons for amino acids Asp-Ser 79-80,
which is abolished in isolates carrying a mutation at codon 80.
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PCR amplification yielded a product of 197 bp in all isolates (Figure 5.4). Hinf I
restriction of PCR products from the isolates with ciprofloxacin MIC values of 2-8
mg/L produced 2 DNA fragments of 144 bp and 53 bp (Figure 5.4), indicating that
the HinfI site was intact. Restriction of the PCR products from the majority of
isolates with a ciprofloxacin MIC value of > 16 mg/L failed to produce these
restriction fragments, indicating that the I site had been lost. However,
restriction ofPCR products from four isolates with MIC values of 16 mg/L resulted in
visualisation of fragments of 144 bp and 53 bp, indicating that the Hinf I restriction
site had not been lost in these particular isolates (Table 5.4).
Figure 5.4 HinfI restriction of PCR-amplified parC of
ciprofloxacin-resistant clinical isolates














Non-restricted PCR product of isolate 779 (Cip MIC value of
64 mg/L)
Hinf I-restricted PCR product of 779
Non-restricted PCR product of isolate 811 (Cip MIC value of 8 mg/L)
Hinf I-restricted PCR product of isolate 811
Negative control (no primers)
Negative control (no DNA)
100 bp DNA ladder
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Sequencing ofPCR products detected a change at Ser-80 to Leu (C—► T transversion
from codon TCG) in the majority of high-level ciprofloxacin-resistant isolates
(> 16 mg/L) (Figure 5.5). However, sequencing of the product from isolate 830
(MIC of 16 mg/L) which had retained the Hint I restriction site revealed that this
change was not present, but a Glu-84 to Lys change had occurred (Figure 5.5). No
parC mutation was found in the absence of the gyrA mutation.
Figure 5.5 Comparison of partial DNA sequences of the QRDR of the
parC gene of high-level ciprofloxacin-resistant clinical isolates
Isolate Cip MIC
80 84 (mg/L)
A. baumanniiparC GGT GAC TCG GCA TGT TAT GAA GCC
Gly Asp Ser Ala Cys Tyr Glu Ala
836 GGT GAC TCG GN- TGT TAT GAA GCC 128
Ser
779 GGT GAC TTG GCA TGT TAT GAA GCC 64
Leu
780 GGT GAC TTG GCA TGT TAT GAA GCC 32
Leu
825 GGT GAC TTG GN- TGT TAT GAA GCC 32
Leu
830 GGT GAC TCG GCA TGT TAT AAA GCC 16
Ser Lys
Mutation at Ser-80 is indicated in bold. Mutation at Glu-84 to Lys in isolate 830 also
indicated in bold.
The deduced amino acid sequences are given below the nucleotide sequences.
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+ = mutation present
- = mutation not present
The gyrA Ser-83 to Leu mutation was present in all isolates
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A STUDY OF THE EFFICACY OF SULBACTAM AGAINST




The penicillanic acid sulphone derivative, sulbactam was first reported by Pfizer's
chemists in 1978 and was shown to have potent inhibitory activity, particularly against
molecular class A P-lactamases, although it also demonstrated a greater affinity than
clavulanic acid for class C enzymes (English et al., 1978). Sulbactam is most
frequently used in combination with ampicillin (2:1 ratio ampicillin), which increases
the spectrum of this |3-lactam to include P-lactamase-producing strains of among
others, Klebsiella spp., Proteus spp., S. aureus and E. coli (Sutherland, 1995). This
combination has been reported to be effective against both imipenem-sensitive
(Pandey et al., 1998; Faas et al., 1996) and imipenem-resistant A. baumannii isolates
(Jimenez-Mejias et al., 1997).
Although sulbactam displays only modest antimicrobial activity in its own right, its
specific in vitro activity against Acinetobacter spp. has been documented (Go et al.,
1994; Corbella et al., 1998). This has been attributed to the selective affinity of
sulbactam for PBPs in particular, PBP2 (Urban et al., 1995). There have been reports
of multi-resistant Acinetobacter spp. that are also resistant to imipenem but remain
susceptible to sulbactam (Go et al., 1994; Corbella et al., 1998), which has raised the
possibility of the use of this inhibitor in treating infections caused by these bacteria.
However, resistance has already been observed (Wood and Reboli, 1993; Traub and
Spohr, 1989; Fernandez-Viladrich et al, 1999). In addition, reports have advised
against the use of sulbactam as monotherapy for A. baumannii infections because of
its poor bactericidal activity against many strains ( Aubert et al., 1996).
Several studies have reported the effectiveness of other sulbactam combinations.
Cefoperazone plus sulbactam is available in a number of countries, including Japan
(Sutherland, 1995), and this combination along with imipenem has been used in
Turkey to treat A. baumannii infections (Akalm et al., 1999). Other combinations
include sulbactam with ticarcillin (Joly-Guillou et al., 1995) or with cefpirome
(Aubert et al., 1996). The use of sulbactam in combination with the carbapenems has
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not been documented, however, one study has reported a superior bacteriostatic and
cidal effect with this combination against imipenem-sensitive isolates (Aubert et a/.,
1996).
The aim of this study was therefore to evaluate the efficacy of sulbactam alone and in
combination with imipenem against imipenem-sensitive and imipenem-resistant clinical
isolates of Acinetobacter spp. in order to establish whether carbapenem/p-lactamase
inhibitor therapy could provide an alternative means of successfully treating infections
caused by these bacteria.
6.2 Bacterial isolates
A total of 35 clinical isolates ofAcinetobacter spp. were analysed in this study (Table
6.1). Of these, 13 isolates were from Buenos Aires, Argentina, of which 92% were
imipenem-resistant and produced the ARI-2 P-lactamase. Another 13 isolates
originated from 2 hospitals within Scotland, the majority of which were
imipenem-sensitive. The other 9 isolates comprised 4 from Spain, of which 2 were
imipenem-resistant (including 1 ARI-2-producing isolate), and 5 from Hong Kong, of
which 4 were imipenem-resistant (including 3 that produced an unknown P-lactamase
of pi 8.25, and 1 ARI-2-producing isolate).
The majority of isolates were identified as A. baumannii, with the exception of 7 that
comprised 5 A. junii and 2 A. haemolyticus isolates (Table 6.1).
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Table 6.1 Details of clinical isolates ofAcinetobacter spp.
Isolate number Identification Origin
779 A. baumannii Buenos Aires, Argentina
780 A. baumannii Buenos Aires, Argentina
781 A. baumannii Buenos Aires, Argentina
782 A. baumannii Buenos Aires, Argentina
783 A. baumannii Buenos Aires, Argentina
784 A. baumannii Buenos Aires, Argentina
785 A. baumannii Buenos Aires, Argentina
786 A. baumannii Buenos Aires, Argentina
787 A. junii Buenos Aires, Argentina
788 A. baumannii Buenos Aires, Argentina
789 A. baumannii Buenos Aires, Argentina
790 A. baumannii Buenos Aires, Argentina
791 A. baumannii Buenos Aires, Argentina
792 A. baumannii RIE, Edinburgh
803 A. baumannii RIE, Edinburgh
804 A. junii RIE, Edinburgh
806 A. baumannii Barcelona, Spain
807 A. baumannii Barcelona, Spain
808 A. baumannii Barcelona, Spain
809 A. baumannii Barcelona, Spain
811 A. baumannii Hong Kong
812 A. baumannii Hong Kong
813 A. baumannii Hong Kong
814 A. baumannii Hong Kong
815 A. baumannii Hong Kong
819 A. baumannii RIE, Edinburgh
ZT 73 A. haemolyticus RIE., Edinburgh
ZT 94 A. haemolyticus SGH, Glasgow
ZT 102 A. baumannii SGH, Glasgow
ZT 106 A. baumannii SGH, Glasgow
ZT 145 A. junii RIE, Edinburgh
ZT 253 A. junii RIE, Edinburgh
ZT 259 A. baumannii RIE, Edinburgh
ZT 264 A. baumannii RIE, Edinburgh
ZT 265 A. junii RIE, Edinburgh
RIE; Royal Infirmary of Edinburgh, SGH; Southern General Hospital, Glasgow
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6.3 Antimicrobial susceptibility testing
The MIC range of sulbactam was 0.5 - >16 mg/L. A total of 14 of the 35 isolates
(38.9%) had MIC values above the concentration of sulbactam (4 mg/L) that is
routinely used in combination with ampicillin (Table 6.2). This total included all
imipenem-resistant isolates that produced the AR.I-2 (3-lactamase. As expected, the
lowest MIC values were demonstrated with the isolates from Scotland (MIC range
0.5-2 mg/L, although a slightly higher MIC value was detected with the
imipenem-resistant isolate 792. The highest MIC values were observed with the
isolates from Argentina (MIC range 4 - >16 mg/L). Tazobactam demonstrated
considerable less activity, with all isolates demonstrating higher MIC values (MIC
range 2 - >16 mg/L) compared with sulbactam.
Table 6.2 MIC values of sulbactam, tazobactam and imipenem




779 8 >16 8
780 4 >16 8
781 4 >16 8
782 8 >16 8
783 8 >16 16
784 8 >16 16
785 8 >16 32
786 4 >16 8
787 8 16 16
788 8 >16 8
789 16 8 0.25
790 >16 >16 16
791 >16 >16 32
792 4 >16 16
803 2 8 1
804 1 16 0.25
806 16 >16 128
807 1 8 0.25
808 2 16 2






811 4 >16 8
812 2 >16 8
813 2 >16 4
814 2 >16 4
815 2 8 2
819 8 >16 1
ZT 73 1 16 0.06
ZT 94 1 8 0.06
ZT 104 2 8 0.12
ZT 106 1 16 0.06
ZT 145 1 8 0.12
ZT 253 1 16 0.12
ZT 259 0.5 2 0.12
ZT 264 2 16 0.12
ZT 265 2 >16 0.12
6.4 Investigation of the inhibitory effect of sulbactam on clinical
isolates ofA. baumannii
Three imipenem-resistant isolates demonstrating MIC values of sulbactam of 4 mg/L
(isolate 811) and >16mg/L (isolates 790 and 791), and 1 imipenem-sensitive isolate
with a MIC value of sulbactam of 0.5 mg/L (ZT 259), were challenged with
increasing doses of sulbactam (range 1-128 mg/L) over a 3 hour period.
A minimal inhibitory activity of sulbactam was detected against isolates 790 and 811,
although the growth rate of each increased slightly at a concentration of >32 mg/L
(Figure 6.1). The activity of sulbactam against isolate 791 was greatest at 4 mg/L (1
log decrease); however, no further decrease in growth rate was observed at higher
concentrations. Significant inhibitory activity was demonstrated against isolate ZT
259 at all concentrations of sulbactam (2 log decrease) (Figure 6.1). These findings
indicated that for the sulbactam-resistant isolates 790, 791 and 811 (MIC values
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of > 4 mg/L), sulbactam did not have a significant bactericidal effect at concentrations
above their MIC values. However, the growth rate of the sensitive isolate ZT 259
(MIC value of sulbactam of 0.5 mg/L) continued to decrease at concentrations above
its MIC value.
Figure 6.1 Dose response curve of isolates 790, 791, 811 and ZT 259
following challenge with sulbactam
8.5
5 . , ; , ,




A— strain ZT 259
—strain 790
6.5 Investigation of the in vitro activity of sulbactam in combination
with imipenem against imipenem-resistant clinical isolates of
A. baumannii
The combined activity of imipenem and sulbactam against isolates 790, 791 and 811,
was evaluated by chequerboard titration.
Synergy was detected with a combination of imipenem 8 mg/L and sulbactam 2.0
mg/L (ZFIC = 0.56) against isolate 790 (Figure 6.2.1). Partial synergy was
demonstrated with a combination of imipenem 12 mg/L and sulbactam 1.5 mg/L
(ZF1C = 0.83) against isolates 791 (Figure 6.2.2) and 811 (Figure 6.2.3). Although
177
this study involved only 3 isolates, these results suggested that the enhanced activity
of imipenem in combination with sulbactam may prove to be therapeutically useful
against imipenem-resistant isolates.
Figure 6.2.1 In vitro activity of combinations of imipenem and
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Figure 6.2.2 In vitro activity of combinations of imipenem and
sulbactam against isolate 791
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178
Figure 6.2.3 In vitro activity of combinations of imipenem and
sulbactam against isolate 811
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6.6 Bactericidal in vitro activity of imipenem and sulbactam
combinations against imipenem-resistant clinical isolates of
A. baumannii
The activity of imipenem and sulbactam alone at 32 mg/L and 128 mg/L respectively
had no effect against isolate 790 (Figure 6.3.1). However, an increased inhibitory
effect was observed with imipenem and sulbactam together (15 log decrease) after 4
hours, and it can be seen that this combination produced bactericidal activity by 5
hours (3.5 log decrease). This suggests that there is bactericidal synergy with these
drugs with this strain.
Against isolate 791, sulbactam alone at 8 mg/L had a bacteriostatic effect after 5
hours (<0.5 log decrease) (Figure 6.3.2). After 4 hours, a bacteriostatic effect was
observed with imipenem alone at 12 mg /L. The combined activity of imipenem and
sulbactam produced no greater effect on viability than imipenem alone (<0.5 log
decrease). This suggests that the two drugs together do not work synergistically to
give bactericidal activity.
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Figure 6.3.1 Bactericidal activity of imipenem and sulbactam against
isolate 790
Figure 6.3.2 Bactericidal activity of imipenem and sulbactam against
isolate 791
8 -
0 1 2 3 4 5
Time (h)
A limited bactericidal effect was obtained with imipenem at 16 mg/L against isolate
811 (2.5 log decrease) over the 5 hour period (Figure 6.3.3). Sulbactam alone at 64
mg/L had only a bacteriostatic effect against this isolate after 5 hours (1 log decrease).
The addition of sulbactam did not enhance the bactericidal effect seen with imipenem,
as a bacteriostatic response similar to that of sulbactam alone was observed with the
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combination of imipenem and sulbactam after 5 hours (1.5 log decrease). This
suggests that sulbactam could antagonise the action of imipenem in some strains.
Figure 6.3.3 Bactericidal activity of imipenem and sulbactam against
isolate 811
In summary, the combination of imipenem and sulbactam produced the greatest
bactericidal effect against isolate 790. The addition of sulbactam did not enhance the
low bactericidal activity of imipenem observed against isolate 811, and no bactericidal






A total of 54 randomly-collected clinical isolates of Acinetobacter spp. from
Argentina, Turkey, Hong Kong, Spain and Singapore were investigated in this study.
The majority were identified as A. baumannii, which is in agreement with the findings
of other studies that have reported A. baumannii as the most prevalent species found
in clinical isolates (Traub, 1989; Jang et a/., 1999; Villari et al., 1999). However, it
should be noted that the API 20NE identification system used in this thesis does not
reliably distinguish the different Acinetobacter genomic species, particularly strains
belonging to the A. baumannii-A. calcoaceticus complex (Bergogne-Berezin and
Towner, 1996).
The majority of isolates (33%) originated from Buenos Aires, Argentina (18 in total),
and from Izmir, Turkey (15 in total). In Argentina, multi-resistant A. baumannii is
now the most important Gram-negative pathogen in the ITU (C. Bantar, personal
communication). An antimicrobial surveillance program of 556 strains from
hospitalised patients in 6 Latin American countries reported that more than half of
Gram-negative isolates were non-fermentative species, of which A. baumannii was
the most frequently isolated species (Sader et al., 1998). A recent survey of aerobic
Gram-negative isolates from ITUs in 8 hospitals in Turkey reported isolation rates of
Acinetobacter spp. of between 10-23% (Giinseren et al., 1999). Indeed, an increase
in general in the incidence ofAc/>?eto£acfer-associated infections is well documented.
A recent review of ITUs in the UK reported that 45 out of 70 units isolated
Acinetobacter spp. (Humphreys and Towner, 1997), and in a surveillance study of
ITUs in 5 European countries, Acinetobacter spp. accounted for 2-10% of
Gram-negative isolates; the highest incidence was observed in France (Hanberger et
al., 1999). Acinetobacters are now the third most frequently isolated pathogen among
hospitalised patients with pneumonia in Latin America (Sader et al., 1998).
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7.2 Antimicrobial susceptibility profiles of Acinetobacter clinical
isolates
Antimicrobial susceptibility studies identified a high level of resistance in all isolates,
which were resistant to the majority of antibiotics tested. Resistance rates of 100%
were detected for both amoxycillin and amoxiclavulanic acid, and for cephaloridine.
The majority were resistant to both cefotaxime and ceftazidime (resistance rates of
96.3% and 98.1% respectively). Both ciprofloxacin and gentamicin demonstrated
poor activity against these isolates (resistance rates of 91% and 72% respectively).
Multi-resistance is now a common feature among the majority of reported
A. baumannii strains (Giinseren et al., 1999; Sader et al., 1998; Biendo et al., 1999).
The excessive use of antimicrobials in the hospital setting has undoubtedly provided a
strong selective force that has contributed to the current levels of resistance. Clinical
isolates of Acinetobacter from community-acquired infections do not appear to
possess the same resistance profiles as those of isolates from nosocomial infections
(Gerner-Smidt, 1987). In addition, several studies have correlated antibiotic use with
a corresponding increase in resistance levels in clinical isolates (Joly-Guillou et al.,
1990; Kolar et al., 1999; Villers et al., 1998).
A total of 69% of all isolates demonstrated MIC values of imipenem above the
breakpoint value (4 mg/L), of which the highest percentages of resistance were
observed in the isolates from Argentina (89%) and Singapore (82%). Although
several studies have declared the carbapenems as the only suitable therapy against
many multi-resistant isolates ofAcinetobacter spp. (Mokaddas et al., 1998; Giinseren
et al., 1999), there are now equivalent numbers of reports that demonstrate an
increase in resistance to this class of antibiotic (Sader et al., 1998; C. Bantar,
unpublished data). A recent survey of resistance among clinical isolates of
Acinetobacter in Spain over a 6 year period has highlighted this growing trend. The
study reported an overall average increase in antibiotic resistance levels of 42%
between 1991 and 1996. Alarmingly, however, the highest increase was detected
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with imipenem resistance, which rose from 1.3% in 1991 to 80% in 1996 (Ruiz et al.,
1999).
A significantly lower level of resistance was observed to meropenem (38.9%),
although 46.3% of all isolates demonstrated MIC values of this carbapenem at the
recommended breakpoint value (Working Party on Antibiotic Sensitivity Testing,
1998a), and approximately 38% of all resistant isolates had MIC values of
meropenem that were either equal to or greater than those of imipenem.
Although the primary target of both carbapenems in E. coli is PBP2, meropenem also
has an affinity for PBP3 in P. aeruginosa (Kitzis et al., 1989). Meropenem has also
been demonstrated to penetrate the outer membrane of Enterobacteriaceae and
Pseudomonas spp. via more than one type of OMP (Kitzis et al., 1989). This, along
with its PBP affinity pattern, may explain the enhanced activity of meropenem against
these bacteria.
Although these results correlate with the current view that resistance to meropenem is
less common than to imipenem (Livermore, 1997; Jones and Pfaller, 1998), it is
alarming that such a large percentage of isolates demonstrated high MIC values of this
carbapenem. Indeed, the appearance of resistance to meropenem has been
documented. In P. aeruginosa, resistance has been attributed to loss of the D2 OMP
(Buschner et al., 1987). In addition, this antibiotic appears to be a substrate of the
MexAB-OprM efflux pump in this species, and it has been demonstrated to select for
strains that are over-producers of this pump as a secondary resistance mechanism in
OprD-deficient strains (Kohler et al., 1999). Expression of high levels of
metallo-enzymes in S. maltophilia and Aeromonas hydrophila can result in resistance
to meropenem (Sanders et al., 1989), as can expression of chromosomal (3-lactamase
in combination with loss of the D2 porin in P. aeruginosa (Livermore, 1992).
Interestingly, one isolate from Spain (806) demonstrated unusually high MIC values
of both carbapenems (128 mg/L of both). Resistance to meropenem in Acinetobacter
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spp. has been reported. Following treatment with this carbapenem, an increase in
MIC value from <1 mg/L to >32 mg/L was observed in a clinical isolate of
Acinetobacter (also isolated in Spain) (Nunez et al., 1998). Sader et al (1998) also
reported equivalent resistance levels of both carbapenems in clinical isolates of
Acinetobacter.
7.3 The (3-lactamases ofAcinetobacter
Analysis of the P-lactamase content of imipenem-resistant isolates by IEF revealed the
presence of P-lactamase bands of pi >8.0 in 98%. These were presumed to be
chromosomally-encoded cephalosporinases because of their high pi. A number of
these (3-lactamases have been identified in Acinetobacter spp. and four have been
named ACE-1, 2, 3 and 4, the pi values of which range from 7.3 and 7.7 (ACE-4) to
8.6 and 8.8 (ACE-1) (Hood and Amyes, 1991). Other cephalosporinases of high pi
values have also been described (Morohoshi and Sato, 1977; Hikida et al., 1989;
Blechschmidt et al., 1992; Perilli et al., 1996). A study by Vila et al (1993) identified
cephalosporinase activity in 98% of clinical isolates of A. baumannii based on IEF
bands with a pi value of greater than 8.0. Cephalosporinases were the only enzymes
visualised in 2 of the imipenem-resistant isolates from Turkey and 6 from Singapore.
A total of 22 (54%) of the 41 imipenem-resistant isolates also produced P-lactamase
bands that co-focused with the class A P-lactamase TEM-1 (pi 5.4). This enzyme
was first identified in Acinetobacter epidemic strains in the early 1980s, and was
responsible for ampicillin resistance observed in these strains (Philippon et al., 1980).
The closely related TEM-2 enzyme was identified soon after (Devaud et al., 1982).
The inhibitor overlays of this P-lactamase were in agreement with the properties of
TEM-1 in that it was inhibited by the class A inhibitor clavulanic acid, and by BRL
42715, an inhibitor of serine active-site p-lactamases. An additional class A
P-lactamase (CARB-5) that hydrolyses both ampicillin and carbenicillin has been
identified in some Acinetobacter strains (Joly-Guillou et al., 1988). This enzyme has
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a pi value of 6.3, however no bands comparable to that of CARB-5 were detected in
any of the isolates.
In the majority of isolates from Singapore and 2 isolates from Turkey, a P-lactamase
of pi >8.0 that resembled a chromosomal cephalosporinase was the only enzyme
observed, although 3 isolates from Singapore also produced a TEM-1 P-lactamase.
The MIC range of imipenem observed in these isolates was 4.0-16 mg/L. Although
isoelectric focusing had detected partial inhibition of the cephalosporinase bands
following an overlay of imipenem, the microbiological assays provided no evidence
that these P-lactamases alone or in combination were involved in imipenem-resistance
observed in these strains therefore, another mechanism other than p-lactamase activity
was assumed to be responsible.
Alterations in the outer membrane permeability have been well documented as a cause
of resistance in Gram-negatives, and it remains the most common mechanism of
resistance to imipenem. In P. aeruginosa, for example, loss of expression of the
OprD porin results in resistance to imipenem (Lynch et al., 1987). A decrease in the
expression of an outer membrane protein has been attributed to imipenem resistance
in 2 clinical isolates of A. baumannii (Clark, 1996), and a major 40 kDa outer
membrane protein (OmpAb) has recently been characterised and appears to play an
important role in the diffusion properties of the outer membrane of A. baumannii
(Jyothisri et al., 1999). Whether the loss of, or a decrease in, the production of this
protein can result in antibiotic resistance remains to be determined. The presence of a
small number of small-sized porins has been suggested as one of the causes of the
resistance profile of Acinetobacter spp. (Sato and Nakae, 1991). This study also
demonstrated that diffusion rates of the carbapenems through the outer membranes of
Acinetobacter were less than 2% of that detected in E. coli.
It is known that multicomponent efflux systems act synergistically with low
permeability to produce the intrinsic resistance observed in P. aeruginosa (Nikaido,
1996), and the carbapenems are included in the substrate range of one such system
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(MexEF-OprN) (Masuda et al., 1995). Whether a similar system exists in
Acinetobacter spp. has yet to be determined.
7.3.1 Discovery of unknown p-lactamase bands in imipenem-resistant
isolates
Two P-lactamase bands of pi values 8.65 and approximately 8.9 were visualised in
isolate 806 from Spain. These bands were very similar in pi to the bands of ACE-1
(pi values of 8.6 and 8.8) (Hood and Amyes, 1991). Isolate 806 was unusual in that
it demonstrated very high MIC values to both imipenem and meropenem (128 mg/L
of both). Interestingly, IEF inhibitor overlays of imipenem did not diminish the
activity of the band of pi 8.65, but the band of pi 8 .9 was completely inhibited, which
suggested that imipenem binding had occurred. This raised the possibility that these
bands comprised two separate P-lactamases, and that the band of pi 8 .9 was involved
in carbapenem resistance, possibly in combination with other mechanisms. A
P-lactamase of pi 8.0 has recently been implicated in carbapenemase resistance in a
clinical isolate ofAcinetobacter spp. from Spain (Afzal-Shah et al., 1999a).
Three isolates from Hong Kong (812, 813 and 814) produced an identical band of pi
8.25 with associated satellite banding that resembled ACE-3 (pi 8.1 and 8.2).
However, the P-lactamase bands detected in these isolates were inhibited by an IEF
overlay of imipenem. Isolate 876 from Turkey produced a P-lactamase of pi 7.8 that
was also inhibited by an imipenem overlay. This suggested that P-lactamase activity
could be involved in carbapenem resistance in these isolates.
High-level expression of a chromosomally-encoded class C P-lactamase combined
with reduced outer membrane permeability has been associated with carbapenem
resistance among members of Enterobacteriaceae (Lee et al., 1991; Marinardi et al.,
1997; Raimondi et al., 1991). The possibility existed, therefore, that
cephalosporinase activity may contribute to imipenem resistance in those isolates in
which these were the only enzymes detected. There is no documented evidence that
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any of the ACE cephalosporinases play a role in imipenem resistance, although the
production of a cephalosporinase in combination with either modification of OMPs or
PBPs has been suggested as a cause of imipenem resistance in A. banmannii clinical
isolates however, these workers did not fully characterise the (3-lactamases involved
(Dib et al., 1994). To determine whether (3-lactamase activity was indeed involved in
carbapenem resistance in the isolates from Hong Kong, Turkey and Spain would
require further characterisation of their P-lactamases.
7.4 ARI-2 - a novel (3-lactamase involved in carbapenem resistance
A P-lactamase of main band pi 7.0 was identified in 61% of imipenem-resistant
isolates, which included all of the isolates from Argentina, 6 from Turkey, and one
each from Spain and Hong Kong. A P-lactamase of pi 7.0 has also been described in
several clinical isolates of A. baumannii, however these strains remained susceptible
to imipenem with MIC values of <1 mg/L (Vila et al., 1993).
The modified microbiological assay using crude P-lactamase extracts of isolates
demonstrated inactivation of imipenem, and to a lesser extent meropenem, suggesting
that P-lactamase activity was involved in carbapenem resistance observed in these
isolates. This assay has also been used to demonstrate inactivation of imipenem by
the carbapenemase ARI-1 in a clinical isolate of A. baumannii (Paton et al., 1993).
Cmde p-lactamase extracts from both a TEM-1 producer and an imipenem-sensitive
clinical isolate ofA baumannii (789) failed to inactivate imipenem and meropenem by
this method.
7.4.1 Initial characterisation of ARI-2
An imipenem overlay of IEF gels of crude P-lactamase extracts of strains producing
the enzyme of pi 7.0 resulted in loss of activity bands after nitrocephin staining,
indicating that imipenem binding had occurred. Further overlays with inhibitors were
subsequently employed to determine whether this enzyme belonged to Bush group 2f,
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which includes the Ambler molecular class A serine active-site carbapenemases, or
Bush group 3, the molecular class B metallo-enzymes (Bush et al., 1995).
P-lactamase activity was not affected by EDTA, a metal ion chelator that inhibits class
B P-lactamases, but was affected by BRL 42715, an inhibitor of serine active-site
enzymes. These results indicated that the P-lactamase of pi 7.0 was not a
metallo-P-lactamase, but instead possessed a serine residue at its active-site. These
findings were not surprising since the presence of metallo-enzymes in Acinetobacter
spp. is extremely rare. There have been isolated reports of metallo-enzymes in clinical
isolates of A. baamannii from Portugal (Da Silva and Peixe, 1999) and from Cuba
(Perez et al., 1996). Both ^-lactamases were characterised based on their hydrolysis
of imipenem and inhibition by EDTA; however, the genes that encode these enzymes
have yet to be sequenced. A third report from Italy has identified an IMP-1-like
enzyme in a single A. baumanniii isolate based on hybridisation of chromosomal DNA
to a Zj/anvip-specific probe (Cornaglia et al., 1999), and more recently, a
metallo-enzyme has been identified in a clinical isolate of Acinetobacter spp. from
Hong Kong that does not appear to be related to either IMP-1 or VIM-1 (Afzal-Shah
et al., 1999a).
Partial inhibition of the pi 7.0 P-lactamase occurred with clavulanic acid at 1 mM.
This inhibitor primarily inhibits class A but not class C p-lactamases (Bush et al.,
1995). It also weakly inhibits the activities of OXA-type (oxacillin-hydrolysing)
enzymes (Naas and Nordman, 1999), therefore the possibility existed that this
P-lactamase belonged to either class A or class D. Several class A P-lactamases exist
that are able to hydrolyse imipenem (Livermore, 1997); however, until recently, the
carbapenems have not been included in the substrate range of class D enzymes. The
inhibitor profile of this P-lactamase was very similar to that of the ARI-1
carbapenemase (pi 6.65), which was originally thought to be a class A enzyme, but
has recently been identified as a class D oxacillinase (Donald et al., 2000). The
enzyme in this thesis with a pi of 7.0 was subsequently named ARI-2.
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7.4.2 Spectrophotometric analysis of induced and non-induced
ARI-2-producing strain 790
Spectrophotometrical analysis of crude (3-lactamase extracts from a representative
strain (790) that produced ARI-2, failed to detect direct imipenem hydrolysis.
However, this did not rule out its involvement in imipenem resistance, since this
anomaly has also been reported with ARI-1 (Paton et al., 1993). Indeed, analysis of
crude extract from the ARI-1-producing strain 6B 92 in the present study confirmed
these findings. Following pre-incubation with imipenem, the rate of nitrocephin
hydrolysis of crude extract of 790 decreased from 8.39 to 0.32 nmoles hydrolysed
min"1 mg"1 of protein. This suggested that, although hydrolysis of imipenem could not
be measured spectrophotometrically, P-lactamase binding of this carbapenem has
occurred, resulting in a loss of enzyme activity and a subsequent decrease in the rate
of nitrocephin hydrolysis. A similar finding was also detected with ARI-1 (62.43 to
0.33 nmoles hydrolysed min"' mg"1 of protein).
The possibility existed that the ARI-2 p-lactamase hydrolysed imipenem at a rate too
slow to be detected spectrophotometrically during the 5 minute assay time therefore,
the microbiological assay was modified to measure hydrolysis over a period of 90
minutes. The specific activities of crude P-lactamase extracts from strains 790 and 6B
92 were 0.055 and 0.043 nmoles hydrolysed min"1 mg"1 of protein respectively, which
indicated that indeed, both ARI-1 and ARI-2 hydrolysed imipenem slowly at
comparable rates.
Induction studies with imipenem at lA the strain MIC value did not result in an
increase in MIC value of imipenem for either strain 790 or 6B 92. In addition, there
were no significant corresponding increases in nitrocephin hydrolysis detected after
induction, which suggested that both P-lactamases were non-inducible. P-lactams are
known to act as inducers of class C P-lactamases in Gram-negative bacteria, resulting
in derepression of P-lactamase and high level resistance to many P-lactams (Stapleton
et al., 1995; Bennett and Chopra, 1993). Although inducible P-lactamase genes of
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Gram-negative bacteria were considered to be exclusively chromosomal,
plasmid-mediated AmpC type (3-lactamases have now been found (Bauernfeind et al.,
1996; Payne et al., 1992; Tzouvelekis et al., 1993), some of which are inducible
(Barnaud et al., 1998) and are involved in imipenem-resistance in combination with
impermeability (Bradford et al., 1997; Stapleton et al., 1999). Consequently,
although the induction studies with strain 790 suggested that ARI-2 was not a class C
(3-lactamase, they did not provide any evidence as to the genetic location of the gene
encoding this enzyme.
7.4.3 Elimination of plasmid-determined resistance by treatment with
ethidium bromide
The location of the genetic determinant of ARI-2 was investigated by treating strain
790 with ethidium bromide. This is a trypanocidal drug that preferentially inhibits
plasmid synthesis by intercalating between the base pairs of the double helix causing
lengthening and unwinding. The use of this agent has been used to eliminate
plasmid-encoded antibiotic resistance in staphylococci and enterobacteria
(Bouanchaud et al., 1969). In addition, Paton et al (1993) demonstrated the loss of
imipenem resistance in strain 6B 92 following treatment by ethidium bromide.
A cure rate of 36.8% was obtained with strain 790, and 41% with the
ARI-1 -producing strain 6B 92 which was included as a positive control. These rates
were much higher than previous reports employing this method with Acinetobacter.
Goldstein et al (1983) detected a cure rate of only 0.3% with A. calcoaceticus. Paton
et al (1993) obtained a cure rate of 10% of imipenem resistance with 6B 92 compared
with 41% in this study. Indeed, these workers suggested that resistance plasmids in
Acinetobacter spp. may not be as easily eliminated by this method of curing as those
present in Enterobacteriaceae (Paton, 1994); however, the cure rates of nearly 37%
and 41% obtained in this study are comparable with those obtained with E. coli
(Bouanchaud et al., 1969).
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The MIC values of cured colonies of strain 790 provided additional evidence that
carbapenem resistance was indeed associated with the loss of a plasmid. The MIC
value of imipenem decreased to a susceptible level (16 mg/L to 0.5 mg/L). A less
significant decrease however, was observed with meropenem (4 mg/L to 1.0 mg/L).
None of the other (3-lactams tested were affected by curing as indicated by
comparable MIC values for both cured and parent colonies. The decrease in
carbapenem MIC values were in agreement with Paton and colleagues (1993) who
also obtained similar results with 6B 92; however, in contrast to the findings of these
workers, who also noticed a decrease in MIC values of penicillins after curing, no
corresponding decrease in MIC values of this class was observed with strain 790.
This suggested that although similarities existed with both ARI-1 and ARI-2, they
were not identical P-lactamases.
Isoelectric focusing demonstrated loss of the ARI-2 P-lactamase in cured colonies of
strain 790. The P-lactamase band of pi >8.0 (chromosomal cephalosporinase) was
present in both cured and parent extracts, which suggested that it was not involved in
imipenem resistance, but was responsible for the cephalosporin resistance observed in
this strain. These findings are in agreement with those observed with 6B 92, which
also retained its chromosomal cephalosporinase and resistance to the cephalosporins
following ethidium bromide curing (Paton et al., 1993).
Interestingly, the TEM-1 P-lactamase (pi 5.4) was also retained in the cured colonies.
This enzyme is plasmid-encoded (Bush, 1989b), and subsequently would be expected
to be lost after curing. However, colonies were tested for the loss of imipenem
resistance, and not penicillins. Therefore, the possibility existed that in the cured
colonies tested, ethidium bromide curing had not eliminated the plasmid encoding this
particular enzyme.
When crude P-lactamase extracts of cured colonies of strain 790 were subjected to
the microbiological assay, no inactivation of imipenem was observed. In addition, the
modified microbiological assay detected an 11-fold decrease in the rate of imipenem
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hydrolysis compared with the parent strain. Together, these findings provided strong
evidence that the ARI-2 P-lactamase was indeed the major mechanism of imipenem
resistance and that the gene encoding this enzyme was encoded by a plasmid.
However, the possibility still existed that a change in outer membrane permeability or
alterations in PBPs could be involved in imipenem resistance. To investigate this
hypothesis, a series of susceptibility tests were employed with the serine active-site
inhibitor BRL 42715. By determining the MIC values of both carbapenems in the
presence of this agent, the role of ARI-2 activity in carbapenem resistance could be
evaluated. The results demonstrated that P-lactamase inhibition by BRL 42715
resulted in a MIC value of imipenem comparable to that observed with the cured
strain, suggesting that without the activity of ARI-2, the strain becomes susceptible to
this carbapenem. It is interesting to note that there was not as significant a decrease
in the MIC value of meropenem in the presence of this inhibitor (from 8 mg/L to 4
mg/L), which suggests that, in this particular strain, P-lactamase activity is not the
sole mechanism of reduced susceptibility to this particular carbapenem. Paton et al
(1993) confirmed that activity of the ARI-1 P-lactamase was responsible for imipenem
resistance in strain 6B 92 by this method however, in contrast to ARI-2, these
workers also demonstrated that this p-lactamase was also responsible for the high
MIC value ofmeropenem observed in this strain.
In order to obtain additional evidence that the genetic determinant of ARI-2 was
indeed plasmid-located, a series of experiments were employed in an attempt to
transfer the resistance plasmid. Although the presence of a plasmid of approximately
40 kb in size was visualised in the parent strain, but not in cured colonies of strain
790, all efforts to transfer this plasmid at both 25°C and 37°C were unsuccessful. In
addition, transformation experiments with the highly competent Acinetobacter sp.
BD413-2 strain also failed.
Transfer of the plasmid harbouring the ARI-1 gene has been carried out successfully
using these methods to strains C4161 and BD413, and exclusively at 25°C, which
suggests that the plasmid encodes a temperature-sensitive transfer mechanism (Scaife
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et al., 1995). The inability to transfer the plasmid observed in strain 790 may reflect a
lack of conjugative functions associated with it, and it is possible that an additional
mobilising plasmid is needed (Chopade et al., 1985). Alternatively, the gene encoding
the ARI-2 enzyme may be located on a mobile genetic element that was subsequently
lost from the plasmid. It is known that chromosomally-located transposons carrying
multiple antibiotic resistance genes are present in Acinetobacter spp. (Towner, 1991),
and plasmid-encoded resistance genes, including the genes encoding the
metallo-enzymes 1MP-1 (Arakawa et al., 1995) and V1M-1 (Lauretti et al., 1999)
have been found on integron structures.
The failure to transform Acinetobacter sp. BD413-2 suggests that perhaps the plasmid
observed in strain 790 was larger than initially estimated, and therefore proved too
large to be transferred efficiently. Plasmid transfer was not attempted with recipients
other than Acinetobacter. Both Paton et al (1993) and Scaife et al (1995) failed to
transfer the ARI-1 plasmid to E. coli or P. aeruginosa strains, which is in agreement
with others that have reported an inability of Acinetobacter spp. to transfer
indigenous plasmids to Enterobacteriaceae (Towner, 1991).
The inability of these experiments to demonstrate the transfer of imipenem-resistance
did not invalidate the theory that the ARI-2 gene was located on a plasmid. Rather,
they only confirmed the findings of other workers, that conjugation studies in
Acinetobacter spp. are notoriously difficult (Goldstein et al., 1983; Towner, 1991).
7.4.4 Partial purification and estimation of the Mr ofARI-2
Attempts to separate the ARI-2 (3-lactamase from the other enzymes present in strain
790 were only partially successful in that it could be separated from the
cephalosporinase but not from the TEM-1 (3-lactamase. This suggested that ARI-2
was similar in Mr to this enzyme. This was confirmed by SDS-PAGE with subsequent
renaturation of enzyme activity, which demonstrated 2 bands of activity in close
proximity to each other, with a third band above them.
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The Mr of the lower band (29 .8 kDa) corresponded to that of the TEM-1 P-lactamase
(Bush et al., 1995). The band near the top of the gel was approximately 53 kDa,
which is within the size range reported for the chromosomal cephalosporinases of
Acinetobacter spp., and most closely resembles the cephalosporinase of 58 kDa
described in strain 6B 92 (Paton et al., 1993). Cephalosporinases with Mr values of
30,000 and 38,000 have been described (Morohoshi and Saito, 1977; Hikida et al.,
1989), and the ACE p-lactamases described by Hood and Amyes (1991) range from
35,000 (ACE-3) to >500,000 (ACE-1 and ACE-4) in size.
The third band, presumed to be that of ARI-2 had an Mr value of 35.5 kDa, which is a
higher value than that reported for the ARI-1 P-lactamase (23 kDa) (Paton et al.,
1993), although the value for ARI-1 was estimated by gel filtration rather than
SDS-PAGE, a method that can underestimate the molecular weights of P-lactamases
(Bush, 1989a). Among the serine active-site carbapenemases that have been
characterised, the ARI-2 P-lactamase was more similar in molecular mass to the class
A IMI-1 enzyme (Mr of 32 kDa by SDS-PAGE), which also shares a similar pi value
(7.05) to that of ARI-2 (Rasmussen et al., 1996). Indeed, all of the serine active-site
carbapenemases, including those belonging to Bush group 2d, share similar molecular
masses in the range 28-32 kDa (Bush et al., 1995; Hornstein et al., 1997; Afzal-Shah
etal., 1999b).
7.4.5 Biochemical characterisation of ARI-2
Despite several efforts employing different separation conditions, further purification
of the ARI-2 P-lactamase was unsuccessful however, this problem was solved by
employing another strain (788) from Argentina that contained both a cephalosporinase
and ARI-2, but lacked the TEM-1 P-lactamase.
The substrate profile of ARI-2 demonstrated that this P-lactamase was predominantly
a penicillinase. The highest Vmax values were observed for ampicillin and oxacillin,
although the Vmax/Km ratio for the latter was over 2-fold lower than that observed for
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cephaloridine. Interestingly, slow hydrolysis of imipenem (but not meropenem) was
detected with the purified enzyme. Indeed, the lowest Km value (demonstrating a high
affinity) was detected with this carbapenem (11 pM). The Vmax value for imipenem
(46.8 nmoles hydrolysed min"1 ml"1) was 1.5-fold lower than that detected for AR1-1
(Donald et al., 1999), but almost 2-fold higher than that reported for a carbapenemase
from a clinical isolate ofA. baumannii from Buenos Aires (Afzal-Shah et al., 1999b).
Incidentally, failure to detect meropenem hydrolysis by spectrophotometric means has
also been documented with both these (3-lactamases (Donald et al., 1999; Afzal-Shah
etal., 1999b).
The inability to detect imipenem hydrolysis spectrophotometrically with crude
(3-lactamase extract from ARI-2-producing strains may have been as a result of the
enzyme being too dilute. Considerable enzyme dilution is known to occur during the
extraction procedure (Livermore, 1985). It had been noted that in preparing
(3-lactamase extracts of both strains 788 and 790, the cells resisted sonication
therefore, the possibility existed that an insufficient (3-lactamase yield may have
contributed to this anomaly. The cell walls of Acinetobacter spp. are notoriously
difficult to break open (Towner, 1996). Interestingly, the direct hydrolysis of
imipenem by ARI-1 has recently been reported (Donald et al., 1999), even though
initial studies by Paton et al (1993) failed to demonstrate this. The former workers
achieved this only after purification and subsequent concentration of the enzyme.
Slow hydrolysis of both oxacillin and cloxacillin was demonstrated, which suggested
that the ARI-2 (3-lactamase was not a Bush group 2f carbapenemase, since none of
the enzymes in this group have been shown to hydrolyse either antibiotic, but that it
may be related to one of the OXA-type enzymes of Bush group 2d, although such
enzymes tend to hydrolyse these (3-lactams far more effectively (>50% that for
benzylpenicillin) (Bush et al., 1995) than was demonstrated with ARI-2. However,
there are exceptions to this criterion, notably OXA-4 (Philippon et al., 1983), and the
AmpS oxacillinase from Aeromonas jandei that hydrolyses cloxacillin poorly (Walsh
et al., 1995). Another characteristic of oxacillinases is that they are not as well
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inhibited by clavulanic acid as class A P-lactamases (Bush et al., 1995), a feature that
ARI-2 also demonstrated. Indeed, an identical ID5o value (100 pM) was also detected
for ARI-1 by Paton et al (1993) using this inhibitor, compared with a value of 0.5 pM
for the class A p-lactamase TEM-1.
Further evidence to suggest that the ARI-2 p-lactamase was OXA-derived was
provided by the observation that inhibition of activity occurred with sodium chloride
(ID5o value of 3.2 mM), a characteristic shared by oxacillinases (Naas and Nordmann,
1999). Cloxacillin (an inhibitor of class C P-lactamases) was not an effective inhibitor
of enzyme activity, as demonstrated by a ID50 value that was almost 2000-fold higher
than that observed for the ACE cephalosporinases (Hood and Amyes, 1991). Low
ID50 values were detected for imipenem and meropenem, indicating high enzyme
affinity for both carbapenems.
The majority of OXA-type p-lactamases are found on plasmids and are subsequently
found in a large number of different species (Naas and Nordman, 1999). However,
the presence of these enzymes in Acinetobacter spp. has only been a recent event. In
addition, an alarming characteristic of the majority of the enzymes discovered so far in
this genus, is an ability to confer resistance to imipenem (Hornstein et al., 1997;
Afzal-Shah et al., 1999a; Afzal-Shah et al., 1999b; Donald et al., 2000), although the
first sequenced oxacillinase to be reported in Acinetobacter spp. (OXA-21) was from
an imipenem-sensitive strain (Vila et al., 1997a). The ARI-1 P-lactamase was
originally classified as an Ambler class A carbapenemase (Paton et al., 1993);
however, this too has now been demonstrated to be an OXA-type enzyme (Donald et
al., 2000).
The substrate profile of ARI-2 was similar to that of the other oxacillinases described
in Acinetobacter in that it was not a hydrolyser of the second and third-generation
cephalosporins. The OXA-type P-lactamases of group 2d differ in their ability to
confer resistance to the extended-spectrum cephalosporins. Derivatives of OXA-10
(OXA 11, -14, -16 and -17), and OXA-15 (a derivative of OXA-2), have broader
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activity than the other oxacillinases (Naas and Nordman, 1999). In contrast, ARI-2
appears similar in substrate range to ARI-1 (Donald et al., 2000), and to other
narrow-spectrum oxacillinases (Naas and Nordmann, 1999).
7.4.6 Molecular characterisation of ARI-2
7.4.6.1 Investigation of homology with other serine active-site P-lactamases
The bands of ARI-2 as observed by IEF were identical to those of the
extended-spectrum SHV-3 P-lactamase. Therefore, a series of PCR reactions and
hybridisation experiments were performed to rule out the possibility that it was an
SHV-derived enzyme. The results of these indicated it was not SHV-derived, and the
identical banding pattern was attributed to the fact that many P-lactamases share
identical pi values even though they are not related to each other (Bush et al., 1995).
The biochemical analysis of the ARI-2 P-lactamase suggested that it belonged to
Ambler class D. OXA-21 was identified in an imipenem-sensitive Acinetobacter
clinical isolate, and shares an identical pi value to that of ARI-1 (Vila et al., 1997a),
therefore it was theoretically possible that ARI-2 was a mutated form of this
P-lactamase that had acquired the ability to confer resistance to imipenem. However,
this hypothesis was unfounded since PCR with intragenic primers, designed from the
gene of OXA-21, failed to detect any product with ARI-2-producing strains.
OXA-21 is included in a phylogenetic group that includes OXA-2, OXA-3, OXA-15
and OXA-21 (Sanschagrin et al., 1995; Naas and Nordman, 1999), and shares 99.6%
amino acid homology with the OXA-3 P-lactamase (Vila et al., 1997a).
Attention was subsequently directed towards identifying possible homology with the
gene encoding ARI-1. However, PCR analysis with intragenic primers again failed to
detect a product, even when reduced annealing temperatures were employed to
encourage the primers to anneal to sequences that have less similarity. This was
surprising since non-specific products were expected, at least with strain 6B 92 that
was present as a positive control. However, the possibility still existed that the ARI-2
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gene may share significant homology with the complete ARI-1 gene sequence
therefore DNA:DNA hybridisation studies were employed to investigate this further.
Although initial results were extremely promising in that plasmid DNA from strain
790 demonstrated moderate cross-hybridisation with an ARI-1-specific gene probe,
subsequent plasmid DNA preparations failed to produce a signal and, in addition,
several chromosomal DNA preparations from the same strain were demonstrated to
hybridise with this probe. These findings suggested that perhaps chromosomal
contamination had produced the initial result. However, the curing experiments had
successfully demonstrated the loss of ARI-2 as a result of plasmid elimination, and a
plasmid of approximately 40 kb had been visualised in the parent strain that was not
apparent in the cured.
Further hybridisation studies with a degenerate probe for a conserved sequence of
bla0xA genes also produced cross-hybridisation with chromosomal DNA but not with
plasmid DNA. Consequently, this raised the possibility that the ARI-2 gene was on a
mobile element that allowed its transfer between the chromosome and plasmid.
Interestingly, the chromosomal DNA of the cured strain also hybridised, albeit weakly
with this probe. One possible explanation could be the presence of a silent copy of
the ARI-2 gene on the chromosome that would be detected by hybridisation with this
probe. Indeed, silent copies of the carbapenem-resistance gene cfA are known to be
carried by a small number of isolates of Bacteroides fragilis, in which insertion of a
small insertion sequence immediately upstream of the gene results in its activation
(Podglajen et al., 1992).
A substantial proportion of antibiotic resistance genes found in Gram-negative
bacteria are located within gene cassettes that are usually within integrons (Hall and
Collis, 1998). Indeed, a common feature of the majority of oxacillinase genes is that
they are located on the variable region of integrons (Philippon et al., 1997; Naas et
al., 1998; Naas and Nordmann, 1999). Of the oxacillinases described in
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Acinetobacter spp., OXA-21 remains the only one so far to be found associated with
an integron (Vila et al., 1997a), although molecular characterisation of many of the
other enzymes is ongoing.
PCR amplification with 2 sets of primers designed to anneal to the 5' and 3' ends of
the IntI 1 gene, and to the variable region of class 1 integrons, failed to produce
products with strain 790, which suggested that there were no class 1 integrons present
in this strain. However, several class 1 integrons do not possess a qacEAl resistance
gene (encoding antiseptic and disinfectant resistance) (Hall and Collis, 1998), to
which the Cass 2 primer anneals, therefore no product will be obtained if such
integrons are present. Furthermore, the sequence of the region containing the
integrase gene and the attl recombination site is distinct in each of the three classes of
integrons (Recchia and Hall, 1995) thus, primers designed to detect this region in
class 1 integrons will not detect those belonging to class 2 or class 3.
Class 1 integrons (of the sull type) are most prevalent in clinical isolates, although the
bla^s> gene cassette has been found in both class 1 and class 3 integrons (Arakawa et
al., 1995). Subsequently, PCR analysis of ARI-2-producing strains with primers
specific for these integrons, or indeed for class 1 integrons that do not contain a qacE
gene may yet identify an integron location of the ARI-2 gene.
Although initial molecular studies had failed to obtain a handle on the sequence of the
ARI-2 gene, they strongly suggested that ARI-2 was indeed a class D enzyme, and,
although not identical to AR1-1, some homology existed between the two
P-lactamases.
7.4.6.2 N-terminal amino acid sequencing of the ARI-2 protein
A different approach was employed in an attempt to gain an initial sequence region of
the gene. Although both sequenced protein bands, from column fractions containing
the ARI-2 P-lactamase, failed to demonstrate homology with any p-lactamases, band
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A was removed from the investigation since it shared 95% amino acid homology with
a ribosomal binding protein. This left the second band (B), and, although no
homology was identified with any relevant proteins, it was possible that this sequence
represented a signal peptide of the ARI-2 (3-lactamase, much in the same way as the
N-terminal sequence of ARI-1 proved to be the signal peptide of this enzyme (H.
Donald, personal communication). Hybridisation studies with a degenerate probe
designed from this sequence however, failed to detect a signal with either
ARI-2-producing strains or with the ARI-1 transconjugant strain, even under low
stringency conditions, and may have been as a result of the degenerate nature of the
probe.
Sequencing of the ARI-1 gene (which has 36% identity with OXA-5 and OXA-IO)
has revealed an unusual substitution in one of the conserved regions found in
OXA-type (3-lactamases called the Y-G-N motif, in which tyrosine (Y) has been
replaced by phenylalanine (F) (Donald et al., 2000). Indeed, the only other class D
carbapenemase (pi value of 9.0) from Acinetobacter that has been sequenced, shows
a similar identity (40%) with OXA-10, and also has this unique substitution (Bou and
Martinez-Beltran, 1999), which suggests that it may be important in the ability of
these enzymes to hydrolyse imipenem. In addition, the Y-G-N motif of the OXA-21
gene (from an imipenem-sensitive A. baumannii isolate) is conserved (Vila et al.,
1997a). It would therefore be interesting to determine whether this substitution was
present in the ARI-2 gene.
7.5 The presence ofARI-2 in clinical isolates from Turkey, Spain and
Hong Kong
The presence of P-lactamases identical to ARI-2 in 8 isolates from these countries
suggests that this enzyme possesses the potential to transfer horizontally. Indeed,
analysis of RFLP patterns of isolates producing ARI-2 indicated that this had
occurred with the strains from Buenos Aires. These findings were further supported
by the fact that none of the patients from which ARI-2-producing strains had been
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isolated had attended any of the other hospital centres, which were geographically
remote from each other (J. Smayevsky, personal communication). However, the
presence of isolates from clusters C and E in more than one hospital in Buenos Aires,
provided evidence that clonal spread had also occurred and indicated that there had
been some contact between the hospitals.
Isolate 787 had been identified as A. junii by the API 20NE system however, the
RFLP pattern of this isolate shared 97% similarity with the A. baumannii isolate 790,
suggesting that the biotyping of this strain was incorrect.
The presence of this P-lactamase in isolates from several countries is of major
concern. Although discovery of the ARI-1 P-lactamase generated interest in the
scientific field, it has only been found in a single clinical isolate (Paton et al., 1993),
although recent research that has identified ARI-1 as a class D enzyme has renewed
interest in this P-lactamase (Donald et al., 2000). The imipenem-hydrolysing
oxacillinase reported in France was also from a single isolate (Hornstein et al., 1997).
However, more recently, there have been incidences of similar enzymes from multiple
isolates world-wide (Afzal-Shah et al., 1999a), although to my knowledge, none of
these strains have been analysed to determine whether they are genetically unrelated,
and none of the P-lactamases have been found in more than one country.
Consequently, the ARI-2 p-lactamase is unique in that it appears to be the first of
these enzymes to be associated with world-wide carbapenem resistance.
7.6 Quinolone resistance in Acinetobacter spp.
The emergence of Acinetobacter species, in particular, A. baumannii as important
nosocomial pathogens has resulted in an increased reliance on the carbapenems for the
treatment of serious infections caused by these organisms. Unfortunately, the recent
development of resistance to this class of P-lactams and, in particular, (as the work of
this thesis has demonstrated) the emergence of imipenem-hydrolysing P-lactamases
has undermined their therapeutic success, with the result that the range of available
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antimicrobial agents that are still active against Acinetobacter is becoming severely
limited. So what are the alternatives? The fluoroquinolones, for example
ciprofloxacin, have until recently proven to be highly active against this genus. In
1995, approximately 80% of strains were susceptible to ciprofloxacin, pefloxacin and
ofloxacin (Bergogne-Berezin, 1996); however, resistance has increased within the last
decade. Recent research into this class of antibiotics has resulted in a plethora of new
fluoroquinolones that are about to emerge into the therapeutic spotlight. The aim of
this particular study was therefore to determine the efficacy of some of the newer
agents against multi-resistant Acinetobacter spp., and to ascertain whether they
represent a therapeutic alternative against imipenem-resistant clinical isolates.
Antimicrobial susceptibility testing revealed significant resistance to all of the agents
tested, with the highest resistance levels observed for ciprofloxacin (nearly 90%),
followed closely by norfloxacin (87%). In addition, the highest MIC50 and MIC90
values were also demonstrated for these agents. A total of 43.5% of isolates
demonstrated resistance to all the quinolone agents tested. Acinetobacter strains
readily develop resistance to the fluoroquinolones, a characteristic of this genus that is
illustrated by the increase in ciprofloxacin resistance in the past decade. A survey of
A. baumannii isolates collected over a 6 year period detected a decrease in
susceptibility levels to ciprofloxacin from 43% in 1991 to 6% in 1997 (Rodriguez-
Bano, 1999), and this appears to reflect an increase in ciprofloxacin resistance that is
being reported generally (Hanberger et a!., 1999; Traub and Spohr, 1989; Vila et al.,
1993; Mokaddas et al., 1998). Over half of all isolates were resistant to levofloxacin,
which is in agreement with a recent survey that reported a resistance rate of 58.9%
among Acinetobacter spp. tested (Sader et al., 1998).
The newer quinolones were generally more active, although resistance rates were over
60% for all with the exception of sparfloxacin (43.6%). A recent surveillance
program of antimicrobial susceptibility patterns in 6 Latin American countries
reported a comparable resistance rate for trovafloxacin among Acinetobacter isolates
(Sader et al., 1998); however, a higher rate of resistance to sparfloxacin was
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demonstrated by these workers (66.4%) than observed in this study. The newest
generation of fluoroquinolones, which includes moxifloxacin and trovafloxacin have
enhanced activity against S. pneumoniae and anaerobes, and were developed
essentially to overcome resistance by these organisms to the earlier agents (Andriole,
1999). A study of the activity of moxifloxacin against both Gram-positive and
Gram-negative organisms (including Acinetobacter spp.), reported that this quinolone
was equal in activity to ciprofloxacin against Gram-negatives (with the exception of
P. aeruginosa) (Peterson et al., 1999), which is in contrast to this study which
indicates that this particular agent is superior in activity to ciprofloxacin against
multi-resistant Acinetobacter spp.
When comparing susceptibility rates, an important point to mention is that the
majority of studies generate their resistance data using the guidelines of the National
Committee for Clinical Laboratory Standards (NCCLS). However, research groups
within the United Kingdom tend to use the guidelines of the British Society for
Antimicrobial Chemotherapy (BSAC) Working Party, although there appears at
present to be a gradual shift towards the NCCLS guidelines in Scotland. Both
guidelines employ different breakpoint values with the result that susceptibility rates
of studies cannot always be readily compared, especially between countries. The
resistance rates in this study were calculated using the breakpoints of the BSAC
guidelines however, when these rates are altered to accommodate the NCCLS
breakpoints, there is a significant decrease in the resistance rates observed for the
newer quinolone agents (Table 7.1).
Using the breakpoint values of the NCCLS guidelines, approximately 52% of isolates,
that were designated resistant to moxifloxacin and trovafloxacin according to the
BSAC guidelines, subsequently move into the susceptible category, and 28% become
susceptible to sparfloxacin.
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Table 7.1 Percentage resistance rates employing BSAC and NCCLS
guidelines
% Resistance







1 resistant = > 2 mg/L (Working Party on Antibiotic Sensitivity Testing, 1991, 1998a)
2 resistant = > 4 mg/L (NCCLS, 1997)
1
% resistance calculated using tentative breakpoint value of 1 mg/L (Andrews et al.,
1999)
Clearly, as these results illustrate, there is a need for the global standardisation of
susceptibility testing guidelines. Although it is generally agreed that neither guidelines
are perfect, a recent correspondence by Hamilton-Miller (1999) has commented that
the most recent publications from the BSAC Working Party (Working Party on
Antibiotic Sensitivity Testing 1998a, 1998b) more closely resemble those of the
NCCLS guidelines in some respects, but as he states, "the most desirable goal of all"
is " - global harmonization". Perhaps the only way this can be achieved is for both
parties to accommodate the views of each other in future publications, or even better,
to amalgamate aspects from both to produce one set of guidelines.
7.6.1 The mechanisms of quinolone resistance in Acinetobacter
clinical isolates
PCR amplification of the QRDR of the gyrA gene of clinical isolates ofAcinetobacter
identified a substitution of Ser83 with Leu in all strains with ciprofloxacin MIC values
of between 2 and 128 mg/L, whereas strains exhibiting MIC values of < 1 mg/L did
not produce this mutation, suggesting that this substitution is required for high level
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resistance to ciprofloxacin in Acinetobacter spp. These findings correlate well with
other studies that have also identified this change as the primary mutation in other
Acinetobacter isolates with ciprofloxacin MIC values of > 4 mg/L (Vila et al., 1995,
Seward and Towner, 1998). Interestingly, the latter study also detected this amino
acid change in an isolate ofAcinetobacter sp. 3, the ciprofloxacin MIC of which was
only 1 mg/L, suggesting that there are other mutations or mechanisms that are
involved in the development of high level resistance.
No substitutions other than at Ser-83 were identified in the present study, in contrast
to Vila et al (1995) who demonstrated a change at Ala-84 to Pro in addition to the
Ser-83 change in an isolate with a ciprofloxacin MIC value of 64 mg/L. In addition,
Seward and Towner (1998) also identified a Ser-83 to Phe change in an isolate with a
ciprofloxacin MIC value of 32 mg/L.
DNA gyrase is the primary target of fluoroquinolones in Gram-negative bacteria, and
within GyrA of E. coli, mutations of Ser-83 and Asp-87, give the greatest reduction
in susceptibility (Drlica and Zhao, 1997). These mutations have also been found in
quinolone-resistant isolates of P. aeruginosa (Kureishi et al., 1994), Campylobacter
jejuni (Wang et al., 1993) and S. aureus (Sreedharan et al., 1991). In Acinetobacter,
Asp-87 of E. coli is changed by Glu however, no changes affecting this amino acid
were identified in this study or indeed in the studies of Vila et al (1995), and Seward
and Towner (1998).
There is considerable conservation between the sequence of the genes encoding the A
subunit of topoisomerase IV (parC, or grlA of S. aureus) (Kato et al., 1990) and the
gyrase A subunit, and it is now known that ParC is a secondary target of the
fluoroquinolones in E. coli and other Gram-negative organisms (Khodursky et al.,
1995). Mutations at Ser-80 and Glu-84 of ParC in E. coli have been detected only in
strains that already have gyrA mutations and at high fluoroquinolone concentrations
(Chen et al., 1996; Kodursky et al., 1995), indicating that both gyrA and parC
mutations are needed to confer higher levels of resistance. Two recent studies have
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investigated whether similar mutations occur in the parC gene of Acinetobacter spp.
and have identified a Ser-80 to Leu mutation in strains exhibiting high level quinolone
resistance that also had gyrA mutations (Vila et al., 1997b, Seward and Towner,
1998).
PCR analysis of the QRDR of parC of isolates that demonstrated a gyrA mutation
was employed to determine whether mutations within this region were responsible for
the varying MIC values observed in these strains. A Ser to Leu change at the position
equivalent to codon 80 of E. coli was identified in the majority of isolates with
ciprofloxacin MIC values of > 16 mg/L, which confirmed the findings of both Vila et
al (1997b), and Seward and Towner (1998). It has been demonstrated that compared
with E. coli, fewer mutations are required by Acinetobacter in order to obtain high
levels of quinolone resistance (Vila et al., 1997b). The undisputed reputation of
Acinetobacter spp. for rapidly acquiring resistance to the fluoroquinolones, as with all
non-fermentative Gram-negatives, has been attributed in part to reduced uptake
mechanisms that are well-known characteristics of these organisms (Amyes and
Young, 1996). It is therefore possible that reduced permeability may be a
contributing factor in quinolone resistance observed in these strains.
Interestingly, the parC mutation was not detected in 4 strains with a ciprofloxacin
MIC value of 16 mg/L. Seward and Towner (1998) also reported this anomaly in an
isolate exhibiting high level ciprofloxacin resistance (64 mg/L). However, in the
present study, a Glu-84 to Lys change was present in the absence of the Ser-80 to Leu
change in one of these isolates (830). Interestingly, this mutation has also been
detected by Vila et al (1997b) in a high level ciprofloxacin-resistant strain which did
not have the Ser-80 change, which indicates that further studies are required to
investigate the role that mutations in other areas of both genes may play in quinolone
resistance. Indeed, from studies involving the second sub-unit of gyrase in E. coli
(GyrB), it is known that there are also hotspots for mutations within this gene,
although it is generally considered that such mutations are rare contributors to
fluoroquinolone resistance (Nakamura et al., 1989). Similarily, hotspots have also
208
been identified in the parE gene of topoisomerase IV in quinolone-resistant
S. pneumoniae (Perichon el al., 19971, E. coli (Breines et a!., 1997), and S. aureus
(Takahashi etal., 1998).
Several efflux systems have been identified in both Gram-positive and Gram-negative
bacteria that are known to be involved in the acquisition of resistance to several
antibiotics, including the fluoroquinolones (Kaatz et al., 1993; Poole et al., 1993;
Poole et al., 1996; Kohler et al., 1997). One hypothesis is that increased expression
of an efflux pump is responsible for low level resistance, and may promote selection
of mutations in target genes that are responsible for higher level resistance (Piddock,
1999; Pechere et al., 1998). Although it is not yet clear whether similar systems are
involved in fluoroquinolone resistance in Acinetobacter spp., it is highly likely that
they are. Several isolates in the present study demonstrated variable levels of
resistance to the quinolones tested, and it would be interesting to discover whether
such efflux systems, or mutations other than those discussed here have an impact on
the relative potencies of the newer members of the fluoroquinolone class.
7.7 The efficacy of sulbactam against imipenem-resistant
Acinetobacter clinical isolates
Overall, sulbactam was not effective against imipenem-resistant isolates tested (MIC
range 2 - >16mg/L), but lower MIC values were detected with imipenem-sensitive
isolates from Scotland (0.5-2.0 mg/L). Furthermore, this inhibitor did not have a
significant inhibitory effect against imipenem-resistant strains. The intrinsic activity of
sulbactam against Acinetobacter spp. has been attributed to its affinity for PBPs 1 and
2 (Urban et al., 1995), and there are several reports that have demonstrated its
efficacy both alone and in combination with ampicillin against this genus (Faas et al.,
1996; Pandey et al., 1998; Vila et al., 1993; Weingarten et al., 1999). The emergence
of imipenem-resistant strains has prompted several workers to investigate whether
sulbactam could be used effectively against them, and there is evidence to suggest that
in some instances, this might be the case. Urban et al (1993) reported that 90% of
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patients infected with imipenem-resistant strains of Acinetobacter improved clinically
after receiving ampicillin plus sulbactam. In addition, Corbella et al (1998) have
suggested that the use of sulbactam alone may provide an alternative therapy for
infections caused by imipenem-resistant strains. However, the results of the present
study suggest otherwise, and there is evidence elsewhere that supports these findings
(Wood and Reboli, 1993).
Interestingly, the highest MIC value of sulbactam (4 mg/L) among the isolates from
Scotland was demonstrated with the imipenem-resistant strain 6B 92 (number 792),
that produces the ARI-1 carbapenemase (Paton et al., 1993). To our knowledge, this
strain was never exposed to either imipenem or sulbactam, but has nonetheless
succeeded in acquiring a reduced susceptibility to both.
The highest MIC values were detected among imipenem-resistant isolates from
Argentina where sulbactam is available for clinical use, with the result that a high
percentage of strains are resistant. A recent surveillance study of nosocomial
resistance in Argentina has reported a resistance rate of 65% to ampicillin/sulbactam
among Acinetobacter spp. (C. Bantar, unpublished data).
Tazobactam demonstrated considerable less activity than sulbactam against both
impenem-sensitive and imipenem-resistant isolates. Although this inhibitor has been
reported to have activity against A. baumannii (Garcia et al., 1983), there is
conflicting evidence of its efficacy in the treatment of Acinetobacter infections
(Mokaddas et al., 1998; Marques et al., 1997; C. Bantar, unpublished findings).
An investigation of the combined effect of imipenem and sulbactam against
imipenem-resistant isolates suggested that this combination may be effective against
such strains however, it was subsequently demonstrated that, although the addition of
sulbactam produced a bactericidal activity with one particular strain, this inhibitor
alone did not possess bactericidal activity, and its addition may in some cases
antagonise the activity of imipenem.
210
The efficacy of imipenem and sulbactam against Acinetobacter is not well
documented; however a lack of synergy between both agents has also been reported
with an imipenem-resistant strain of A. baumannii (Joly-Guillou et al., 1995). In
contrast, Aubert and colleagues (1996) detected a superior bacteriostatic and
bactericidal effect when sulbactam was combined with imipenem, although
imipenem-sensitive strains were used in this study. It appears, therefore, that the
combined effect of imipenem and sulbactam cannot be predicted and is very much
strain-dependant.
7.8 Concluding remarks
This thesis has attempted to shed some light on the mechanisms of antibiotic
resistance in Acinetobacter spp. and, in particular, has highlighted a growing trend of
carbapenem resistance that is emerging world-wide. However, the carbapenems have
been, and will remain, the drugs of choice in the treatment of nosocomial infections
caused by multi-resistant Acinetobacter. It is therefore extremely important that the
use of these antibiotics is limited as much as possible in an attempt to slow this
worrying trend. The consumption of carbapenems in some areas of Argentina has
increased by as much as 300% in little over a year. It is fortunate that in the UK at
least, carbapenem resistance in this genus is still relatively rare. However, the
discovery of the ARI-1 carbapenemase in Scotland is a reminder that this situation
should not be taken for granted. In addition, the ability of Acinetobacter to develop
carbapenem resistance via transfer of novel (3-lactamases, as observed with ARI-2,
also emphasises the need for alternative therapeutic choices.
The fluoroquinolones play an important role in the treatment of serious infections
however, the rapid emergence of quinolone resistance in Acinetobacter, as observed
with ciprofloxacin, indicates the range of effective antimicrobials that can be used
against this genus is becoming limited. The findings of this thesis suggest that the
new emerging quinolones may be effective against multi-resistant strains short-term,
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but it is highly likely that the use of other quinolones may select resistance to these,
with the result that their usefulness may be seriously curtailed.
Sulbactam has been an alternative agent in countries that are faced with increasing
numbers of multi-resistant strains. Unfortunately, this inhibitor does not have
bactericidal activity against Acinetobacter, and as these results have demonstrated, is
ineffective against imipenem-resistant strains. Countries such as Argentina, where
sulbactam is in use are now experiencing resistance rates of over 30%.
Are we now approaching the stage where antibiotics have outlived their usefulness?
It appears that bacteria have always succeeded in staying at least one step ahead of
man's endeavour to combat infection. Perhaps it is naive to expect to win this battle
solely with antimicrobial agents, of which so many are utilised by bacteria themselves
as defence mechanisms. Research is now beginning to embrace areas other than
antimicrobials, but whether these will provide a viable alternative to the current
therapies available remains to be seen.
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preparations administered to individual patients by the
amount of IVIG each patient received during the 5 days
resulted in a mean of 15-71 mg total (active and latent)
TGF(3 (52% TGFpi, 48% TGF|32) received by the patients
during the course of therapy.
We can now report that the powerful immunosuppressive
cytokine TGF(3 is present in substantial amounts in
commercially available IVIG preparations. Since
immunoglobulin has been described as a carrier of TGF(3,4
the high concentrations of TGFp in IVIG may initially be
delivered by IVIG, namely by the immunoglobulin-bound
cytokine. Because our experiments disclosed no adherence of
TGFp to IgG, the methods for the manufacture and long-
term storage of IVIG may facilitate the dissociation ofTGFp
non-specifically bound to IgG. The inference that TGFp
contributes to the therapeutic effects of IVIG therapy is
supported by the results of various animal studies on
autoimmune diseases,5 in which the administration ofTGFp
led to increased immunosuppression similar to that seen
under IVIG therapy. Although TGFp-containing IVIG
preparations may be useful in the treatment of autoimmune
diseases, their value in the treatment of other disorders is
unknown. It remains for future clinical trials to compare the
effects of IVIG preparations with and without TGFp or to
apply TGFp alone in the treatment of human autoimmune
diseases.
This work was supported by a grant from the Bundesministerium fur
Forschung und Technologie, Bonn, Germany (01 kd 89030). We thank
Thilo Kahne and Kathleen Bartels for their technical help.
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Masashi Tanaka, Jian-Sheng Gong, Jin Zhang, Makoto Yoneda,
Kunio Yagi
Mutations of mitochondrial DNA (mtDNA) have been
reported in mitochondrial encephalomyopathies,
cardiomyopathies, and diabetes mellitus. It has been
proposed that accumulation of mtDNA mutations in
somatic cells contributes to ageing and to degenerative
diseases.1 Sequence diversity of mtDNA is marked between
individuals, because the evolutionary rate of mtDNA is
5-10 times higher than that of nuclear DNA. An
epidemiological study on coronary heart disease has
indicated that longevity is more strongly associated with
age of maternal than age of paternal death.2 It may be that
maternally transmitted mitochondrial genotypes influence
oxidative damage to mtDNA, the accumulation rate of
mtDNA mutations, and susceptibility to degenerative
Cumulative number
Age distribution of patients with Mt5178A and Mt5178C
Cumulative number of patients against age of each patient.
diseases—and thereby life span of the individual. To
examine this hypothesis, we analysed mtDNA from 37
Japanese centenarians.
The entire coding regions of mtDNA, including two
rRNA genes, 22 tRNA genes, and 13 protein-coding genes,
from 11 centenarians were sequenced by fluorescence-
based automated direct sequencing.3 Although there were a
variety of nucleotide substitutions, we identified several
that were more frequent among these centenarians than
among the 43 controls whose mtDNA sequences had been
analysed.4 Two nucleotide substitutions causing aminoacid
replacements (a C-to-A transversion at nucleotide position
[np] 5178 within the NADH dehydrogenase subunit 2 gene
[ND2], causing Leu-to-Met replacement; and a C-to-T
transition at np 8414 within the ATP synthase subunit 8
gene [ATP8], causing Leu-to-Phe replacement) as well as a
G-to-A transition at np 3010 within the 16S rRNA gene,
were more frequently observed in the centenarians than in
the controls (Mt5178A in 9/11 centenarians vs 12/43
controls, p<0-01; Mt8414T in 7/11 centenarians vs 11/43
controls, p<0-05; and Mt3010A in 7/11 centenarians vs
11/42 controls, p<0-05). Most of these variations were
linked; all of the seven centenarians with both Mt8414T
and Mt3010A carried Mt5178A.
Among these variations, we focused on Mt5178A and
screened 37 centenarians and 252 healthy blood donors in
Aichi Prefecture for the presence of Mt5178A by PCR-
restriction fragment length polymorphism (PCR-RFLP)
with Alul. The frequency of Mt5178A was significantly
higher in centenarians (23/37, 62%) than in blood donors
(114/252, 45% p=0-04, odds ratio 1-99). This finding
suggests that Mt5178A is related to longevity.
To evaluate the effect of mtDNA variations on the
occurrence of diseases, we analysed the frequencies of
Mt5178A and Mt5178C in 338 randomly selected
inpatients and outpatients at Nagoya University Hospital.
The age distribution of the patients with Mt5178A or
Mt5178C (figure) indicated that the frequency of
Mt5178C was almost the same as that ofMt5178A among
the young patients (Mt5178 A:C ratio 46:40 for patients
aged <46), whereas the frequency of Mt5178C increased
more markedly than that of Mt5178A among old patients
(Mt5178 A:C ratio 86:166 for patients aged 3=46) with a
clear reflection point at age 45. The ratio of Mt5178 A/C
was significantly lower in the old patients (Mt5178 ratio
86:166) than in both the centenarians (23:14, p=0-001)
and the healthy controls (114:138, p=0-01). This result
suggests that the individuals with Mt5178C are more
susceptible to adult-onset diseases than those with
Mt5178A.
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Cann et al reported, in their study on human evolution,5
that among 147 samples from the world, only five Asians
and one European carried Mt5178A. This observation
indicates that Mt5178A is relatively rare among the global
population. The high frequency of Mt5178A among the
Japanese population (45%) may be relevant to the fact that
the life expectancy at birth in Japan is among the highest on
Earth. Life expectancy for females is 83-59 years, while for
males it is 77-01 years.
Our findings support the concept that to carry an
mtDNA genotype predisposing resistance to adult-onset
diseases is one of the genetic factors for longevity. Further
studies are needed to clarify the functional differences
between these mtDNA variations. It will also be interesting
to identify those adult-onset diseases to which individuals
with Mt5178C are susceptible.
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Llic Ministry of Education and Science and Culture of Japan, and a
grant from Ministry of Health and Welfare to MT. We thank Ko
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Limitation of Acinetobacter
baumannii treatment by plasmid-
mediated carbapenemase ARI-2
Susan Brown, Carlos Bantar, Hilary-Kay Young,
Sebastian G B Amyes
Acinetobacter species now account for 10% of nosocomial
infections in intensive therapy units (ITU) in Europe. They
are invariably multiresistant, and one major concern is the
increasing incidence of carbapenem-resistant isolates, since
these antibiotics are frequently the therapeutic choice for
these infections. Carbapenem resistance in South America
has already reached levels that significantly influence
therapeutic choices (Carlos Bantar, unpublished data), and
this looks set to be a problem in some European countries.1
ARI-1, a plasmid-mediated enzyme capable of hydrolysing
imipenem, was the first carbapenemase to be isolated from
this genus.2 We report a novel plasmid-mediated
carbapenemase (ARI-2) from a multiresistant clinical
isolate of A baumannii from Argentina (first described in
1996).3
The strain (1622) was isolated from a bronchial alveolar
lavage specimen and identification was carried out by the
API 20NE identification system. Minimum inhibitory
concentrations (MIC) of a range of antibiotics were
determined by the agar dilution method.4 A cell-free extract
of strain 1622 was prepared and p-lactamase bands were
detected by isoelectric focusing (IEF) on a polyacrylamide
gel. Inhibitors were applied to the gel to detect enzyme
inhibition. Imipenem hydrolysis was demonstrated by a
microbiological assay.2 This assay was modified to increase
sensitivity and quantify the activity of the enzyme.3 Curing
■'iBfr
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Isoelectric focusing gel showing inhibitor overlays
Edetic acid 10~2 mol/L, clavulanate 10-3 mol/L, l=metallo-enzyme
from Stenotrophomonas maltophilia, TEM-l=class A enzyme.
experiments with ethidium bromide were used to
determine if imipenem resistance was plasmid-mediated.
Susceptibility tests and IEF were carried out on cured
colonies.
Strain 1622 was resistant to all antibiotics tested,
including imipenem (MIC 16, mg/L). The addition of
enzyme inhibitors, including sulbactam which is usually
intrinsically active against Acinetobacter spp did not reduce
carbapenem MIC values. IEF detected the presence of a
novel p-lactamase designated ARI-2 (main band of pi 6.5).
Enzyme activity was inhibited by clavulanate and BRL
42715 but not edetic acid (shown by IEF inhibitor
overlays), indicating that ARI-2 was a class A p-lactamase
rather than a metallo-enzyme (figure). Strain 1622
inactivated imipenem as decteted by the microbiological
assay. Slow imipenem hydrolysis was calculated by the
modified microbiological assay (0-75 nmol min"1 mL"1).
After plasmid curing, the ARI-2 enzyme was lost from
strain 1622, detected by IEF. There was also more than a
tenfold decrease in the rate of imipenem hydrolysis (0-067
nmol min"1 mL"1), as well as a reduction in carbapenem
MIC values to susceptible levels, which strongly linked
ARI-2 with plasmid-encoded carbapenemase activity.
These results, and the increasing incidence of
carbapenem-resistant Acinetobacter spp, highlight how the
'role of these antibiotics in the treatment of ITU infections
is severely threatened. Our preliminary investigations have
also demonstrated the presence of ARI-2 in a number of
clinical isolates of Acinetobacter (including A junii)
(unpublished), from Europe and south-east Asia. This
carbapenemase looks set to become a major worldwide
resistance problem which, along with the recent report of a
meticillin-resistant Staphylococcus aureus (MRSA) isolate
with reduced susceptibility to vancomycin,5 is an indication
of the alarming ability of modern pathogens to become
totally resistant in response to the introduction of
therapeutic strategies. The emphasis must now be on
finding alternative antibiotic therapies.
We thank the Acute Healthcare Research Committee of the Scottish
Office for grant number K/MRS/50/C2522 to SGBA and HKY. This
grant supported the above work and partially funds SB.
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Specific HLA class I
down-regulation is an early event in
cervical dysplasia associated with
clinical progression
Hetty J Bontkes, Jan M M Walboomers, Chris J L M Meijer,
Theo J M Helmerhorst, Peter L Stern
Clinical trials of a vaccine directed against HPV oncogenes
for the treatment of cervical carcinoma are in progress.1 The
underlying rationale is to stimulate specific cytotoxic T-cells
against high-risk HPV 16 and 18 E6 and E7 proteins whose
expression is required for tumour development. The high
frequency of down-regulation of HLA class I expression in
tumour cells of cervical carcinomas2 will seriously
compromise the efficacy of such vaccinations because the
cytotoxic T-cells generated will only recognise viral peptides
in association with particular HLA class I molecules. If the
loss of HLA expression in cervical neoplasia is the result of
selection to avoid cellular immunity this may be an
important event necessary for progression of cervical lesions
during the natural history of the disease. A prospective
study in which the natural history of dysplastic cervical
lesions in relation to HPV status was monitored, and where
no intervention occurred until the end of follow-up or when
progression occurred, has provided biopsy samples to
investigate this possibility.3 The patients were recruited
when cytology showed mild to severe dyskaryosis (Pap 3a/b)
and were then monitored every 3-4 months by colposcopy,
cytology, and HPV typing. Clinical progression was defined
by an increase in CIN lesion size to more than two cervical
quadrants of cytological evidence of carcinoma (Pap 5) and
occurred in a period of 12 to 35 months (table).
From 88 HPV-16 positive patients of the cohort, eight
showed clinical progression of their lesions. HLA class I
typing of lymphocytes showed an increased frequency of
HLA-B44 in the patients with lesions showing progression
compared with patients with other HPV-16 positive lesions
(6/8 [75-0%] vs 20/80 [25-0%]; p=0-0074, OR 9-0) and
compared with HPV-negative patients from the same cohort
(75-0% vs 6/30 [20*0%]; p=0-0066, OR 12-0); HLA-B44
frequency in blood donors of the Amsterdam area is 24%.
This increased frequency prompted us to stratify our
patients for the HLA-B44 genotype to study the HLA
class I phenotype of these lesions. Immunohistochemical
analysis of allelic HLA expression2 was done on frozen
biopsy sections from HLA-B44 genotype progressor (n=5)
and non-progressor (n=9) patients which contained
respectively histologically confirmed CIN III or various
grades of CIN.
In four or five CIN Ills from progressor patients studied
there was evidence of allelic loss of HLA-B44 expression
whereas no loss was seen of any HLA class I allele in the
lesions from non-progressors (table). One of the HLA-B44
negative lesions showed down-regulation at all HLA-A and
HLA-B alleles and another some heterogeneous expression
of HLA-A29. These data are consistent with HLA-B44
class I loss occurring at an early stage of cervical neoplasia
and correlate with the increased frequency of HLA-B44 in
late-stage disease4 and its frequent down-regulation in
cervical carcinomas.2
HLA-A A-locus HLA-B Follow-up Histology
Genotype Phenotype* Genotype Phenotype*
expression!
Genotype Phenotype! Phenotype* Genotype Phenotype! Phenotype§ (mo) biopsy(CIN)
Progression
1 01 ND 03 + + 07 + + 44 - - 12 III
2 03 + 29 ± + 07 + + 44 - - 12 III
3 02 + 24 + + ' 07 + + 44 - - 31 III
4 02 - - 39 - ND 44 - - 24 III
5 01 + 24 + + 08 + + 44 + + 35 III
Non-progression
1 02 + 24 + + 35 + ND 44 + + 65 0
2 01 ND 28 + + 39 ND + 44 + + 54 1
3 03 + 24 + + 07 + + 44 + + 45 0
4 02 + + 27 + + 44 + + 41 1
5 11 + 25 + + 18 + + 44 + + 56 II
6 01 ND 23 + + 18 + + 44 + + 46 II
7 02 + + 07 + + 44 + + 39 II
8 02 + 25 + ND 57 ?ll ? 44 + + 29 II
9 02 + 26 + + 57 ? ? 44 + + 29 II
*Allele-specific monoclonal antibodies used. GAP-A3: A3, H173: A29, H41: A23, A24, MA2.1: A2, B57, H213: A26, CRI1-351; A28, BB7.1: B7, MRE4.1: B8, H47: B18. ME-1: B27,
BB7.2: A2.
fA-locus specific monoclonal antibody (A131).
^Monoclonal antibodies specific for Bw4 (HLA-B27, -B44, -B57) and Bw6 (HLA-B7, -B8, -B18, -B39, -B35)
§HLA-B44 specific antibody (H66).
||These patients azre homozygous for Bw4 therefore no statement can be made about the expression of B alleles using the Bw4/6 specific antibodies. Furthermore no HLA-B57 specific
antibody was available; the antibody used (MA2.1) recognises both HLA-A2 and B57.
±=Heterogeneous expression.
ND=not done or no antibody available.
HLA class I expression
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These results indicate that HLA-B44 in conjunction with
a down-regulated phenotype may influence rate of
progression in cervical neoplasia presumably due to evasion
of cellular immunity. While a tumour has potentially six
different HLA class I molecules for cytotoxic T-cell
restriction, the loss of expression of one allele can be
sufficient to allow tumour escape from immune
surveillance.5 The results of this study may reflect the
relative immunogenicity of HLA-B44 presented epitopes in
HPV-associated cervical neoplasia. Loss of other HLA
allelic expression (eg, specimen 4 and ref 2) as well as other
factors (eg, HPV type) will also be important in contributing
to the natural history of cervical neoplasia. These findings
have important implications for immunotherapeutic
strategies in patients with premalignant lesions of the cervix
since vaccination to induce HPV-specific CTL may be
ineffective at the target cell level.
We thank P A Dyer (Tissue Typing Laboratory, St Mary's Hospital,
Manchester) for the HLA typing and N M Lardy (CLB, Amsterdam) for
providing us with the local HLA class I frequencies. This work was
supported by the Prevention Fund (28-1502.2), the University
Stimulation Fund (USF) of the Free University, and the Cancer
Research Campaign (CRC).
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Viscera! leishmaniasis in southern
Croatia
Volga Punda-Polic, Sanda Sardelic, Nikola Bradaric
Visceral leishmaniasis is endemic in many parts of the
world.1 An increased incidence of the disease has been
reported during the past decade in many Mediterranean
countries where the disease is endemic.2,3 Human and
canine leishmaniasis has been reported in southern coastal
Croatia since 1931. In this region cases of the disease had
been declining and were reported only sporadically after
the 1950s, probably because of mass spraying with
antimalarial insecticide.4 However, we are now concerned
about an apparent increase in the incidence of visceral
leishmaniasis in southern Croatia. Clinical suspicion led us
to analyse records of all patients diagnosed with the
infection, at the Department of Infectious Diseases,
University Hospital Split, Croatia, between Jan 1, 1975,
and June 30, 1997. Split is the largest city in the middle of
the eastern coast of Adriatic sea, so the University Hospital
Split is the regional hospital with a catchment population of
about 500 000 from urban and rural areas.
A clinical diagnosis of visceral leishmaniasis was
confirmed by detection of amastigotes in bone-marrow
aspirate and by serology.1 During the study period, 14
patients (six women and eight men) met the clinical and/or
diagnostic criteria for visceral leishmaniasis. All 14 had
fever, hepatomegaly, and splenomegaly. 11 also had pallor
and weight loss. Laboratory findings were typical: raised
erythrocyte sedimentation rate (nine of 14), leucopenia
(nine), thrombocytopenia (eight), and anaemia (12).
Plasma albumin was greatly reduced, and 13 patients had
hypergammaglobulinaemia. Three cases were observed
between 1975 and 1991 (two in 1983 and one in 1985). 11
(78-6%) cases were registered between April, 1992, and
June, 1997, against a background of no cases in the
previous 6 years. Eight of the 14 cases were among infants
aged 8 months to 5 years, and six of them were under 2
years; one boy was aged 9 years. The mean age of the five
adults with visceral leishmaniasis was 40-5 (SD 2-93) years.
The patients infected with Leishmania had lived in the
urban (n=4) or periurban (10) settlement of littoral (12)
and in the insular area of southern Croatia (2). All our
patients were previously healthy, apparently
immunocompetent, and all responded to treatment with
pentavalent antimonials.
The substantial increase in cases of visceral leishmaniasis
was observed during the war (1992-95) and postwar period
in the region. Since the disease is an opportunistic
infection, the reason for the increase must be sought among
changes in living conditions. Decrease of nutrition quantity
and quality and a generally low standard of living during
the war could have affected the immunological state of the
population which would ihcrease the risk of developing
visceral leishmaniasis.2,5 On the other hand, a change in
epidemiological conditions during the war could be
associated with an increase in the number of affected stray
dogs, as well as disruption or irregular spraying of
insecticides necessary to vector control.
In southern Croatia the disease is still a paediatric
disease, since 64-3% of our patients were children under
the age of 10 years. Classic visceral leishmaniasis in
immunocompetent individuals in Mediterranean countries
is found mainly among children, although since 1989 an
increase in the number of cases among adults has been
observed in southwestern European countries mostly due
to Leishmania and HIV-1 coinfection.2,3 For the time being,
Croatia is not severely affected by the HIV-1 pandemic, but
with increasing intravenous-drug use among young people
in the region, the increase in HIV-1 infections is imminent.
Moreover, intravenous-drug users may act as parasite
reservoirs in an artificial transmission cycle of L infantum in
the Mediterranean countries.3
Visceral leishmaniasis is increasing in Mediterranean
countries and in southern Croatia, which suggests that we
are dealing with a pattern common to the whole
geographical area and emphasises the need for control and
increased awareness of this parasitosis.
1 Desjeux P. Information on the epidemiology and control of the
leishmaniases by country and territory. Report no 27. Geneva:
WHO, 1991.
2 Baily GG, Nandy A. Visceral leishmaniasis: more prevalent and
more problematic. J Infect Dis 1994; 29: 241-47.
3 Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and
human immunodeficiency virus coinfection: the first 10 years. Clin
Microbiol Rev 1997; 10: 298-319.
4 Tartaglia P. Visceralna i kozna lismenijaza u Dalmaciji. Lijec Vjesn
1957; 79: 511-22.
5 Bryceson ADM. Leishmaniasis. In: Cook GC, ed. Manson's tropical
disease, 20th edn. London: Saunders, 1996: 1213-45.
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An outbreak of imipenem resistance in Acinetobacter strains from
Buenos Aires, Argentina
S. Brown3, C. Bantarb, H.-K. Youngc, S. G. B. Amyes3,
3University ofEdinburgh, bCEMIC, Buenos Aires, Argentina, University ofDundee
Acinetobacter baumannii infections are difficult to treat because this species is often
multi-resistant and so the current drug of choice is often imipenem. The ARI-1
P-lactamase, encoded by a plasmid, is the only carbapenemase found so far in this
genus and has only been reported in Scotland. This unusual serine-based,
presumptive class A p-lactamase hydrolyses penicillins, first generation
cephalosporins and imipenem. This study reports of an outbreak of
carbapenemase-mediated imipenem resistance in 13 Acinetobacter clinical isolates
from Buenos-Aires, Argentina. Seven of the 13 isolates derived from a hospital
outbreak among neonates whereas three isolates came from a separate outbreak in a
different hospital. Biotyping by 20NE API strips showed 5 biotypes ofA. baumannii
and one isolate ofA. junii. Eleven A. baumannii isolates and the A. junii strain had
MICs of imipenem ranging from 8 to 32mg/l and MICs of meropenem from 4 to
8mg/l. The presence of P-lactamase and imipenem hydrolysis were demonstrated by
the agar plate microbiological assay and 12 isolates, including the A. junii strain,
displayed carbapenemase activity by this method. To detect P-lactamase inhibition,
clavulanic acid was incorporated into the medium at concentrations of 2.0, 1.0 and
0.5mg/l. Inhibition occurred with 11 of the isolates, at one or more inhibitor
concentrations, indicating the presence of a Class A P-lactamase. Iso-electric
focusing showed that one of these strains (1622) possessed three P-lactamase bands.
These focused at different positions (pi 5.8, 6.5 and 6.8) from ARI-1 (pi 6.65) and
were inhibited by imipenem, clavulanic acid and BRL 42715. The results suggest that
imipenem resistance in Acinetobacter spp. in Argentina results from novel Class A
P-lactamases.
Presented at the 4th International Symposium on the Biology ofAcinetobacter, Eilat,
3-5 November 1996
Imipenem resistance in Acinetobacter from Argentina - an outbreak
of carbapenemase-mediated resistance not involving AR1-1.
S. Browna, C. Bantarb, H. Youngc and S. Amyes3.
"University of Edinburgh, bCEMIC, Buenos Aires, Argentina, University ofDundee
Acinetobacter baumannii infections are difficult to treat because this species is often
multi-resistant and, at present, the drug of choice is imipenem. Carbapenemase
activity in this genus has, so far, only been reported in Scotland, and occurs as a result
of an unusual serine-based presumptive Class A P-lactamase, ARI-1. This study
reports an outbreak of carbapenemase-mediated imipenem resistance involving 13
Acinetobacter clinical isolates from Buenos Aires, Argentina which have been
examined and been shown to produce carbapenemases other than ARI-1. Biotyping
by API 20NE API strips showed 5 biotypes of A. baumannii and one isolate of
A. junii. Twelve out of 13 strains had MICs of imipenem between 8-32mg/l and of
meropenem between 4-8mg/l. Spectrophotometric analysis could not demonstrate
imipenem hydrolysis by any of the isolates. Twelve isolates including the A. junii
strain displayed carbapenemase activity by the agar plate microbiological assay. To
detect P-lactamase inhibition, the serine inhibitors clavulanic acid and BRL 42715
were incorporated into the medium at concentrations of 2, 1, and 0.5mg/l, and 0.5,
0.25 and 0.12mg/l respectively. Inhibition occurred with 10 isolates for clavulanic
acid at one or more inhibitor concentrations and with all 12 isolates to BRL 42715 at
all inhibitor concentrations, suggesting most, if not all, are Class A serine-based
P-lactamases. Iso-electric focusing showed that one of these strains (1622) possessed
P-lactamase bands which focused at different positions (pis 5.8, 6.5 and 6.8) from
ARI-1 (pi 6.65). These enzymes and ARI-1 were inhibited by imipenem, clavulanic
acid and BRL 42715 but not EDTA by the IEF overlay method. Induction of 1622
and ARI-1 (with imipenem at 1/4 MIC concentration) demonstrated no increase in
MIC of imipenem. However, the induced 1622 demonstrated a greater enzyme
activity against imipenem when tested by a modified microbiological assay method.
These results suggest this outbreak of imipenem resistance is caused by novel Class A
serine-P-lactamases which are not identical to ARI-1.
Presented at the 20th International Congress on Chemotherapy, Sydney, 29 June-3
July 1997.
ARI-2 - A plasmid-mediated carbapenemase in Acinetobacterl
aSusan Brown, bCarlos Bantar, cHilary-Kay Young and aSebastian Amyes.
aUniversity of Edinburgh, bCEMIC, Buenos Aires, Argentina and University of.
Dundee.
Acinetobacter baumannii is now recognised as an important nosocomial pathogen.
Its intrinsic antibiotic resistance has led to the use of imipenem as the drug of choice.
However, this therapy is now under threat with the emergence of imipenem resistant
strains. A plasmid-mediated carbapenemase, ARI-1, from a clinical isolate of
A. baumannii has, until recently, been the only reported case of P-lactamase-mediated
carbapenemase resistance in this genus. This study reports of a serine-site P-lactamase
which confers imipenem resistance in a clinical isolate ofA. baumannii from Buenos
Aires, Argentina. The strain (1622) had an MIC of imipenem of 16mg/l and an MIC
ofmeropenem of 4mg/l. The presence of P-lactamase and imipenem hydrolysis was
demonstrated by agar plate microbiological assay. Enzyme inhibition by clavulanic
acid was detected by this method, indicating the presence of a class A P-lactamase.
Two P-lactamase bands focused at different positions (pi 6.5 and 6.8) from ARI-1
(pI6.65) by isoelectric focusing. They were inhibited by imipenem, clavulanic acid
and BRL 42715 overlays. A modified IEF technique showed the main p-lactamase
band to be pi 6.5 (ARI-2). Plasmid curing was carried out using ethidium bromide
and susceptibility testing was carried out on cured colonies. A decrease in MIC
values of imipenem (0.5mg/l) and meropenem (1.0mg/l) was demonstrated in the
cured strain. Isoelectric focusing demonstrated the loss of bands at pi 6.5 and 6.8
which strongly associated the ARI-2 p-lactamase with plasmid-encoded carbapenem
resistance. These findings have severe implications for the future therapy of
Acinetobacter infections.
Presented at the 9th European Congress of Clinical Microbiology and Infectious
Diseases, Berlin, 21-24 March 1999.
The differential activity of seven fluoroquinolones against multi-resistant
Acinetobacter baumannii clinical isolates
S. Browna, S, Cameronb, S. G. B. Amyesa,
aUniversity ofEdinburgh, bUniversity of Dundee
Acinetobacter baumannii is now universally recognised as an important nosocomial
pathogen, with many outbreaks occurring in intensive care units in which extensive
antibiotic use has selected for the emergence of multi-resistant strains. Many of these
strains are now resistant to all commonly used antibiotics, including many of the
fluoroquinolones and the carbapenems. In some countries, such as Argentina, the
situation has become so bad that they are already beginnning to encounter totally
resistant clinical strains ofAcinetobacter. This study investigates the activity of seven
fluoroquinolones, including the new quinolones moxofloxacin and trovafloxacin,
against 41 multi-resistant A.baumannii clinical isolates from Argentina, Spain and
Hong Kong. Fifty-six percent of these strains have previously been determined as
imipenem resistant, and they represent some of the most resistant clinical Gram-
negative bacteria to date. Minimum Inhibitory Concentrations (MIC) were determind
by the agar dilution method, with the exception of levofloxacin which was tested by
the Stokes method. At standard breakpoints, there was significant resistance amongst
these strains to ciprofloxacin (68%), norfloxacin (78%) and grepafloxacin (49%).
Disc sensitvity tests revealed 56% of the strains were resistant to levofloxacin. The
least active antibiotic was norfloxacin with the highest MIC5o and MIC90 values
(>256mg/L for both). Sparfloxacin, moxifloxacin and trovafloxacin were the most
active (resistance rates of 14.6%, 14.6% and 9.7% respectively) with similar MIC50
and MIC90 values. These newer fluoroquinolones were originally developed to treat
Gram-positive bacteria but these results demonstrate the possibility of a much needed
role for these drugs in the treatment of severe Gram-negative infections caused by
multi-resistant Acinetobacter baumannii.
Presented at the 39th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, 26-29 September 1999.
Transferable Spread of Imipenem Resistance in Clinical Isolates of
Acinetobacter Isolated in Argentina, Turkey and Spain.
S. BROWN,*1 C. BANTAR2, H-K. YOUNG3, S.G.B. AMYES1
Edinburgh University, Edinburgh, Scotland., 2CEMIC, Buenos Aires, Argentina.,
3Dundee University, Dundee, Scotland.
The carbapenems are invariably the last choice in the treatment of Acinetobacter
baumcmnii infections, however, there are now reports emerging of clinical isolates
which are resistant to this class of antibiotics. We recently described a novel
(3-lactamase (ARI-2) from a clinical isolate of A. baumannii from Buenos Aires,
Argentina which confers resistance to imipenem (minimum inhibitory concentration of
16mg/L). This study reports the presence of ARI-2 in other clinical Acinetobacter
isolates from Argentina, Turkey and Spain. Eleven clinical isolates from Argentina,
seven from Turkey and two from Spain were tested for carbapenem resistance by the
agar dilution method. Isoelectric focusing (IEF) was used to detect the presence of
(3-lactamase bands in cell-free extracts. Enzyme inhibition was demonstrated by
inhibitor overlays applied to the gels. Strains were differentiated by analysing DNA
Restriction Fragment Length Polymorphisms (RFLPs) determined by Pulsed-Field Gel
Electrophoresis (PFGE). All isolates were resistant to imipenem and meropenem with
MIC values of 4.0-128mg/L for both antibiotics. IEF detected identical (3-lactamase
bands to those of ARI-2 in all strains from Turkey and Argentina, and in one strain
from Spain. Beta-lactamase activity was inhibited by imipenem (10"4M) and BRL
42715 (10"3M). Partial inhibition was demonstrated by clavulanic acid (10"3M). No
inhibition was detected by EDTA (10"2M). These inhibitor profiles were identical to
that of ARI-2. PFGE revealed two distinct patterns in the strains from Argentina. A
third pattern was common to all the strains from Turkey. A fourth pattern was found
in the strain from Spain. These results demonstrate the presence of ARI-2 in strains
of different genotype from around the world, suggesting transferable spread of the
ARI-2 gene is an important factor in the dissemination of carbapenem resistance,
although clonal spread may be more significant in a defined area. These findings
indicate that the ARI-2 (3-lactamase already plays an important role in the emergence
ofworld-wide imipenem resistance in Acinetobacter spp.
